


Journal Pre-proof



Anaphylaxis – a 2020 Practice Parameter Update, Systematic Review and GRADE Analysis

Marcus S. Shaker, MD, MSc, Dana V. Wallace, MD, David BK. Golden, MD, John Oppenheimer, MD, Jonathan A. Bernstein, MD, Ronna CL. Campbell, MD, Chitra Dinakar, MD, Anne Ellis, MD, Matthew Greenhawt, MD, MBA, MSc, David A. Khan, MD, David M. Lang, MD, Eddy S. Lang, MD, Jay A. Lieberman, MD, Jay Portnoy, MD, Matthew A. Rank, MD, David R. Stukus, MD, Julie Wang, MD, Collaborators, N. Riblet, A.M.P. Bobrownicki, T. Bontrager, J. Dusin, J. Foley, B. Frederick, E. Fregene, S. Hellerstedt, F. Hassan, K. Hess, C. Horner, K. Huntington, P. Kasireddy, D. Keeler, B. Kim, P. Lieberman, E. Lindhorst, F. McEnany, J. Milbank, H. Murphy, O. Pando, A.K. Patel, N. Ratliff, R. Rhodes, K. Robertson, H. Scott, A. Snell, R. Sullivan, V. Trivedi, A. Wickham

PII: S0091-6749(20)30105-6

DOI: <https://doi.org/10.1016/j.jaci.2020.01.017>

Reference: YMAI 14384

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 2 October 2019

Revised Date: 21 December 2019

Accepted Date: 2 January 2020

Please cite this article as: Shaker MS, Wallace DV, Golden DB, Oppenheimer J, Bernstein JA, Campbell RC, Dinakar C, Ellis A, Greenhawt M, Khan DA, Lang DM, Lang ES, Lieberman JA, Portnoy J, Rank MA, Stukus DR, Wang J, Collaborators, Riblet N, Bobrownicki A, Bontrager T, Dusin J, Foley J, Frederick B, Fregene E, Hellerstedt S, Hassan F, Hess K, Horner C, Huntington K, Kasireddy P, Keeler D, Kim B, Lieberman P, Lindhorst E, McEnany F, Milbank J, Murphy H, Pando O, Patel A, Ratliff N, Rhodes R, Robertson K, Scott H, Snell A, Sullivan R, Trivedi V, Wickham A, Anaphylaxis – a 2020 Practice Parameter Update, Systematic Review and GRADE Analysis, *Journal of Allergy and Clinical Immunology* (2020), doi: <https://doi.org/10.1016/j.jaci.2020.01.017>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of

record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.

Anaphylaxis – a 2020 Practice Parameter Update, Systematic Review and GRADE Analysis

Authors: Marcus S Shaker MD, MSc¹, Dana V Wallace, MD², David BK Golden, MD³, John Oppenheimer MD⁴, Jonathan A Bernstein, MD⁵, Ronna CL Campbell, MD⁶, Chitra Dinakar, MD⁷, Anne Ellis, MD⁸, Matthew Greenhawt, MD, MBA, MSc⁹, David A Khan, MD¹⁰, David M Lang, MD¹¹, Eddy S Lang, MD¹², Jay A Lieberman, MD¹³, Jay Portnoy, MD¹⁴, Matthew A Rank, MD¹⁵, David R Stukus, MD¹⁶, Julie Wang, MD¹⁷

Collaborators: Riblet N¹⁸, Bobrownicki AMP¹⁸, Bontrager T¹⁹, Dusin J¹⁹, Foley J¹⁹, Frederick B¹⁹, Fregene E¹⁸, Hellerstedt S¹⁸, Hassan F¹⁹, Hess K¹⁹, Horner C²⁰, Huntington K¹⁹, Kasireddy P¹⁸, Keeler D¹⁹, Kim B¹⁹, Lieberman P¹³, Lindhorst E¹⁹, McEnany F¹⁸, Milbank J¹⁸, Murphy H¹⁹, Pando O¹⁸, Patel AK¹⁸, Ratliff N¹⁹, Rhodes R¹⁹, Robertson K¹⁹, Scott H¹⁹, Snell A¹⁹, Sullivan R¹⁹, Trivedi V¹⁸, Wickham A¹⁹

Chief Editor(s): Shaker MS and Wallace DV

Workgroup Contributors: Shaker M, Wallace DV, Bernstein JA, Campbell RL, Dinakar C, Ellis AK, Golden DBK, Greenhawt M, Lieberman JA, Rank MA, Stukus DR, Wang J

Joint Task Force on Practice Parameters Reviewers: Shaker M, Wallace DV, Golden DBK, Bernstein JA, Dinakar C, Ellis AK, Greenhawt M, Horner CC, Khan DA, Lieberman J, Oppenheimer J, Rank MA, Shaker MS, Stukus DR, Wang J

¹Section of Allergy and Clinical Immunology, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Nova Southeastern Allopathic Medical School, Fort Lauderdale, FL, ³Division of Allergy-Clinical Immunology, Johns Hopkins University, Baltimore, MD, ⁴Department of Internal Medicine, Pulmonary and Allergy, UMDNJ-Rutgers New Jersey Medical School and Pulmonary and Allergy Associates, Morristown, NJ, ⁵Department of Internal Medicine, Division of Immunology, Allergy Section, University of Cincinnati College of Medicine, Cincinnati, Ohio, ⁶Department of Emergency Medicine, Mayo Clinic, Rochester, MN, ⁷Allergy, Asthma, and Immunodeficiency, Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, ⁸Division of Allergy & Immunology, Department of Medicine, Queen's University, Kingston, ON Canada, ⁹Section of Allergy and Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, Denver, Colorado, ¹⁰Department of Internal Medicine, Division of Allergy and Immunology, UT Southwestern Medical Center, Dallas, Tx, ¹¹Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic, Cleveland, OH, ¹²Department of Emergency Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada, ¹³Department of Pediatrics, The University of Tennessee Health Science Center, Memphis, TN, ¹⁴Pediatric Allergy & Immunology, Children's Mercy Hospital, Kansas City School of Medicine, Kansas City, MO, ¹⁵Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic in Arizona, Scottsdale, Arizona, ¹⁶Division of Allergy and Immunology, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio, ¹⁷Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁸The Dartmouth Institute for Health Policy and Clinical Practice, Hanover NH, ¹⁹Office of Evidence-Based Practice, Children's Mercy Hospital, Kansas City MO,

²⁰Department of Pediatrics, Division of Allergy, Immunology, and Pulmonary Medicine, Washington University School of Medicine, St. Louis, MO

Reprints: Joint Task Force on Practice Parameters (JTFPP) Liaison: Peris Flagg (American Academy of Allergy, Asthma, and Immunology, 555 E. Wells Street, Suite 1100, Milwaukee, WI 53202, pflagg@aaaai.org; JTFPP.allergy@gmail.com)

Previously published Practice Parameters of the Joint Task Force on Practice Parameters for Allergy & Immunology are also available at <http://www.allergyparameters.org>; <http://www.AAAAI.org>, and <http://www.ACAAI.org>.

Disclosures: The JTFPP members and work group members' conflict of interest disclosure forms can be found at www.allergyparameters.org. Jonathan Bernstein has received financial support from Sanofi Regeneron, AstraZeneca, Merck, Optinose, Takeda, CSL Behring, Biocryst, Pharming, the National Institutes of Health (NIH), Taylor Francis; is Editor in Chief of the Journal of Asthma, INEOS Medical Immunosurveillance Director, Vice Chair and Lectureship Chair of the American Academy of Allergy, Asthma, and Immunology (AAAAI) Foundation, Chairman of AFI, American College of Asthma, Allergy, and Immunology (ACAAI) Asthma Chair, Scientific Chair, and Young Investigator Award Chair, and serves of the Board of Directors and Scientific Committee of Interasma. Ronna Campbell has served as a peer reviewer for EB Medicine and an author for UpToDate. Chitra Dinakar has received financial support from Propeller Health, DBV Technologies, ACAAI (stipend for Editorial Board of AllergyWatch), the American Association of Allergists of Indian Origin; serves on the Board of Directors of the AAAAI and on the Medical Advisory Board of Food Equity Initiative; is Assistant Editor of AllergyWatch. Anne Ellis has received financial support from ALK Abello, Astra Zeneca, Green Cross, Merck, Novartis, Nuvo, Pediapharm, Pfizer, Kaleo, Novartis, Sanofi, Regeneron; serves on the Board of Directors of the Canadian Allergy Society of Allergy and Clinical Immunology. David Golden has received financial support from Aquestive, Sandoz, ALK-Abello, Sandoz, Genentech, Stallergenes-Greer, and UpToDate. Matthew Greenhawt has received financial support from Aquestive, Merck, Allergenis, Allergy Therapeutics, Sanofi Genzyme, Genentech, Aravax, Protas, Before Brands, the Institute for Clinical and Economic Review, ACAAI, DBV, Intrimmune, and is supported by the Agency of Healthcare Research and Quality; has served on the advisory board of International FPIES Association, the Asthma and Allergy Foundation of America, and the National Peanut Board; is Associate Editor of the Annals of Allergy, Asthma, and Immunology. Caroline Horner has served as committee chair for the AAAAI Asthma Diagnosis and Treatment Interest Section, Interest Section Coordinating Committee, and In-Training Exam Coordinating Committee. David Khan has received financial support from UpToDate and Aimmune; serves on the Board of Directors of the AAAAI, ACAAI Chair of Literature Review, Co-Chair of Conjoint Board Review, Texas Allergy, Asthma, and Immunology Society Chair of Meetings Committee, and is Associate Editor of the Journal of Allergy and Clinical Immunology In Practice. Eddy Lang received an honorarium from the JTFPP for GRADE methods support. Jay Lieberman has received financial support from the ACAAI, Aquestive, Aimmune, DBV, Biotest Pharma, and Regeneron; is Associate Editor of the Annals of Allergy, Asthma, and Immunology, Vice Chair for the ACAAI Food Allergy Committee, and Medical Director for Food Allergy Alliance of the MidSouth. John Oppenheimer has received financial support from DBV, TEVA, GlaxoSmithKline adjudication/data safety monitoring board, AstraZeneca, Novartis, and Sanofi; is Associate Editor of the Annals of Allergy, Asthma, and Immunology and AllergyWatch, an American Board of Internal Medicine (ABIM) Council Member and American Board of Allergy and Immunology Liaison to the ABIM, UpToDate Reviewer, ACCP Cough Guideline Committee Member, and WebMD Editor. Jay Portnoy has received financial support from Thermofisher, Kaleo, TEVA, Novartis, Hycor, and Boehringer-Ingelheim. Matthew Rank has received financial support from the ACAAI, NIH, and Levin Family Foundation; has served as Chair of the AAAAI HEDQ Interest Section, and is Research Director of the Phoenix Children's Hospital Breathmobile. Marcus Shaker has received financial support from the Eastern Allergy Conference and has a family member who is CEO of Altrix Medical. David Stukus has received financial support from Aimmune, Before Brands, Abbott Nutrition, the American Academy of Pediatrics (AAP), ACAAI; has served as Committee Chair for the AAAAI and ACAAI. Dana Wallace has received financial support from Mylan, Kaleo, Optinose, ALK, Bryan, and Sanofi; is Education Council Chair and Rhinitis/Sinusitis/Ocular Committee Chair for the ACAAI; is Website Content Editor and ESP/WATS Committee Chair for the World Allergy Organization. Julie Wang has received financial support from ALK Abello, Regeneron, DBV, Aimmune; is an

UpToDate author; serves on the Executive Committee of the American Academy of Pediatrics Section on Allergy and Immunology; serves as Vice Chair of the AAAAI Anaphylaxis, Dermatitis, Drug Allergy Interest Section.

The JTFPP is committed to ensuring that the Practice Parameters are based on the best scientific evidence at the time of publication, and that such evidence is free of commercial bias to the greatest extent possible. The JTFPP recognizes that experts in a field are likely to have interests that could come into conflict with the development of a completely unbiased and objective practice parameter. To take advantage of their expertise, a process has been developed to acknowledge potential conflicts of interest (COI) and attempt to prevent them from influencing the final document in a negative way. To preserve the greatest transparency regarding potential conflicts of interest, all members of the JTFPP and the practice parameters work groups will complete a standard potential conflict of interest disclosure form prior to the development of each document, which will be available for external review by the sponsoring organization and any other interested individual. In addition, before confirming the selection of the work group chairperson and members, the JTFPP will discuss and resolve all relevant potential conflicts of interest associated with this selection. Finally, all members of parameter work groups will be provided a written statement regarding the importance of ensuring that the parameter development process is free of commercial bias.

During the review process there are additional measures to avoid bias. At the workgroup level, all the sections are reviewed by all workgroup members to ensure that content is appropriate and without apparent bias. If a section is deemed to have apparent bias, it will be appropriately revised without the section author's involvement, in an attempt to remove potential bias. In addition, the entire document is then reviewed by the Joint Task Force on Practice Parameters (JTFPP), and any apparent bias is acknowledged and removed at that level. For each and every recommendation, a vote is required by the workgroup and JTFPP, and any member with any perceived COI is recused from that vote (and so explained in the document). Any dissenting votes that cannot be resolved are described and explained in the document. In a final stage of review, the practice parameter is sent to invited expert reviewers for review, selected by the American Academy of Allergy, Asthma, and Immunology (AAAAI) and the American College of Allergy, Asthma, and Immunology (ACAAI). The document is also posted on the AAAAI and ACAAI websites for general membership and the public-at-large to review and offer comment. All reviewers must provide statements of potential COI. Although the JTFPP has the final responsibility for the content of the documents submitted for publication, each reviewer's comments will be discussed and reviewers will receive written responses to comments when appropriate.

Disclaimer: The American Academy of Allergy, Asthma, and Immunology and the American College of Allergy, Asthma, and Immunology have jointly accepted responsibility for establishing **Anaphylaxis – a 2019 Practice Parameter Update, Systematic Review and GRADE Analysis**. This is a complete and comprehensive document and is current at the time of publication. The medical environment is rapidly changing, and not all recommendations will be appropriate or applicable to all patients and may change over time. Because this document incorporated the efforts of many participants, no single individual, including members serving on JTFPP, are authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information or interpretation of this practice parameter by the AAAAI or ACAAI should be directed to the executive offices of the AAAAI and the ACAAI. These parameters are not designed for use by the pharmaceutical industry in drug development or promotion.

Contributors: The Joint Task Force has made a concerted effort to acknowledge all contributors to this parameter. If any contributors have been excluded inadvertently, the Task Force will ensure that appropriate recognition of such contributions is made subsequently.

Key Words: Anaphylaxis; GRADE; Epinephrine; Risk Factors: Biphasic; Severity; Glucocorticoids; Antihistamines; Pretreatment; Radiocontrast Media; Chemotherapy; Monoclonal antibody; Infliximab; Allergen Immunotherapy; Systematic meta-analysis; Evidence to Recommendations; Guideline; Practice Parameter

Abbreviations:

AAAAI	American Academy of Allergy, Asthma, and Immunology
ACAAI	American College of Allergy, Asthma, and Immunology
ACE	Angiotensin-converting enzyme
ADR	Adverse drug reaction

ADRs	Adverse drug reactions
C3a, C4a, C5a	Complement 3a, Complement 4a, Complement 5a
CI	Confidence interval
CysLTs	Cysteinyl leukotrienes
DHR	Drug hypersensitivity reaction
ED	Emergency department
EMS	Emergency medical services
FAAN	Food Allergy and Anaphylaxis Network
FIA	Food-induced anaphylaxis
GRADE	Grading of Recommendations, Assessment, Development and Evaluation
H1, H2, H3, H4	Histamine 1, 2, 3, 4
HVA	Hymenoptera venom allergy
I ²	Inconsistency of studies' results
ICON	International consensus on
IgE	Immunoglobulin E
IL	Interleukin
JTFPP	Joint Task Force on Practice Parameters
LL	Large local
LT	Leukotriene
NIAID	National Institutes of Allergy and Infectious Diseases
NNT	Number needed to treat
NPV	Negative predictive value
OR	Odds ratio
PAF	Platelet-activating factor
PEER	Patient expected event rate
PPV	Positive predictive value
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
QOL	Quality of life
RCM	Radiocontrast media
RCT	Randomized controlled trial
RIT	Rush immunotherapy
RR	Relative Risk
TNF	Tissue necrosis factor
UK	United Kingdom

Corresponding Author:

Marcus S. Shaker, MD, MSc, FAAAAI, FACAAI, FAAP
 Section of Allergy and Clinical Immunology
 Dartmouth-Hitchcock Medical Center
 One Medical Center Drive
 Lebanon, NH 03756-0001
 Email: Marcus.shaker@dartmouth.edu

Figures: Box 1 is a 1- column image; all other figures are 2-column fitting images, but we welcome editorial input on this suggestion.

EXECUTIVE SUMMARY

Anaphylaxis is an acute, life-threatening systemic allergic reaction that may have a wide range of clinical manifestations. (1) The clinical criteria proposed in 2006 by National Institutes of Allergy and Infectious Diseases (NIAID) continue to provide a helpful framework in approaching patients with acute allergic symptoms, because diagnosis and management of anaphylaxis must occur rapidly and confirmatory testing for anaphylaxis has poor sensitivity. (2) While NIAID anaphylaxis diagnostic criteria have a sensitivity of 95% with a specificity of 71% in an emergency department setting (3), fulfilling diagnostic criteria is not a prerequisite for epinephrine administration in a patient experiencing an acute allergic reaction.

The lifetime prevalence of anaphylaxis has been estimated at 1.6% to 5.1%. (1, 4) Risk factors for severe anaphylaxis include cardiovascular disease, asthma, older age, and additional coexisting, comorbid conditions. (5-9) Medications and stinging insects are the leading triggers in adults, with foods and stinging insects the most frequently implicated triggers in children and adolescents. (1, 10-12) Food allergy impacts 8% to 11% of children and adults in the United States (13-15), while adverse drug reactions (ADRs) affect up to 10% of the population (and 20% of hospitalized patients), with hypersensitivity reactions accounting for 10% of all ADRs. (16) While medical complexity increases for patients with prior hypersensitivity reactions to radiocontrast media (RCM), fortunately the prevalence of RCM ADRs has decreased in recent decades. (17) Systemic reactions to Hymenoptera venom occur in 0.5% to 3.3% of the US population, with most fatalities occurring in patients who have no prior history of systemic allergic reaction to Hymenoptera.(16)

IgE binding and cross-linking of the high-affinity receptor FcEpsilonRI on the surface of mast cells and basophils is an important mechanism in many cases of anaphylaxis. (18) Some patients with anaphylaxis have low or undetectable circulating allergen-specific IgE. (19) Additional cell types involved in anaphylaxis may include neutrophils, monocytes, macrophages, and platelets, signaling through mediators that include complement components, CysLTs, platelet activating factor, IL-6, IL-10 and TNF-receptor 1. (20) (21)

Epinephrine administered intramuscularly (in a dose of 0.01 mg/kg of a 1:1,000 (1mg/mL) solution to a maximum of 0.5 mg in adults and 0.3 mg in children) into the anterolateral thigh is the first-line treatment for anaphylaxis.(22) Epinephrine is the cornerstone of anaphylaxis management but continues to be underutilized. (23-25) As a nonselective adrenergic agonist, epinephrine works rapidly to increase peripheral vascular resistance through vasoconstriction, to increase cardiac output, to reverse bronchoconstriction and mucosal edema, and to stabilize mast cells and basophils. (26, 27) Despite underuse of rapidly acting epinephrine as first-line treatment, fatal anaphylaxis is a rare outcome, with population prevalence rates between 0.47 to 0.69 per million persons (0.25%-0.33% of anaphylaxis hospitalizations or emergency department visits). (9, 28-31) Antihistamine agents are considered second-line treatment for anaphylaxis, given their slow onset of action, inability to stabilize or prevent mast cell degranulation, or to target additional mediators of anaphylaxis. (32) Unlike epinephrine, antihistamines will not effectively treat cardiovascular and respiratory symptoms such as hypotension or bronchospasm. Although glucocorticoids are frequently used as an adjunctive therapy for anaphylaxis, evidence is lacking to support clinical benefit and they should also not be administered in place of epinephrine in the treatment of acute anaphylaxis. (33, 34)

Biphasic anaphylaxis is recurrent anaphylaxis occurring 1 to 72 hours after resolution of an initial anaphylactic episode, though an outside limit of 78 hours has also been suggested. (35)(36) Estimates of biphasic anaphylaxis vary from less than 1% to 20% of patients; however, the ability of antihistamines and glucocorticoids to affect this outcome is unclear. (37-44) Despite a lack of clear evidence supporting the role of antihistamines and glucocorticoids in anaphylaxis, these agents continue to be routinely used in anaphylaxis management. To evaluate the role for these second-line, supplemental therapies, the JTFPP undertook a systematic review and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis of antihistamines and glucocorticoids in anaphylaxis. Specifically, the JTFPP sought to better inform the practice of anaphylaxis prevention in two broad topic areas through (i) identification and mitigation of risk factors for biphasic anaphylaxis and (ii) evaluation of the use of supplemental glucocorticoid and/or antihistamine premedication. While the goal of the JTFPP was to rigorously evaluate the literature to form evidence-based recommendations, there are limits to the available evidence in human anaphylaxis due to ethical considerations and the

absence of double-blind studies in a potentially fatal, acute condition. This GRADE analysis incorporated the balance of relative benefits and harms of treatments under consideration, the certainty of the evidence, and the impact of patient preferences and values.

Key Questions Assessed by this Systematic Review on Anaphylaxis:

Topic Area 1: Identification and mitigation of risk factors for biphasic anaphylaxis

Question 1. What risk factors should clinicians take into consideration in determining the likelihood of biphasic anaphylaxis?

Topic Area 2: Evaluation of the use of supplemental glucocorticoids and/or antihistamine premedication for the prevention of anaphylaxis

Question 2. Should antihistamines and/or glucocorticoids be used to prevent biphasic anaphylaxis?

Question 3. Should antihistamine and/or glucocorticoid premedication be used to prevent index hypersensitivity/infusion reactions to chemotherapy?

Question 4. Should antihistamine and/or glucocorticoid premedication be used to prevent recurrent hypersensitivity reactions to radiocontrast media?

Question 5. Should antihistamine and/or glucocorticoid premedication be used to prevent hypersensitivity reactions to allergen immunotherapy or other agents?

Question 1: What risk factors should clinicians take into consideration in determining the likelihood of biphasic anaphylaxis?

Recommendation 1: We suggest that a clinician incorporate severity of anaphylaxis presentation and/or the administration of more than one dose of epinephrine for the treatment of initial anaphylaxis as a guide to determining a patient's risk for developing biphasic anaphylaxis. Conditional recommendation; Certainty rating of evidence: very low

While the ability to accurately predict which patients with resolved initial anaphylaxis will experience biphasic anaphylaxis is imperfect, an understanding of risk factors allows a more

tailored approach to patient management. Risk factors also provide useful parameters to incorporate into decision making regarding duration of observation following initial resolution of anaphylaxis.

The JTFPP findings suggest biphasic anaphylaxis is associated with a more severe initial presentation of anaphylaxis (OR=2.11, 95% CI 1.23-3.61) or repeated epinephrine doses (i.e., more than one dose of epinephrine) required with the initial presentation (OR 4.82, 95% CI 2.70-8.58). Additional risk factors include wide pulse pressure (OR 2.11, 95% CI 1.32 – 3.37), unknown anaphylaxis trigger (OR 1.63, 95% CI 1.14-2.33), cutaneous signs and symptoms (OR 2.54, 95% CI 1.25-5.15), and drug trigger in children (OR 2.35, 95% CI 1.16-4.76). While presence of dyspnea on presentation was associated with a decreased risk for anaphylaxis, overall confidence in this estimate was low (OR 0.6, 95% CI 0.38-0.96). Prompt and adequate treatment of anaphylaxis appears central to reducing biphasic anaphylaxis risk, in the opinion of the JTFPP. While the possibility of biphasic anaphylaxis should be emphasized in this higher risk group, it is important to educate all patients on the chance of a biphasic reaction as well as avoiding known triggers, identifying symptoms of anaphylaxis, the use of auto-injector epinephrine for the treatment of anaphylaxis, and timely follow-up with an allergist.

Recommendation 2: We suggest in favor of extended clinical observation in a setting capable of managing anaphylaxis (to detect a biphasic reaction) for patients with resolved severe anaphylaxis and/or those who need more than one dose of epinephrine. Conditional recommendation; Certainty rating of evidence: very low

While wide pulse pressures may be considered a marker for severe anaphylaxis, the clinician may also consider extended observation for patients with an unknown anaphylaxis trigger and children with a drug trigger. Incorporating cutaneous signs and symptoms into a clinical decision for extended observation may be limited by the common occurrence of cutaneous signs and symptoms in patients presenting with anaphylaxis. The estimated number needed to monitor with extended observation to be able to detect one episode of biphasic anaphylaxis before discharge would be 41 (range, 18 to 195) for patients with a more severe initial presentation of anaphylaxis and 13 (range, 7 to 27) for patients with multiple epinephrine doses. The implication

for the clinician, based upon this systematic review and meta-analysis, is that the patient presenting with severe anaphylaxis and/or requiring more aggressive treatment (e.g., more than one dose of epinephrine) should be considered for longer observation time for a potential biphasic reaction following complete resolution of signs and symptoms. At present, evidence is lacking to clearly define the optimal duration of observation (e.g., number of hours) that would prove to be cost-effective for patients with initial resolution of severe anaphylaxis and/or those requiring multiple doses of epinephrine. However, for patients without severe risk features, discharge after a 1-hour asymptomatic observation may be reasonable. If the clinical impression is that a patient has a higher risk of biphasic reaction (i.e., 17% or greater) or risk factors for anaphylaxis fatality (e.g., cardiovascular comorbidity, lack of access to epinephrine, lack of access to emergency medical services, poor self-management skills, etc) then extended observation of up to 6 hours or longer (including hospital admission) may be appropriate. Regardless of severity, after diagnosis and treatment of anaphylaxis, all patients should be kept under observation until signs and symptoms have fully resolved.

Question 2: Should antihistamines or glucocorticoids be used to prevent biphasic anaphylaxis?

Recommendation: We suggest against administering glucocorticoids or antihistamines as an intervention to prevent biphasic anaphylaxis. Conditional recommendation; Certainty rating of evidence: very low

Although we suggest against the use of antihistamines and/or glucocorticoids as an intervention to prevent biphasic anaphylaxis, these may be considered for the secondary treatment of anaphylaxis. (45) In particular, antihistamines may treat urticaria and itching to improve comfort during anaphylaxis, but if used prior to epinephrine administration, antihistamine administration could lead to a delay in first-line treatment of anaphylaxis. The JTFPP analysis did not identify clear benefit in prevention of biphasic anaphylaxis from either H1 antihistamines (OR 0.71, 95% CI 0.47-1.06), H2 antihistamines (OR 1.21, 95% CI 0.80-1.83), or glucocorticoids (OR 0.87, 95% CI 0.74-1.02). An interaction was identified between age and glucocorticoid use, with glucocorticoids actually increasing risk for biphasic anaphylaxis in children (OR 1.55, 95% CI

1.01-2.38); however, confounding effect of severity could not be excluded. At a biphasic anaphylaxis patient expected event rate (PEER) of 5%, the number needed to treat (NNT) for H1 antihistamines and glucocorticoids is 72 and 161 to prevent one episode of biphasic anaphylaxis, with significant uncertainty in the estimate.

Question 3: Should Antihistamine and/or Glucocorticoid Premedication Be Used To Prevent Index Hypersensitivity/Infusion Reactions to Chemotherapy?

Recommendation: We suggest in favor of administering glucocorticoids and/or antihistamines to prevent anaphylaxis or infusion-related reactions when indicated for specific agents in chemotherapy protocols. Conditional recommendation; Certainty rating of evidence: very low

The JTFPP analysis did identify a significant change in rates of anaphylaxis and/or infusion reactions for some chemotherapy protocols. The use of premedication was associated with a decreased rate of hypersensitivity reactions for chemotherapy (OR 0.49, 95% CI 0.37-0.66). In contrast to chemotherapy premedication, benefit was not observed when using premedication to prevent anaphylaxis in the setting of infliximab without prior reaction to the administered agent (RR 1.58, 95% CI 0.87-2.87). We did not evaluate premedication in the context of desensitization to chemotherapy agents and to monoclonal antibodies. Furthermore, the use of premedication in patients who had previously experienced anaphylaxis from these agents was not evaluated.

Question 4: Should Antihistamine and/or Glucocorticoid Premedication Be Used To Prevent Recurrent Hypersensitivity Reactions Radiocontrast Media ?

Recommendation: We suggest against routinely administering glucocorticoids and/or antihistamines to prevent anaphylaxis in patients with prior radiocontrast hypersensitivity reactions when re-administration of a low- or iso-osmolar, non-ionic radiocontrast media agent is required. Conditional recommendation; Certainty rating of evidence: very low

The JTFPP analysis did not identify significant benefit from the use of premedication prior to RCM administration to prevent anaphylaxis (RR 1.07 95% CI 0.67-1.71). The absence of benefit of premedication in patients with prior immediate hypersensitivity reactions to RCM who are receiving a different low- or iso-osmolar agent is consistent with prior literature; however, it is important to distinguish the immediate index reaction associated with RCM from a severe, delayed, cutaneous T-cell mediated reaction, where premedication may add value to management.⁽¹⁷⁾ Given the diversity of clinical circumstances evaluated and low confidence in the literature base, higher certainty evidence is needed to better inform practice, and future recommendations could potentially change as a result of new information. As such, clinicians may reasonably consider premedication in clinical circumstances associated with a high level of perceived risk of anaphylaxis or comorbidities associated with greater anaphylaxis fatality risk (such as underlying cardiovascular disease, use of beta-blockers, or prior severe anaphylaxis), although evidence is lacking to clearly support this practice. This analysis evaluated patients with both mild and severe prior RCM reactions but we were unable to stratify prophylaxis by severity of index reaction. Furthermore, only low- and iso-osmolar non-ionic radiocontrast agents were evaluated because these are the most commonly used agents at present. This recommendation does not apply to patients receiving high-osmolar contrast agents for whom prophylaxis may be appropriate in some circumstances.

Question 5: Should Antihistamine and/or Glucocorticoid Premedication Be Used To Prevent Hypersensitivity Reactions to Allergen Immunotherapy or Other Agents?

Recommendation: We suggest the administration of glucocorticoids and/or antihistamines as an intervention to prevent anaphylaxis in patients undergoing aeroallergen rush immunotherapy (RIT). Conditional recommendation; Certainty rating of evidence: very low

Evidence suggests that in the setting of aeroallergen RIT, premedication may provide value in reducing systemic reactions and anaphylaxis (immunotherapy analysis including RIT, RR 0.62, 95% CI 0.41- 0.94). The evidence base for premedication before conventional aeroallergen immunotherapy is limited; however, one study suggested some benefit with fexofenadine

pretreatment 2 hours before conventional immunotherapy using cedar pollen or dust mite allergens.(46) The JTFPP is unable to exclude the possibility that specific situations and subpopulations may exist where premedication could provide benefit to immunotherapy in those with concomitant risk factors (e.g., in situations associated with higher rates of systemic reactions). As such, clinicians may reasonably consider immunotherapy premedication in other clinical circumstances associated with a high level of perceived risk of anaphylaxis or comorbidities associated with greater anaphylaxis fatality risk (such as underlying cardiovascular disease or use of beta-blockers), although high-certainty evidence is lacking to support this practice.

Additional Good Practice Statements

Good Practice Statement # 1: Administer epinephrine as the first line pharmacotherapy for uniphasic and/or biphasic anaphylaxis.

Good Practice Statement #2: Do not delay the administration of epinephrine for anaphylaxis, as doing so may be associated with higher morbidity and mortality.

Good Practice Statement #3: After diagnosis and treatment of anaphylaxis, all patients should be kept under observation in a setting capable of managing anaphylaxis until symptoms have fully resolved.

Good Practice Statement #4: All patients with anaphylaxis should receive education on anaphylaxis, including avoidance of identified triggers, presenting signs and symptoms, biphasic anaphylaxis, treatment with epinephrine, and the use of epinephrine auto-injectors and referral to an allergist. Of note, there may be some circumstances where self-injectable epinephrine is deferred (i.e., resolved anaphylaxis and drug trigger with high likelihood of successful avoidance) and shared decision-making may play a role in some circumstances.

Suggested Key Clinical Advice

- Severe anaphylaxis and/or the need for more than one dose of epinephrine to treat anaphylaxis are risk factors for biphasic anaphylaxis. Additional risk factors include wide pulse pressure, unknown anaphylaxis trigger, cutaneous signs and symptoms, and drug trigger in children.
- Extended observation is suggested for patients with resolved severe anaphylaxis and/or those with need for more than one dose of epinephrine.
- Antihistamines and/or glucocorticoids are not reliable interventions to prevent biphasic anaphylaxis but may be considered as secondary treatment.
- Evidence supports a role for antihistamine and/or glucocorticoid premedication in specific chemotherapy protocols and rush aeroallergen immunotherapy.
- Evidence is lacking to support the routine use of antihistamines and/or glucocorticoid premedication in patients receiving low- or iso-osmolar contrast material to prevent recurrent radiocontrast media anaphylaxis.
- Administer epinephrine as the first-line pharmacotherapy for uniphasic and/or biphasic anaphylaxis.
- Do not delay the administration of epinephrine for anaphylaxis.
- After diagnosis and treatment of anaphylaxis, all patients should be kept under observation until symptoms have fully resolved.
- All patients with anaphylaxis should receive education about anaphylaxis, risk of recurrence, trigger avoidance, self-injectable epinephrine, and thresholds for further care and be referred to an allergist for follow-up evaluation.

INTRODUCTION AND DIAGNOSIS

Anaphylaxis is an acute, life-threatening systemic allergic reaction associated with different mechanisms, triggers, clinical presentations, and severity.⁽¹⁾ The wide range of clinical manifestations and complex underlying mechanisms of anaphylaxis contribute to the difficulty in establishing a definition and diagnostic criteria for anaphylaxis. The poor sensitivity of confirmatory laboratory testing further complicates accurate diagnosis of anaphylaxis. Furthermore, a lack of use of established diagnostic criteria plays a major role in the under-diagnosis and inconsistent management of anaphylaxis. (47-49) In 2005, a multinational and multidisciplinary workgroup that included allergist-immunologists, emergency physicians, pediatricians, critical care specialists, internists and key stakeholders was assembled by the National Institutes of Allergy and Infectious Diseases (NIAID) and Food Allergy and Anaphylaxis Network (FAAN) to address the need for universally accepted anaphylaxis diagnostic criteria. The diagnostic criteria proposed by this workgroup were published in 2006

(22) and describe anaphylaxis as likely when one of three criteria are fulfilled: (1) acute onset of an illness (minutes to hours) with involvement of the skin, mucosal tissue, or both with either respiratory involvement or reduced blood pressure / associated symptoms of end-organ dysfunction; or (2) two or more of the following that occur rapidly after exposure to a likely allergen for the patient, including (a) involvement of skin-mucosal tissue, (b) respiratory involvement, (c) reduced blood pressure or associated symptoms, or (d) gastrointestinal symptoms; or (3) reduced blood pressure as a result of exposure to a known allergen trigger. These criteria have since been recognized and endorsed by the American Academy of Allergy, Asthma, and Immunology (AAAAI), American College of Allergy, Asthma, and Immunology (ACAAI)(50), and the World Allergy Organization. (51)

The NIAID/FAAN criteria were developed to “provide the emergency responder or treating physician with a relatively simple and rapid means to make the diagnosis of anaphylaxis.” The criteria (shown in Figure 1) incorporate features related to the onset of the reaction, exposure to an inciting trigger, as well as signs and symptoms. Importantly, using these criteria, anaphylaxis can be identified among patients lacking hemodynamic compromise, patients lacking cutaneous manifestations, and patients with mild presentations (for example, those with a rash and vomiting after exposure to a likely trigger). The NIAID/FAAN anaphylaxis diagnostic criteria were prospectively validated in patients seeking care for an allergic reaction and possible anaphylaxis in an emergency department setting and were shown to provide a positive likelihood ratio of 3.26 and negative likelihood ratio of 0.07. (3) Thus, although these criteria are helpful clinically, they should not replace clinician judgment. It is important to recognize, as acknowledged by those who developed the criteria, that epinephrine administration is not limited to those patients meeting the NIAID/FAAN diagnostic criteria. For example, a patient undergoing immunotherapy who immediately develops generalized urticaria after an injection may appropriately receive epinephrine if impending anaphylaxis is suspected, despite the fact that the diagnostic criteria for anaphylaxis have not yet been met. In such instances, management relies heavily on clinical judgment. However, the role of preemptive epinephrine prior to the development of anaphylaxis has been questioned.(52-54) Isolated allergen associated urticaria, which may respond to antihistamines, should be distinguished from anaphylaxis for which prompt epinephrine administration is indicated. Additionally, in the emergency department, a

stable, asymptomatic patient who provides a history of symptoms meeting NIAID/FAAN anaphylaxis diagnostic criteria but whose symptoms have completely resolved prior to arrival, should still be given an anaphylaxis diagnosis despite the fact that epinephrine administration is no longer acutely indicated.

Biphasic anaphylaxis is a well-recognized potential complication of anaphylaxis and has been defined as recurrent anaphylaxis *after complete improvement*; this has been reported to occur between 1 to 78 hours after the onset of the initial anaphylactic reaction, and this must be clinically differentiated from a reaction that does not fully respond to initial treatment and persists or quickly returns. (35, 36, 55, 56) Some (although not all) earlier studies of biphasic reactions, prior to the NIAID/FAAN criteria, which included patients with severe anaphylaxis, reported rates of biphasic anaphylaxis as high as 20%. (37-39) More contemporary studies of biphasic anaphylaxis utilizing the NIAID/FAAN diagnostic criteria or similar criteria for diagnosis of both the initial anaphylactic reaction and the biphasic reaction have demonstrated lower rates of biphasic reactions closer to 4-5% (range 0.18% - 14.7%) (40-44) No studies have systematically evaluated therapies for the second phase reaction; however, therapy for the second phase is similar to the initial phase. (36) Optimal duration of extended observation following resolution of biphasic anaphylaxis is unknown.(36) One recent meta-analysis of twelve studies including 2,890 adult patients with anaphylaxis suggested the pooled negative predictive value (NPV) of 1-hour observation was 95%, with an NPV for biphasic anaphylaxis after ≥ 6 hours of observation (following resolved anaphylaxis) of 97.3%.(57) A recent cost-effectiveness analysis suggested that extended observation could be cost-effective, i.e., not exceeding \$10 million per death prevented, at high rates of fatality risk reduction (76%) from an additional 5 hours of asymptomatic observation.(58)

EPIDEMIOLOGY AND RISK FACTORS

Prevalence estimates of anaphylaxis vary widely, and many studies suggest that the prevalence is increasing, particularly in developed countries. The lifetime prevalence of anaphylaxis has been estimated at 1.6% to 5.1 % (1, 4, 11), with an incidence rate of 42 per 100,000 person-years, but estimates may be susceptible to ascertainment bias. (59) Data from a European anaphylaxis registry revealed that over one quarter of cases occurs in patients under 18 years of age. (60) As

indicated in an international consensus on (ICON) anaphylaxis document, cardiovascular disease and asthma are well-recognized risk factors for severe anaphylaxis. (5) Additional risk factors potentially associated with severe or fatal anaphylaxis include older age, mast cell disorder, and beta-blocker or ACE inhibitor use. (6-9) Atopy is a risk factor for anaphylaxis triggered by food, exercise and latex. (61) While one survey of Turkish beekeepers (n = 29 subjects with systemic reactions, 9 with anaphylaxis, out of 444 subjects with a history of a sting exposure in the prior 12 months) suggested atopic disease as a risk factor for systemic reactions (OR 3.3, 95% CI 1.2-8.7) (62), it has not been otherwise established that atopic disease increases the risk for Hymenoptera sting-associated anaphylaxis.

Medications and stinging insect venom are leading causes of adult anaphylaxis (1), while foods and stinging insect venom are the most common triggers of anaphylaxis in children and adolescents. (10-12) In the middle-aged adult population, anaphylaxis most often occurs at home. (1) Medications most frequently implicated in the United States are antibiotics, NSAIDs, immunomodulators, and biological agents. (63) In contrast, in Portugal a review of 313 patients with a history of drug-induced anaphylaxis revealed the most common trigger to be NSAIDs, followed by antibiotics and anesthetics (64). An anaphylaxis registry of German-speaking countries (Germany, Austria and Switzerland) reported the most common trigger to be insect venom, followed by food and drugs, respectively (when all age groups are considered). (65) In studies of food-induced anaphylaxis, incidence ranges from as low as 1 per 100,000 to as high as 70 per 100,000 have been reported by using data from hospitalizations, emergency department visits, and medical record reviews. (66-68) When examining anaphylaxis etiology, the proportion due to foods varied between 13-65% depending on age and study. (66-71) The specific trigger may not be identified during the acute anaphylactic event or in subsequent evaluations, especially if the reaction is occurring for the first time, and the trigger may only be identified retrospectively at a follow-up evaluation. For example, one study of ED records in Florida found that only 37% of patients could pinpoint a specific trigger upon initial presentation. (72) Furthermore, initial suspected culprits are often not confirmed on subsequent allergy testing, which suggests caution in presumption of potential triggers and supports the necessity of follow-up evaluation by an allergy specialist.(47, 73, 74)

With respect to treatment, delayed use of epinephrine has been associated with increased risk for fatality, and several observational studies and case-reports series suggest a continued disparity between the diagnosis of anaphylaxis and frequency of appropriate epinephrine treatment. (48, 75-88) In one study of drug-induced anaphylaxis evaluated and managed in an emergency department, only 8% of patients received epinephrine. (76) While early epinephrine is the bedrock of anaphylaxis management, anaphylaxis fatality is fortunately a rare outcome. The overall prevalence of fatal anaphylaxis in recent years in the United States and United Kingdom (UK) is between 0.47 to 0.69 per million persons. (8, 9, 28-30) The 3 leading causes of fatal anaphylaxis are drugs (29%-58.5%) (8, 28, 89, 90), insect stings (3.3%-54%)(8, 28, 89, 90), and food (2%-6.7%). (8, 28, 90) While anaphylaxis-related hospitalizations have increased, general case fatality rates have been stable in the range of 0.25%-0.33% of hospitalizations or ED presentations for anaphylaxis. (31) However, in contrast to other causes of fatal anaphylaxis, drug-induced anaphylaxis rates have increased. (8) In the United Kingdom fatal drug anaphylaxis has been reported to be mostly due to general anesthetics, (91) whereas antibiotics predominate in Australia (28) and France. (92) A review by Pichichero et al. described the population incident risk of anaphylaxis to penicillin between 0.004% to 0.015% with a fatality rate of 0.0002% to 0.0015%. (93) The UK fatal anaphylaxis registry reported that while those dying from food anaphylaxis often have a prior history of a food reaction, those with fatal Hymenoptera venom and drug anaphylaxis usually do not. (91, 94) Additional observational case-series have shown patients dying from food anaphylaxis often have a history of previous food-induced allergic reactions. (28, 38, 95) Notably, respiratory arrest may occur more commonly with foods (86% of fatalities in the UK registry), with shock more common in fatalities due to medications and venom reactions. (91) It is important to note that most fatal reactions are unpredictable and statistically occur very rarely; however, appropriate trigger identification after recovery from a severe reaction may decrease the risk for a subsequent severe reaction, including fatality. (94) Referral to an allergy specialist after recovery from anaphylaxis is recommended in order to confirm the diagnosis, evaluate for potential triggers, and educate the patient on the risk of future reactions and measures to reduce that risk, including self-injectable epinephrine access and autoinjector education.

BURDEN OF DISEASE

Food-induced Anaphylaxis

Prevalence

Food allergy (or presumed food allergy) is a leading cause of anaphylaxis presenting to US emergency departments, with an estimated 30,000 cases per year. (96) Food allergy (assessed through a nationally-representative internet self-report study) is estimated to affect up to 8% to 11% of the United States population. (13-15) Food allergens may be attributed to upwards of 50% of emergency department reported anaphylaxis cases in developed countries, including the United States. (97)

Trends

According to the Centers for Disease Control and Prevention, rates of food allergies in US children increased by about 50% between 1997 and 2011. (98) Whereas Clark et al. (99) reported stable trends in the frequency of US emergency department visits for food allergy in the period of 2001-2009, they did find a statistically significant decline among individuals ≥ 18 years of age. In a retrospective cohort study of 37 pediatric hospitals from 2007-2012 (100), an increasing rate of food-induced anaphylaxis (FIA)-related ED visits was reported but without any increase in the proportion of ED patients hospitalized or admitted to the ICU. This decrease in the proportional rate of ED visits to utilization of inpatient and ICU facilities may be due to the increased utilization of ED or inpatient observation units, as approximately 36% of US EDs reported having observation units in 2007. (101) More recently, Motosue et al. (102) reported a fourfold increase in FIA-related ED visits for adolescents from 2005 through 2014.

Economic Burden

Food allergies can burden patients and families by affecting finances, social relationships, and personal perceptions of health. (103) Patients with food allergies and their families experience anxiety and other stresses that affect quality of life given the risk of potentially severe reactions and inability to completely control these risks. [16] The impact of food allergies is not limited to just the patients and their families but can also lead to a significant economic effect on society and the health care system. Food-induced anaphylaxis can result in prehospital emergency care by ambulance personnel, ED visits, hospitalizations, or even death. Mild as well as more severe

allergic reactions require comprehensive evaluation, including diagnostic studies and regular follow-up outpatient visits. (104)

Patel et al. in 2011 (104) estimated total annual direct medical costs of food allergy and anaphylaxis at \$225 million (2007 US dollars). Office visits accounted for 52.5% of direct medical costs, and the remaining was split between ED visits (20%), inpatient hospitalizations (11.8%), outpatient department visits (3.9%), ambulance runs (3%), and epinephrine devices (8.7%). Children accounted for 46.6% of the total inpatient costs, 31.5% of the ED visit costs, 67.3% of the office visit costs, and 97.7% of the total outpatient department visit costs. US national estimates for epinephrine auto-injector use after a suspected reaction triggered by a food allergy obtained from the published literature suggest that between 30% and 86% of patients at risk for a severe allergic reaction are prescribed an epinephrine auto-injector and have it available when needed. (95, 105) Prevalence estimates and mean costs for office, inpatient, and ED visits have the largest effect on total societal direct costs. Indirect costs have been estimated at \$115 million (104) with morbidity-related costs accounting for 85% of indirect costs, resulting from disease-related sick days (lost productivity and wages). (104) Simulations from probabilistic sensitivity analyses have generated mean annual direct costs of \$307 million and indirect costs of \$203 million in the US. (104) While evidence suggests that activation of emergency medical services (EMS) and prolonged ED observation of resolved food anaphylaxis is a low-value practice, prompt EMS activation is appropriate for patients who do not immediately completely respond to timely epinephrine, or for recurrence of symptoms. (106)

Drug-induced Anaphylaxis

Adverse drug reactions (ADR) may affect up to one tenth of the general population and up to 20% of all hospitalized patients. More than 10% of all ADR are drug hypersensitivity reactions (DHR). In a systematic review, 53 observational studies were synthesized to estimate that 8% of patients self-report drug allergy, and that 11% of self-reported drug allergy is reported to be anaphylaxis. (107) The most common DHR involves antibiotics such as penicillins, cephalosporins, and sulfonamides, aspirin, and other non-steroidal anti-inflammatory drugs. DHR can be severe and life threatening and are associated with significant mortality rates. The incidence of anaphylaxis due to medication triggers is increasing over time. (59) DHR have a

significant socioeconomic impact related to both direct costs (management of reactions and hospitalizations) and indirect costs (missed work/school days; alternative drugs); however, there is, overall, a major gap in the literature for summarizing the economic burden of DHR. (16) A US nationwide cross-sectional telephone self-reported survey reported a prevalence of anaphylaxis in the general population of 1.6% with medications being the most common trigger (35%). (1) Excluding pediatric cohorts (where food is the most common trigger), medications are the most frequent cause of fatal anaphylaxis in reports from the United States, as well as the United Kingdom, Australia and New Zealand. (8, 16) Perioperative anaphylaxis presents unique challenges. Recently, the 6th National Audit Project of the Royal College of Anaesthetists (NAP6) reviewed 266 reports of Grade 3-5 anaphylaxis across all UK NHS hospitals over the course of 1 year, reporting prompt recognition and treatment of anaphylaxis in 83% of cases. (108) Cardiac arrest occurred in 15% of cases reviewed, with fatalities occurring in 3.8% of patients. (108) Risk factors for perioperative anaphylaxis fatality included older age and cardiovascular disease. (108)

ADR from RCM occur less frequently than prior to 1990 when patients received high-osmolar, ionic RCM. Prior ADR to RCM can contribute to burden of disease by creating medical complexity associated with premedication; however, while glucocorticoid premedication has become common practice for patients with prior RCM hypersensitivity, evidence supporting the use of prophylaxis in high risk patients receiving low or iso-osmolar, non-ionic contrast agents is lacking. ADR associated with RCM do not relate to iodine, and the term iodine allergy should not be used in the context of RCM reactions.

Insect-venom Anaphylaxis

Hymenoptera venom allergy (HVA) describes both anaphylactic and non-anaphylactic hypersensitivity reactions to stings. Reaction types include sting-induced large local (LL) or systemic allergic reactions. LL reactions last over 24 hours in which signs and symptoms are confined to tissues contiguous with the sting site. In contrast to LL reactions, acute onset systemic reactions involve generalized signs and symptoms and include a spectrum of manifestations, ranging from mild urticarial reactions to life-threatening anaphylaxis. It is estimated that 2-3% of adults and up to 1% of children have had a systemic reaction to a sting,

and LL reactions occur in more than 5% of adults. (109) In a review of 10 studies published between 2001-2009, Bilo et al. found that 23% of 2577 cases of anaphylaxis were caused by an insect sting.(110) Fatal anaphylaxis can result from HVA; the reported average of 40 deaths per year in the US is highly suspected to underestimate the true event rate.(53, 111) Even the first reaction can be fatal, but no validated screening test is available because of the very high frequency of asymptomatic sensitization (more than 20% of adults have detectable venom-specific IgE).(112, 113) Patients often express fears of anaphylaxis because of their family history or atopic history, but HVA has not been shown to be familial.(112)

Patients often present with concern about potential anaphylaxis after having LL or generalized cutaneous systemic reaction.(114) The morbidity of living with HVA may be underestimated.(114) Fear of life-threatening anaphylaxis whenever one is outdoors, and the burden of ensuring that injectable epinephrine is readily accessible at all times, affects the daily activities and level of stress in affected individuals.(115) Even people with non-anaphylactic (LL or cutaneous systemic) reactions to stings share the same concerns and can be impacted as severely as the patients with anaphylactic reactions. (114) These concerns persist in these mild reactors even though their risk of severe anaphylaxis is quite low, and the prescription of injectable epinephrine is not cost-effective in such cases.(53) Whether it is mild or severe, HVA impairs long-term quality of life (QOL) and may be a cause of substantial socioeconomic impairment.(116) HVA can impact career choices, especially in beekeepers, groundskeepers, gardeners, and greenhouse workers.(117) HVA has important adverse consequences in terms of employment, earning capacity, and leisure and sporting activities. (117) For these reasons, discussion of HVA usually includes not only anaphylactic, but also mild systemic and non-anaphylactic reactions.(109)

PATHOGENESIS OF ANAPHYLAXIS

Data regarding pathophysiologic mechanisms and effector cells are limited on humans but mouse models have offered some insight.(118) IgE binding and cross-linking of the high-affinity receptor FcEpsilonRI on the surface of mast cells and basophils is an important mechanism in many cases of anaphylaxis. This causes the immediate release of preformed mediators, as well as *de novo* synthesis of inflammatory mediators.(18) Interestingly, some patients with life-

threatening anaphylaxis have low or undetectable circulating allergen-specific IgE and mouse models have demonstrated a potential role for IgG-dependent anaphylaxis.(19) Furthermore, the complement system, anaphylatoxins C3a, C4a, C5a, and neutrophils (119) have also been shown to be involved in anaphylaxis in human subjects. Lastly, a newly recognized form of anaphylaxis occurring in patients receiving chemotherapy suggests a mixed type of reaction with both features of IgE and non-IgE dependent anaphylaxis.(120) Cytokine storm-like reactions have recently been described for patients with chemotherapy-induced anaphylaxis.(120)

Animal and human studies have linked multiple mediators to the signs and symptoms of anaphylaxis. The most important effector cells involved in anaphylaxis are mast cells, but basophils, neutrophils, monocytes, macrophages, and platelets have also been implicated.(118, 121) Histamine is an important mediator of anaphylaxis, and studies have demonstrated that intravenous histamine can induce symptoms of anaphylaxis, including flushing, airway obstruction, systemic hypotension and tachycardia.(122, 123) While histamine appears to play a significant role, other mediators have also been implicated. Therefore, pharmacologic targeting of histamine alone, e.g., administration of antihistamines, is not appropriate and is thus considered second-line treatment for anaphylaxis and should not be used in place of epinephrine. Given the slow onset of antihistamine agents, ineffectiveness in treating cardiovascular and respiratory symptoms such as hypotension or bronchospasm, and the inability to stabilize or prevent mast cell degranulation, these agents should not delay definitive treatment of anaphylaxis.

Elevated tryptase levels have been less consistently found in patients presenting with anaphylaxis, particularly in cases triggered by allergic response to food.(124) While the positive predictive value of an elevated serum tryptase is high (93%), the negative predictive value of a serum tryptase is low (17%).(2) However, several studies have reported an association between elevation of tryptase and severity of anaphylaxis from food and other causes.(125-129) In a study of prospectively recruited ED patients with anaphylaxis, mediators in addition to tryptase correlated with hypotension, a symptom of severe anaphylaxis.(20) These included histamine, IL-6, IL-10 and TNF-receptor 1.(20, 21) Several other mediators have been shown to be important in murine models of anaphylaxis, but their contribution in human anaphylaxis has not

been clearly demonstrated – these include PAF (platelet-activating factor), CysLTs, and anaphylatoxins. PAF is a lipid-derived mediator elevated in serum of patients with cold urticaria during cold challenge.(130) The role of PAF is supported by studies demonstrating that injection of PAF into the skin of healthy volunteers can induce early wheal and flare and late-phase flare responses.(131) These responses are not associated with increased dermal histamine levels, (132) suggesting that the effects of PAF are independent of mast cell degranulation. While some evidence suggests antihistamine attenuation of experimental intradermally injected PAF-mediated wheal and flare response, antihistamines had no protective effect against PAF-mediated bronchoconstriction during PAF bronchial provocation.(133) Associations have been noted with increased PAF in cases of anaphylaxis. (125) In one study, increased PAF levels demonstrated the highest correlations with severe anaphylaxis (when compared to histamine and tryptase levels), with PAF elevations in 20%, 67%, and 100% of patients with grades 1, 2, and 3 allergic reactions, respectively (grade 1: acute allergic reactions with cutaneous signs and symptoms only; grade 2: mild to moderate anaphylaxis; grade 3: severe anaphylaxis).(134) Data to support the role of CysLTs stem from studies showing that intradermal injection of LTB₄, LTC₄ and LTD₄ can induce wheal and flare responses (135) and aerosolized LTC₄ and LTD₄ can trigger bronchoconstriction. (136, 137) In a small study of insect sting challenges, elevated serum C3a was associated with severe anaphylaxis.(138) Additional studies suggest that specific allergens such as peanut can contribute to anaphylaxis by activating complement,(139) and tryptase can generate anaphylatoxins under specific conditions.(140) These findings are important because they demonstrate some of the pathophysiologic explanations that underpin why antihistamine use may be ineffective in management of anaphylaxis.

Less is understood about the pathophysiology of protracted reactions.(141) A prospective study of anaphylaxis cases seen in emergency departments in Australia reported delayed deterioration (defined as any worsening of the reaction while under observation in the ED) in 17% of reactions. (21) Of the delayed deteriorations, 53% were treated with epinephrine and 69% of these started within 4 hours of arriving in the ED. A delay in the administration of epinephrine or too small a dose of epinephrine are considered risk factors for delayed deterioration, though the “optimal” timeframe for epinephrine delivery to prevent delayed deterioration has not been established.(36, 142) Principal component analysis revealed an association between delayed

deterioration with elevated levels of histamine, tryptase, IL-6, IL-10 and TNF-receptor 1 (peak concentrations on serial assessment at ED arrival, 1 hour later, and discharge). These are the same mediators found to be correlated with severe anaphylaxis, (20, 21) lending support to the hypothesis that severity of the initial reaction may be intrinsically linked to protracted symptoms.

TREATMENT STRATEGIES AND PARADIGMS

Role of Epinephrine

An understanding of the pathophysiology and effector cells involved in anaphylaxis reinforces the recommendation to use epinephrine as first-line treatment, while antihistamines and glucocorticoids are considered solely second-line therapy. Anaphylaxis is a clinical diagnosis that can present with any combination of symptoms affecting various organ systems. (22) The clinical presentation and severity of symptoms differ among individuals and may change over time within the same individual.

There is international consensus that the most effective treatment for anaphylaxis is epinephrine, with evidence supporting clinical guidelines based on observational studies, extrapolation from retrospective case reports, and limited clinical trials. However, a thorough understanding of the pathophysiology of anaphylaxis, existing evidence, and mechanisms of action for various medications provides the basis for treatment recommendations.

Epinephrine administered intramuscularly (in a dose of 0.01 mg/kg of a 1:1,000 (1mg/mL) solution to a maximum of 0.5 mg in adults and 0.3 mg in children) into the anterolateral thigh is the first-line treatment for anaphylaxis.(22) The availability of newer auto-injector dose formulations (0.1mg for infants) allows greater epinephrine dosing accuracy; however, a 0.15 mg intramuscular dose is also widely prescribed for infants at risk for anaphylaxis. (105, 143) Particularly in settings where a 0.1mg autoinjector dose is not available, the speed and precision gained from a 0.15 mg autoinjector dose compared with having caregivers draw up doses using an ampule and syringe method may justify trade-offs in dosing accuracy, especially in infants weighing more than 7.5 kg. (105, 143) Depending on response to the initial injection, the dose can be repeated every 5 to 15 minutes. (61) Epinephrine is a nonselective agonist of all

adrenergic receptors, which are present within every organ system affected by anaphylaxis.(26) By increasing peripheral resistance via alpha-1 receptors and increasing cardiac output via beta-1 receptors, epinephrine treats hypotension, shock, urticaria, angioedema, and upper airway mucosal edema. Epinephrine can reverse bronchoconstriction and treat lower respiratory symptoms through its effect on beta-2 adrenergic receptors. In addition, epinephrine has been shown to activate beta-2 adrenergic receptors on mast cells and basophils and prevent additional release of histamine and other mediators.(27) Thus, epinephrine not only treats all symptoms associated with anaphylaxis but also can prevent the escalation of symptoms.

US, European, and international anaphylaxis guidelines recommend intramuscular epinephrine in the anterolateral thigh rather than subcutaneous epinephrine in the deltoid region of the upper arm for the treatment of anaphylaxis. (5, 75, 144) This is based upon a limited number of pharmacodynamic studies in volunteers (not in anaphylaxis) which demonstrated that when administered intramuscularly into the thigh, epinephrine works rapidly and reaches maximal pharmacodynamic efficacy within 10 minutes of injection, though no proof exists that subcutaneous delivery is not effective.(26) A small study conducted in children 4-12 years of age demonstrated a higher mean peak plasma concentration (2136 ± 351 vs. 1802 ± 214 pg/ml) and faster onset of action (8 ± 2 vs. 34 ± 14 minutes) for intramuscular compared with subcutaneous administration of epinephrine.(145) A similar study in adult males also demonstrated higher mean peak plasma concentration for intramuscular epinephrine in the thigh (9722 ± 4801 pg/ml) compared with both intramuscular administration in the deltoid (1821 ± 426 pg/ml) and subcutaneous administration in the deltoid region (2877 ± 567 pg/ml).(146) From these limited data, experts have advocated the intramuscular rather than the subcutaneous route of delivery, though for years subcutaneous delivery was the mainstay, without any evidence that it was not effective. Importantly, studies comparing intramuscular and subcutaneous injections in the thigh have not been completed. (146) Furthermore, the studies described above were conducted in healthy adults and children who were not experiencing anaphylaxis and were taken from small samples, and thus the generalizability of these findings to the clinical setting has not been established. (144) There are also no data that have evaluated if the peak plasma concentration, the time to peak plasma concentration, or the area under the curve is the most important feature to effective epinephrine delivery in anaphylaxis. For pediatric patients, administration of

epinephrine into the anterolateral thigh is preferred to the deltoid region as this likely decreases the risk for inadvertent intraosseous administration due to needle length. (147-150) Efforts to develop alternative epinephrine delivery routes (such as sublingual and intranasal epinephrine formulations) are underway. (151-154) Intravenous administration of epinephrine is also not recommended as first-line treatment of acute anaphylaxis, even in a medical setting, due to risk for cardiac adverse events such as arrhythmias and myocardial infarction.(155) However, for patients with inadequate response to intramuscular epinephrine and intravenous saline, intravenous epinephrine can be given by continuous infusion by micro-drip, preferably using an infusion pump in a monitored hospital setting. In more remote settings when immediate treatment is required on an outpatient basis, one might consider adding 1 mg (1 mL of 1:1,000) of epinephrine to 1,000 mL of 0.9 NL saline; starting the infusion at 2 mcg/min (2 mL/min, equivalent of 120 mL/h) and increase up to 10 mcg/min (10 mL/min, equivalent of 600 mL/h); titrating the dose continuously according to blood pressure, cardiac rate, and oxygenation. Although potential epinephrine-related adverse events must be balanced in high risk patients (i.e. elderly patients with multiple comorbidities and patients with complex congenital heart disease, pulmonary hypertension, prior epinephrine associated cardiomyopathy), there is no absolute contraindication to epinephrine use in the treatment of anaphylaxis. (61, 156) Providers should be aware of the need to appropriately counsel patients when using epinephrine. It is important to discuss technique of administration and the need to appropriately restrain young children and infants to avoid inadvertent epinephrine needle injuries. (157) While there is a lack of evidence to inform treatment approaches to biphasic anaphylaxis, the same treatment recommended for initial anaphylactic events applies to the biphasic response, with prompt epinephrine the cornerstone of management. (36)

An interesting conundrum surrounds those individuals who recover fully without sequelae despite never receiving treatment for anaphylaxis. Variations in the cause and severity of their symptoms and metabolism of mediators are likely involved but this remains poorly understood.(118) Given the inability to identify which individual is at risk for life-threatening or fatal anaphylaxis, particularly in the acute setting, and the well-recognized significant benefit from rapid administration of epinephrine, treatment should never be withheld for ongoing symptoms and this should be advocated as a best-practice strategy.(22) The mortality from

anaphylaxis, though real, is remarkably low at less than 0.5% per episode of anaphylaxis.(158) Herein lies the anaphylaxis paradox – patients having anaphylaxis may survive despite lack of treatment (or “inappropriate” treatment), but delay in treatment is widely presumed to be associated with death (though limited by lack of studies that compare fatality to non-fatality situations where provoking conditions and treatment factors were identical to determine a relative risk).(31, 158)

Role of Antihistamines and Glucocorticoids

Antihistamines are often included as adjunctive therapy for cutaneous signs and symptoms associated with anaphylaxis but should not be administered before, or in place of, epinephrine. Histamine is an important mediator released during anaphylaxis and can cause anaphylaxis when administered intravenously or when ingested (i.e, scombroid poisoning).(122, 159) There are four histamine receptors located through the body (H1, H2, H3, and H4), but H1 receptors are the most clinically relevant during anaphylaxis. H2 receptors are mostly found within the gastrointestinal tract with limited distribution in the vascular smooth muscle cells and play a minor role in the pathophysiology of anaphylaxis. H1 and H2 antihistamine medications are widely available and often administered concurrently for the treatment of anaphylaxis, without supporting data for their efficacy, in particular with H2 antihistamines. Compared with older first generation H1-antihistamines, second generation H1-antihistamines have a longer duration of action, less anticholinergic effects, less sedation, yet similar onset of action.(32) Antihistamines act as inverse agonists at histamine receptors; they are effective therapy for patients with urticaria and can treat many of the cutaneous signs and symptoms associated with anaphylaxis including pruritus, flushing, and urticaria.(160) Unlike epinephrine, antihistamines are poorly effective in treating cardiovascular and respiratory symptoms such as hypotension or bronchospasm when used acutely as monotherapy. Epinephrine is the first-line treatment of anaphylaxis because it has a faster onset of action and more appropriate and robust pharmacologic action compared with antihistamines. When given orally, the onset of action of antihistamines may occur within 30 minutes (161) but peak plasma concentrations are not reached until 60-120 minutes, and an additional 60-90 minutes may be necessary for diffusion of the medication into extravascular tissues to exert maximal effect. (32, 162, 163) Given the rapid and potentially fatal nature of anaphylaxis, the timing of onset for antihistamines is considered

too slow and could lead to incomplete or ineffective treatment. Furthermore, antihistamines lack the vasoconstrictive, bronchodilatory, ionotropic, and mast cell stabilization properties of epinephrine. While intravenous administration of H1-antihistamines may be used in a medical setting or by emergency medical services, it should never be utilized in place of timely intramuscular epinephrine administration, but it may have an adjunct role in treatment after epinephrine has been administered.(164)

Glucocorticoids are also frequently used as adjunctive (or sometimes primary) therapy in the treatment of anaphylaxis but also should not be administered prior to, or in place of, epinephrine. Glucocorticoids have no proven role in the treatment of an acute reaction as they work with slow onset of action by binding to the glucocorticoid receptor on cell membranes, translocating the glucocorticoid/glucocorticoid receptor complex to the nucleus, and inhibiting gene expression and production of new inflammatory mediators. They are non-selective, ineffective in treating acute symptoms, and have multiple adverse effects related to high doses and prolonged use. There is a scarcity of data demonstrating the efficacy of glucocorticoids in the treatment of acute anaphylaxis despite common anecdotal administration in this setting, and no studies have clearly established their benefit when combined with epinephrine and/or antihistamines.(34, 164) Studies investigating the use of glucocorticoids for treatment of anaphylaxis have shown that their use is associated with reduced length of hospital stay but have not shown any benefit of preventing return visits to the emergency department following discharge.(165, 166)

Given the mechanism of action, glucocorticoids may not result in clinical improvement for 4 to 6 hours after administration, regardless of route. Although animal studies and *in vitro* data have demonstrated inhibitory effects within 5 to 30 minutes through up-regulation of anti-inflammatory mediators and by decreasing mast cell mediator release on a cellular level (33, 167), there are no data demonstrating similar rapid onset of action or clinical improvement in human subjects. As such, given the slow onset of action and inability to reverse acute symptoms, it is again emphasized that glucocorticoids have a limited role in the acute management of anaphylaxis.

REVIEW OF EVIDENCE FOR SUPPLEMENTAL THERAPIES IN ANAPHYLAXIS TREATMENT

Despite a lack of clear evidence supporting the use of antihistamines and glucocorticoids in anaphylaxis, these treatments continue to be a part of anaphylaxis management in routine practice. While it is critical to ensure that use of these agents does not delay administration of epinephrine, the question of whether or not use of these therapies adds value in the management of anaphylaxis has not been subjected to rigorous methodologic assessment in previous anaphylaxis practice parameters. To evaluate the role of these supplemental therapies, the JTFPP undertook systematic reviews to better inform practitioners' treatment of anaphylaxis.

Methods & Overview

The Anaphylaxis Workgroup that developed this guideline was composed of volunteers from the AAAAI and the ACAAI with a specific interest in the topic and the guideline process. The JTFPP and Anaphylaxis Workgroup were asked to submit questions regarding "anaphylaxis" that they considered to be of importance for both the clinician and the patient for which currently there was not a clear-cut answer. The workgroup used the Population, Intervention, Comparator, Outcome (PICO) evidence-based framework for formulating each question. (168) After all questions were discussed and informal preliminary searches completed, the workgroup used the modified Delphi process (169, 170) to select and list top questions in priority order prior to presenting them to the AAAAI/ACAAI for consideration. The top questions chosen by the AAAAI/ACAAI were then submitted to the workgroup for Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis.(171)

Literature Search: Design, Inclusion and Exclusion Criteria, and databases

The workgroup agreed to include cohort and observational studies, nonrandomized clinical trials, and articles with multiple case studies provided a comparator was reported. While review articles, guidelines, and editorials were excluded from analysis, they were reviewed to locate primary research studies within the bibliography. The search was limited to human subjects and to articles published in the English language. For each of the questions, the described databases were searched and duplicates removed, the abstracts were uploaded into Covidence (Melbourne, Australia) or Rayyan (Doha, Qatar), web-based software platforms used by guideline writing

groups (e.g., Cochrane Reviews) to streamline the production of systematic reviews. Each abstract was reviewed by two workgroup members or collaborators and categorized as relevant or irrelevant based upon the predetermined inclusion/exclusion criteria. When required, a third workgroup member resolved any disagreement by consensus. For all relevant abstracts, full-text articles were uploaded into Covidence or Rayyan. Two members assessed each full-text article for eligibility for qualitative analysis with any disagreement resolved by consensus of a third member. Supplemental searches were performed to address questions in more targeted areas including prophylaxis to prevent recurrence of anaphylaxis to nonionic low-osmolar or iso-osmolar, radiocontrast media, and prevention of index anaphylaxis with chemotherapeutic agents. The resultant studies were extracted by JTFPP members and methodology groups, who assessed each article to determine if they were appropriate for quantitative meta-analysis. In that each question used varying databases, dates, and inclusion/exclusion criteria, these were discussed within the methodological review for each question.

Certainty Assessment of the Included Studies: Risk of Bias Using GRADE Analysis

An assessment of risk of bias factors (random sequence generation, allocation concealment, blinding adequacy, completeness of data, reporting, and other potential biases) that may contribute to risk of bias was performed by the JTFPP/methodology groups. The workgroups and the JTFPP reviewed draft assessments, applied assessments of clinical importance for each patient-important outcome, and determined an overall certainty of evidence across outcomes. The level of methodologic certainty for the identified literature is summarized after each clinical question.

Certainty of the Body of Evidence Using GRADE Analysis

For GRADE analysis of the certainty of the evidence (171), five areas were evaluated: inconsistency, indirectness, imprecision, risk of bias, and publication bias.

Inconsistency: studies are reviewed in terms of populations, interventions, and outcomes for similarity, or consistency, among the compared studies.

Indirectness: analysis occurs around comparisons, populations, and outcomes among intervention studies. Indirectness in comparisons occurs when one drug is compared with placebo and another drug is compared with placebo, but the researchers do not compare the first

drug and the second drug in a head-to-head comparison. Indirectness in populations means that the population in which the drug was studied does not reflect the population in which the study drug would be used. Indirectness of outcome refers to a primary or secondary outcome that does not exactly measure the intended outcome and thus is not powered for the outcome of choice.

Imprecision: when too few study participants were enrolled or too few events occurred in the study, imprecision is detected as studies do not meet optimal information size (OIS). However, low OIS may be offset by critical vs important outcome or valued trade-off desirable/undesirable consequences. In systematic reviews, if the confidence interval crosses a threshold of 1.0, there will usually be downgrading for imprecision.

Levels of Certainty of Evidence

High (⊕⊕⊕⊕): The team is very confident that the true effect lies close to the estimate of the effect.

Moderate (⊕⊕⊕○): The team is moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low (⊕⊕○○): The team confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.

Very low: (⊕○○○) The team has very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect.

Implications of strong and weak recommendations

The implications of a strong recommendation are:

- For patients—most people in your situation would want the recommended course of action and only a small proportion would not; request discussion if the intervention is not offered
- For clinicians—most patients should receive the recommended course of action
- For policy makers—the recommendation can be adopted as a policy in most situations

The implications of a weak (conditional) recommendation (suggestion) are:

- For patients—most people in your situation would want the recommended course of action, but many would not
- For clinicians—you should recognize that different choices will be appropriate for different patients and that you must help each patient to arrive at a management decision consistent with her or his values and preferences
- For policy makers—policy making will require substantial debate and involvement of many stakeholders

Reaching Workgroup Consensus on Certainty of Evidence, Recommendations, Clinical Statement Profiles and Conclusions

To achieve consensus and resolve any differences in judgment within the workgroup and JTFPP, a modified Delphi method was used. The Delphi method is a structured, interactive, decision-making process used by a panel of experts to arrive at a consensus when there are differing views and perspectives. (169, 170, 172) The workgroup and/or JTFPP members discussed all the answers and were encouraged to modify their answers on the next round(s) of email voting and anonymous “summary of the experts” feedback until a consensus was reached.

Determination of Certainty of Evidence for a specific outcome and across critical outcomes

The certainty of evidence indicates the extent to which one can be confident that an estimate of effect is correct. The GRADE system for evaluating the certainty of evidence (<http://gdt.guidelinedevelopment.org/app>) defines the elements that guideline writing groups need to consider when evaluating the certainty of references that address a specific outcome. These elements include factors that assess the risk of bias and the certainty of evidence as described above, as well as the article design (e.g. randomized controlled trial (RCT) or observation study). Methodology groups may designate a method of rating the certainty of individual references to assist in this analysis. Following a determination of the certainty of each individual reference, the GRADE handbook recommends that in the final analysis for each outcome of interest, the certainty of evidence for the entire group of references should be determined by the guideline writing group, using their collective expert opinion. The outcomes of interest are then categorized as “critical” or “important but not critical” to reaching a decision for a recommendation. For the determination of the “overall certainty of evidence” supporting a

recommendation, all “critical” outcomes are reviewed together, and the lowest certainty grade assigned to any critical outcome of interest will determine the certainty assigned for the “overall certainty of evidence” to support a recommendation.

GRADE: From Certainty in Evidence to Recommendations for diagnosis, treatment, or course of action

The strength of a recommendation indicates the extent to which one can be confident that adherence to the recommendation will do more good than harm. After the certainty of evidence is evaluated, the GRADE analysis continues to consider additional factors before recommending or suggesting in favor or against a certain diagnostic strategy, therapeutic approach, or course of action: balance of desirable and undesirable effects, certainty of evidence, safety of the intervention, cost, likelihood of achieving adherence, acceptability, feasibility, equity, and patient’s preference. The JTFPP primarily focused on the US population when reaching these conclusions. Therefore, the GRADE analysis is not only a system focused on grading the level of evidence but also a much more complete system aimed at formulating recommendations for specific populations. Individual subgroups drafted the recommendations and justifications based on the GRADE analysis. Subsequently, all recommendations were reviewed by the workgroup and JTFPP. Both groups were provided the opportunity to comment, propose changes, and approve or disapprove each statement. Consensus was sought and reached for each recommendation’s direction and strength. Actual or potential conflicts of interest were disclosed semiannually and at the completion of the guideline with transparency maintained during all discussions.

External Review: External peer review was through appointed official reviewers and membership at large of the AAAAI and the ACAAI. All comments were discussed by the JTFPP, and revisions made when the work- group and JTFPP believed this to be appropriate.

TOPIC AREA 1: Identification and mitigation of risk factors for biphasic anaphylaxis

Question 1: What risk factors should clinicians take into consideration in determining the likelihood of biphasic anaphylaxis?

1058

1059 Patients: Adults and children treated for anaphylaxis

1060 Intervention: Any treatment or characteristic associated with a decreased risk of biphasic

1061 anaphylaxis including medication or other trigger; epinephrine, antihistamine, glucocorticoid, or

1062 other treatment; age, severity, physical examination finding, or other patient characteristic

1063 Comparator: Dichotomous comparator of characteristic under evaluation

1064 Outcome: Occurrence of biphasic anaphylaxis

1065

1066 **Background:** A prior single-center review of biphasic anaphylaxis in 103 patients suggested

1067 biphasic reactions were more common in patients who received less epinephrine ($p=0.048$) and

1068 possibly less glucocorticoid ($p=0.06$) treatment.(39) A systematic review by Lee et al. (43)

1069 found twenty-seven observational studies that reviewed predictors of biphasic anaphylactic

1070 reactions. Of the studied predictors, food as an anaphylactic trigger was associated with a

1071 decreased risk of a biphasic reaction, $OR = 0.62$, 95% CI [0.4, 0.94], and the ‘unknown’

1072 anaphylactic trigger was associated with increased risk of a biphasic reaction, $OR = 1.72$, 95% CI

1073 [1.0, 2.95]. An initial presentation with hypotension was also associated with an increased risk of

1074 a biphasic reaction, $OR = 2.18$, 95% CI [1.14, 4.15].

1075

1076 **Study characteristics.** The search for suitable studies was completed by the JTFPP. In the

1077 search 283 articles were identified after removal of duplicates, with full text eligibility assessed

1078 in 112 studies, and 32 studies included in the quantitative evidence synthesis (Figure 2 depicts

1079 the Topic 1 Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)

1080 diagram).

1081

Question 1 Included Studies:

Alqurashi 2015 (42); Brady 1997 (173); Brazil 1998 (174); Brown 2013 (21); Calvani 2011 (175); Cianferoni 2011 (176); Confino-Cohen 2010 (177); Douglas 1994 (178); Ellis 2007 (39); Grunau 2014 (40); Inoue 2013 (179); Jirapongsananuruk 2007 (180); Ko 2015 (181); Lee 2013 (182); Lee 2017 (59); Lertnawapan 2011 (183); Manivannan 2014 (184); Manuyakorn 2015 (185); Mehr 2009 (186); Noone 2015 (187); Orhan 2011 (188); Poachanukoon 2006 (189); Rohacek 2014 (41); Sampson 1992 (38); Scranton 2009 (190); Smit 2005 (191); Sricharoen 2015 (55); Stark 1986 (37); Vezir 2013 (192); Yang 2008 (193)

Key results. Based on very low-certainty evidence, the following associated factors significantly increase the risk of biphasic anaphylaxis: (a) anaphylaxis caused by any drug in patients less than 18 years of age, *Peto OR* = 2.35, 94% *CI* [1.16, 4.76] (b) anaphylaxis caused by an unknown trigger, *Peto OR* = 1.63, 95% *CI* [1.14, 2.33] (c) anaphylaxis symptoms with cutaneous manifestations, *Peto OR* = 2.54, 95% *CI* [1.25, 5.15] (d) wide pulse pressures, *Peto OR* = 2.11, 95% *CI* [1.32, 3.37] (e) severe initial anaphylaxis symptoms, *Peto OR* = 2.11, 95% *CI* [1.23, 3.61] (f) anaphylaxis in patients less than 18 years of age treated with glucocorticoids, *Peto OR* = 1.55, 95% *CI* [1.01, 2.38] and (g) patients requiring more than one dose of epinephrine *Peto OR* = 4.82, 95% *CI* [2.70 to 8.58]. The bias of the studies ranged from moderate to high due to retrospective data, exclusions due to missing data, limited patient populations, and limited follow-up.

Summary by Predictive Variable

Twenty-six predictive variables were analyzed. Nine outcomes showed a positive or negative association with biphasic anaphylaxis. Of these outcomes, time to first epinephrine was reviewed qualitatively due to the heterogeneity of the data.

Unknown Trigger. Twenty-one retrospective observational studies ($n = 4275$) are included for this outcome (Alqurashi et al., 2015; Brady Jr, Lubner, Carter, Guertler, & Lindbeck, 1997; Brazil & MacNamara, 1998; Cianferoni et al., 2001; Douglas, Sukenick, Andrade, & Brown, 1994; Ellis & Day, 2007; Grunau et al., 2014; Inoue & Yamamoto, 2013; Jirapongsananuruk et al., 2007; J. M. Lee & Greenes, 2000; S. Lee, Peterson, Lohse, Hess, & Campbell, 2017;

Lertnawapan & Maek-a-nantawat, 2011; Manivannan et al., 2014; Manuyakorn et al., 2015; Mehr et al., 2009; Rohacek, Edenhofer, Bircher, & Bingisser, 2014; Smit, Cameron, & Rainer, 2005; Sricharoen, Sittichanbuncha, Wibulpolprasert, Srabongkosh, & Sawanyawisuth, 2015; Stark & Sullivan, 1986; Vezir et al., 2013; Yang et al., 2008). The pooled *Peto OR* was 1.63, 95% *CI* [1.14, 2.33]. Using a fixed-effect analysis, patients with anaphylaxis from an unknown trigger have a higher risk of having a biphasic reaction. The evidence is graded very low-certainty based on very serious risk of bias and serious inconsistency between the included studies. Biases include (a) the use of retrospective data, (b) limited or no follow-up, (c) limited patient selection (inpatient setting), and (d) exclusion of subjects due to missing data. Inconsistency was graded as serious due to moderate heterogeneity as evidenced by an $I^2 = 45\%$.

Drug Trigger in Patients ≤ 18 years of age. Five retrospective observational studies ($n = 996$) measured this outcome (Alqurashi et al., 2015; Manuyakorn et al., 2015; Mehr, Liew, Tey, & Tang, 2009; Orhan et al., 2011; Vezir et al., 2013). The pooled *Peto OR* was 2.35, 95% *CI* [1.16, 4.76]. Using a fixed-effect analysis, patients ≤ 18 years of age who have anaphylaxis from a drug trigger are at a higher risk of having a biphasic reaction than patients ≥ 18 years of age with a drug trigger. The evidence is graded very low-certainty based on (a) very serious risk of bias as the studies were retrospective in nature with limited or no follow-up; (b) serious inconsistency as the studies had moderate heterogeneity, $I^2 = 46\%$; and (c) serious imprecision as the studies had a low number of events.

Cutaneous Signs and Symptoms. Six retrospective observational studies ($n = 1949$) are included for this outcome (Alqurashi et al., 2015; Grunau et al., 2014; Inoue & Yamamoto, 2013; J. Lee, Garrett, Brown-Whitehorn, & Spergel, 2013; Manuyakorn et al., 2015; Mehr et al., 2009). The pooled *Peto OR* was 2.54, 95% *CI* [1.25, 5.15]. Using a fixed-effect analysis, patients with cutaneous signs and symptoms are at higher risk of having a biphasic reaction than patients without cutaneous signs and symptoms. The evidence is graded very low-certainty based on very serious risk of bias and inconsistency, and serious imprecision. The biases include (a) the use of retrospective data, (b) limited or no follow-up, (c) limited patient selection (inpatient setting). Inconsistency is graded as very serious because the definition of cutaneous signs and symptoms varied across studies and the I^2 was 43%. Finally, the included studies are downgraded for

serious imprecision, as there was a low number of events, and the confidence interval for the summary statistic is wide.

Dyspnea. Six retrospective observational studies ($n = 1841$) are included for this outcome (Brazil & MacNamara, 1998; Inoue & Yamamoto, 2013; S. Lee et al., 2017; Rohacek et al., 2014; Smit et al., 2005; Sricharoen et al., 2015). The pooled *Peto OR* was 0.6, 95% *CI* [0.38, 0.96]. Using a fixed-effect analysis, patients with dyspnea are at lower risk of having a biphasic reaction than patients without dyspnea. The evidence is graded very low- certainty based on (a) serious risk of bias as the studies are retrospective observational studies and included studies had limited or no follow-up; (b) serious inconsistency as the studies had substantial heterogeneity $I^2 = 73\%$; (c) serious imprecision as the studies had a low number of events.

Wide Pulse Pressure. Two retrospective observational studies ($n = 1356$) are included for this outcome (Alqurashi et al., 2015; S. Lee et al., 2017). The pooled *Peto OR* was 2.11, 95% *CI* [1.32, 3.37]. Using a fixed-effect analysis, patients with a wide pulse pressure are at higher risk of having a biphasic reaction than patients without a wide pulse pressure. The evidence is graded very low- certainty based on (a) serious risk of bias as the studies are retrospective observational studies and (b) serious imprecision as the studies had a low number of events.

Severe Initial Anaphylaxis. Five retrospective observational studies ($n = 724$) are included for this outcome (Brown et al., 2013; Confino-Cohen & Goldberg, 2010; J. M. Lee & Greenes, 2000; Manuyakorn et al., 2015; Vezir et al., 2013). The pooled *Peto OR* was 2.11, 95% *CI* [1.23, 3.61] (Figure 3). Using a fixed-effect analysis, patients with a severe initial anaphylaxis are at higher risk of having a biphasic reaction than patients without severe anaphylaxis. The evidence is graded very low- certainty based on (a) very serious risk of bias as the studies are retrospective observational studies and included studies with limited or no follow-up; (b) serious inconsistency as the studies used different definitions for severe anaphylaxis; (c) serious imprecision as the studies had a low number of events.

Greater than One Epinephrine Treatment. Five retrospective observational studies ($n = 1584$) are included for this outcome (Alqurashi et al., 2015; Inoue & Yamamoto, 2013; S. Lee et al.,

2017; Mehr et al., 2009; Scranton, Gonzalez, & Waibel, 2009). The pooled *Peto* OR was 4.82, 95% CI [2.70 to 8.58] (Figure 3). Using a fixed-effect analysis, patients who receive more than one epinephrine treatment initially are at increased risk of having a biphasic reaction. The evidence is graded very low- certainty based on (a) very serious risk of bias as the studies are retrospective observational studies and included studies with limited or no follow-up; (b) serious imprecision as the studies had a low number of events.

Glucocorticoid Treatment In Patients ≤ 18 years of age. Seven retrospective observational studies ($n = 1203$) are included for this outcome (Alqurashi et al., 2015; Calvani et al., 2011; Inoue & Yamamoto, 2013; J. M. Lee & Greenes, 2000; Manuyakorn et al., 2015; Mehr et al., 2009; Vezir et al., 2013). The pooled *Peto* OR was 1.55, 95% CI [1.01, 2.38]. Using a fixed-effect analysis, patients ≤ 18 years of age who receive glucocorticoid treatment are at a higher risk of having a biphasic reaction than patients ≥ 18 years of age who receive glucocorticoid treatment. The evidence is graded very low-certainty based on (a) very serious risk of bias as the studies are retrospective observational studies, included studies with limited or no follow-up, and included limited patient selection (inpatient setting); (b) serious imprecision as the studies had a low number of events.

Time to First Epinephrine. Eight retrospective observational studies ($n = 1469$) are included for this outcome. Reviewers were unable to perform an analysis for this outcome since the authors provided interquartile range (IQR) and median values and therefore this outcome could not be pooled together. Three of the eight studies showed delayed administration of epinephrine resulted in higher rates of biphasic anaphylaxis while the other five studies showed no statistical difference. S. Lee et al. (2017) identified 872 anaphylaxis-related visits to an emergency department from 2008-2015. There was a statistically significant association with biphasic reactions when the first dose of epinephrine was administrated more than 60 minutes after symptoms developed, OR = 2.29, 95% CI [1.09, 4.79]. J. M. Lee and Greenes (2000) also performed a retrospective analysis of 108 children admitted to a children's hospital. The median time from initial symptoms to initial dose of epinephrine for patients with a biphasic reaction was 190 min and 48 min for patients without a biphasic reaction ($p = .03$). Lertnawapan and Maekanantawat (2011) conducted an observational study on patients ($n = 208$) presenting to an

emergency department with anaphylaxis. Time from symptom onset to administration of epinephrine was significantly longer in the biphasic group than the no biphasic group, at 240 minutes (IQR 122.5-380) vs 70 minutes (IQR 40-135) minutes, $p = 0.002$. Alqurashi et al. (2015) found median time from the onset of the reaction to first dose of epinephrine was not statistically different between patients with biphasic reactions (64 minutes, IQR 25-175) and without biphasic reactions (59 minutes, IQR 25-105), $p = 0.35$. In a subgroup analysis of subjects who received epinephrine for the initial reaction, Alqurashi identified a protective effect from early epinephrine (a time delay of epinephrine longer than 90 minutes increased biphasic risk, $p = 0.01$). Ko et al. (2015) showed no association between the timing of epinephrine and the occurrence of biphasic reactions ($p = .52$). Median time from symptoms to epinephrine was 30 minutes (IQR 20-60) in the no biphasic group and 70 minutes (IQR 20-570) in the biphasic groups. Poachanukoon and Paopairochanakorn (2006) found the median time from the onset of symptoms to the initial administration of epinephrine in the patients with biphasic reactions was longer than in the no biphasic group but the difference did not reach statistical significance. Median time to initial dose of epinephrine in the no biphasic group was 82 minutes and 263 minutes in the biphasic group. No range was given. Scranton et al. (2009) found no difference in mean time to epinephrine between the no biphasic group 8.5 minutes $\pm$ 13.8 and the biphasic group 8.2 minutes $\pm$ 12.8, $p = .94$. J. Lee et al. (2013) found no difference in time from first reaction onset to first epinephrine dose between the no biphasic group 23.0 minutes and the biphasic group 28.5 minutes, $p = .60$

Food Trigger: Although previously found to be associated with a decreased risk for biphasic anaphylaxis,(43) the current analysis did not find a significant association of foods with decreased risk for biphasic anaphylaxis (Peto OR 0.89, 95% CI [0.68 , 1.17].

[Table 1]

1233

EVIDENCE TO RECOMMENDATIONS: TOPIC AREA #1

Identification and Mitigation of Risk Factors for Biphasic Anaphylaxis	
POPULATION:	Adults and children with anaphylaxis
INTERVENTION:	Using the presence of risk factors associated with biphasic anaphylaxis to advise regarding medical observation time following resolution of the initial phase of anaphylaxis.
COMPARISON:	Standard medical observation without risk factor stratification following resolved initial anaphylaxis.
MAIN OUTCOMES:	The occurrence of biphasic anaphylaxis
SETTING:	Emergency Departments, Allergy clinics, and Primary Care offices.
PERSPECTIVE:	Healthcare providers and patients want to know what risk factors predict biphasic anaphylaxis and how best to prevent it.
BACKGROUND:	Biphasic reactions may occur in up to 20% of patients with anaphylaxis but can be difficult to predict. Because biphasic anaphylaxis may occur from 1 to 78 hours after anaphylaxis resolution, there is uncertainty as to optimal medical observation to detect biphasic reactions. Prior studies have suggested more severe initial presentation (including hypotension) is associated with a greater risk for biphasic anaphylaxis.
CONFLICT OF INTERESTS:	None

1234

1235 CLINICAL STATEMENT

- Very low-certainty evidence suggests patients with severe initial anaphylaxis and those requiring more than one dose of epinephrine are at risk for biphasic anaphylaxis after resolution of initial anaphylaxis.
- Very low- certainty evidence suggests extended observation is appropriate for patients with severe initial anaphylaxis and/or who have required more than one dose of epinephrine. For patients with resolved non-severe anaphylaxis who are without significant comorbidities that would increase the risk for fatal anaphylaxis, who have had a prompt response to epinephrine, and will have reliable access to medical care following discharge, a 1-hour observation may be reasonable.
- Prior to discharge all patients should be prescribed and receive education on how and when to use self-injectable epinephrine, the risk of biphasic anaphylaxis, trigger avoidance, and the need for follow-up care with an allergist.

1236

1237 ASSESSMENT

Problem Is the problem a priority?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
☐ No ☐ Probably no ☐ Probably yes ☒ Yes ☐ Varies	The lifetime prevalence of anaphylaxis is estimated between 1.6% to 5.1%, and biphasic anaphylaxis may occur in up to 20% of	There is some uncertainty as to the exact rate of biphasic anaphylaxis and evidence regarding optimal treatment for biphasic anaphylaxis is scant.

o Don't know	patients.(1, 4) Medications are a leading trigger of anaphylaxis in adults.(1, 11) The prevalence of fatal anaphylaxis is between 0.47 to 0.69 per million persons 0.25%-0.33% of ED visits or hospitalizations.(9, 10, 29-31)	
Desirable Effects How substantial are the desirable anticipated effects?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
o Trivial o Small • Moderate o Large o Varies o Don't know	Understanding risk factors that could predict patients more likely to have biphasic reactions may allow more focused triage for patients who could benefit from additional education or medical observation. Very low-certainty evidence suggests biphasic anaphylaxis is associated with: (a) severe initial anaphylaxis symptoms, OR = 2.11, 95% CI [1.23, 3.61], (b) more than one dose of epinephrine, OR = 4.82, 95% CI [2.70 to 8.58], and (c) wide pulse pressures, OR =	More severe anaphylaxis carries a greater risk for biphasic anaphylaxis. Additional associations are quite broad (e.g., cutaneous signs and symptoms) or may be confounded by anaphylaxis severity (e.g. wide pulse pressure and children receiving glucocorticoids).

	2.11, 95% CI [1.32, 3.37]. Additional associations include: (d) anaphylaxis caused by any drug in patients less than 18 years of age, OR = 2.35, 94% CI [1.16, 4.76], (e) anaphylaxis caused by an unknown trigger, OR = 1.63, 95% CI [1.14, 2.33], (f) anaphylaxis symptoms with cutaneous manifestations, OR = 2.54, 95% CI [1.25, 5.15], and (g) anaphylaxis in patients less than 18 years of age treated with glucocorticoids, OR = 1.55, 95% CI [1.01, 2.38].	
Undesirable Effects How substantial are the undesirable anticipated effects?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
- o Large - o Moderate - o Small - o Trivial • Varies - o Don't know	For ED or hospital presentations of anaphylaxis, the case-fatality rate is estimated at 0.25% to 0.33%, including both uniphasic and biphasic anaphylaxis.(31) To reduce the fatality rate for	Patients identified to have risk factors may be observed much longer in the ED or admitted, increasing the cost of anaphylaxis treatment. Patients with these risk factors may be reluctant to go the ED for fear

	biphasic anaphylaxis one would ideally have the patient under direct observation; however, it is not cost-effective to observe all patients for a prolonged time following resolution of uniphasic anaphylaxis. Furthermore, it has been shown that the majority of patients monitored for 1 asymptomatic hour after resolved anaphylaxis will not experience a biphasic reaction.(57) Therefore the risks and benefits need to be balanced. While harm may result from missed cases of anaphylaxis in discharged patients, an overly cautious observation time for patients at low risk for both biphasic anaphylaxis and anaphylaxis fatality would be very costly. Depending on how evidence is incorporated into clinical practice, undesirable effects could include adoption of prolonged periods of medical observation which would be unnecessary for the majority of	of having an extended stay.
--	--	------------------------------------

	patients with resolved anaphylaxis.	
Certainty of evidence (Intentional vagueness) What is the overall certainty of the evidence of effects?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• Very low ○ Low ○ Moderate ○ High ○ No included studies	Across variables evaluated, heterogeneity ranged from low ($I^2=0\%$) to high ($I^2=89\%$). Due to very low-certainty of evidence and absence of a randomized controlled trial to address this question, there remains uncertainty as to the degree of benefit and fatality risk reduction obtained from extended observation in patients with resolved anaphylaxis. However, when comparing a 1-hour to a ≥ 6 hour observation, the number needed to treat by extended observation to prevent one biphasic reaction following discharge is 41 (range, 18-195)	Patients with severe initial anaphylaxis are likely to experience the greatest potential benefit from more extended observation. All patients should receive anaphylaxis education, including the risk for biphasic anaphylaxis. Patients should be prescribed self-injectable epinephrine and provided with an action plan, instructing them on how and when to administer epinephrine. Upon discharge, patients should be instructed to see an allergist-immunologist. (45)

	for patients presenting with severe anaphylaxis and 13 (range, 7-27) for those requiring more than one dose of epinephrine.(57, 194)	
Values (Value judgments) Is there important uncertainty about or variability in how much people value the main outcomes?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
○ Important uncertainty or variability ● Possibly important uncertainty or variability ○ Probably no important uncertainty or variability ○ No important uncertainty or variability	All patients would prefer to avert biphasic anaphylaxis. Apart from prompt and appropriate treatment of initial anaphylaxis with epinephrine, evidence is lacking to support a clear role for any additional therapy or management strategy to decrease biphasic anaphylaxis risk. However, if initial anaphylaxis was severe, if the clinical impression is that a patient has a higher risk of biphasic reaction (i.e., 17% or greater), or if risk factors for anaphylaxis fatality are present (e.g., cardiovascular comorbidity, lack of access to epinephrine, lack of access to	While all patients would choose to minimize biphasic anaphylaxis, a differential value may be placed on the importance of prolonged observation even for patients having experienced severe anaphylaxis. Conversely, patients with non-severe anaphylaxis may prefer more extended observation (beyond 1-hour). Development of a patient-decision aid could facilitate shared decision-making.

	emergency medical services, poor self-management skills, etc.) then extended observation of up to 6 hours or longer (including hospital admission) may be appropriate. (58) There is an absence of patient-preference sensitive evidence to inform physicians of the relative valuation of trade-offs when prolonged observation is compared to the risk of biphasic anaphylaxis following discharge.	
Balance of effects (Benefit-harm assessment) Does the balance between desirable and undesirable effects favor the intervention or the comparison?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ● Probably favors the intervention ○ Favors the intervention ○ Varies Don't know	Potential harm could result from over-reliance of risk factors. While universal prolonged observation could lead to patients delaying medical care (or avoiding medical observation all together), triage of patients with severe index anaphylaxis may facilitate a balance of	Biphasic anaphylaxis may occur in any patient with anaphylaxis and all patients should seek care if anaphylaxis recurs after initial resolution.

	benefits and harms.	
Resources required How large are the resource requirements (costs)?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
○ Large costs ○ Moderate costs ○ Negligible costs and savings ○ Moderate savings ○ Large savings • Varies ○ Don't know	Direct and indirect costs may vary depending on how risk factors are incorporated into patient management. Prolonged emergency department observation or inpatient admission could dramatically increase costs of anaphylaxis management. Biphasic anaphylaxis occurring outside of medical observation may be more severe and life-threatening, leading to greater costs of care; however, availability of self-injectable epinephrine would be expected to mitigate these risks and costs.	Anaphylaxis patient education, referral to an allergist, and prescription of an epinephrine auto-injector at discharge are important for all patients with anaphylaxis.(45)

Certainty of evidence of required resources

What is the certainty of the evidence of resource requirements (costs)?

JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
○ Very low ● Low ○ Moderate ○ High ○ No included studies	There is low-certainty in evidence of resource requirements due to variation in treatment setting, costs, duration of observation, and incorporation of risk factors. However, a time-dependent activity-based cost strategy can be used to estimate hourly costs from allergy clinic or emergency department observation.(195, 196)	Indirect costs involve job-related opportunity costs and may vary significantly across patient populations. Additional costs would be incurred for patients receiving overnight hospital admission for post-anaphylaxis monitoring.

Cost effectiveness

Does the cost-effectiveness of the intervention favor the intervention or the comparison?

JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison ● Probably favors the intervention	Medical observation of patients with severe anaphylaxis for ≥ 6 hours can be a cost-effective strategy if it provides at least a 76% fatality risk reduction compared to a shorter, e.g., 1 hour, observation. (58)	Cost-effectiveness may be sensitive to rates of biphasic reactions, cost of observation, hospitalization rates, and anaphylaxis fatalities.

○ Favors the intervention ○ Varies Don't know ○ No included studies		
Equity What would be the impact on health equity?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
○ Reduced ○ Probably reduced ○ Probably no impact ○ Probably increased ○ Increased • Varies ○ Don't know	The impact on equity may vary depending on how risk factors are incorporated into patient management. Prolonged periods of medical observation in patients with resolved anaphylaxis could negatively impact equity and may discourage patients from seeking medical care.	All patients experiencing anaphylaxis should be closely observed until they are stable and suitable for discharge. Recognizing that a biphasic anaphylaxis may only develop many hours following total resolution of symptoms, it is difficult to determine the most appropriate and cost-effective time for medical observation. A risk-stratified approach to observation following resolved anaphylaxis should include a shared decision-making conversation with the patient and family, as both the medical risks and patient values and preference must be taken into

		consideration.
Acceptability & Quality improvement opportunity Is the intervention acceptable to key stakeholders?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
☐ No ☐ Probably no ☐ Probably yes ☒ Yes ☐ Varies ☐ Don't know	Evidence suggests that a 1-hour symptom-free observation period of non-severe anaphylaxis has a 95% NPV for biphasic anaphylaxis.(57)	The concept that more severe anaphylaxis is associated with a greater risk for biphasic anaphylaxis is intuitive and would be acceptable to most stakeholders.
Feasibility Is the intervention feasible to implement?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
☐ No ☐ Probably no ☐ Probably yes ☐ Yes ☒ Varies ☐ Don't know	One recent meta-analysis suggests a 95% NPV associated with a 1-hour medical observation, and a 97.3% NPV associated with an observation period of at least 6 hours.(57)	Given the prolonged duration of possible biphasic reactions it would not be feasible to observe all patients for the entire duration of risk (up to 78 hours).
Intentional Vagueness		
☐ No	Evidence was drawn from a	Due to very low-certainty of

○ Probably no ○ Probably yes ● Yes ○ Varies ○ Don't know	heterogeneous population of non-randomized clinical studies and is susceptible to methodologic bias. The optimal extended observation time following resolved anaphylaxis is poorly defined. While a ≥ 6-hour observation period could be suggested in higher-risk patients, uncertainty remains regarding the cost-effectiveness of such an approach in many circumstances.(58)	evidence and absence of a randomized controlled trial to address this question, there remains uncertainty and potential bias. A role for shared decision-making in relation to extended observation may exist in some clinical situations of resolved anaphylaxis.
Role of Patient Preference		
○ No ○ Probably no ● Probably yes ○ Yes ○ Varies ○ Don't know	Patients with resolved severe-anaphylaxis may reasonably choose to defer prolonged observation beyond 6-hours.(58) Furthermore, an aversion to prolonged medical observation may deter some patients from seeking appropriate care. However, other patients, including those with less severe anaphylaxis, may prefer an extended period of observation based upon fear, anxiety, past experiences, or specific psycho-social	While patients with more severe anaphylaxis have a greater risk for biphasic reactions, the management of this increased risk may warrant practice variation based on a construct of shared decision-making. In addition, patients with non-severe anaphylaxis should have the option for more extended observation.

	circumstances.	
Exclusions		
☐ No ☒ Probably no ☐ Probably yes ☐ Yes ☐ Varies ☐ Don't know	It is important to distinguish biphasic anaphylaxis from uniphasic anaphylaxis without complete resolution (protracted anaphylaxis). Specific subpopulations were not excluded.	Additional factors associated with biphasic anaphylaxis would be difficult to incorporate into clinical triage strategies, such as anaphylaxis caused by a drug trigger in children, anaphylaxis with cutaneous signs and symptoms, and use of glucocorticoids in children. Some clinical associations identified may be confounded by anaphylaxis severity. Given the low-certainty of evidence it is not possible to completely exclude that subpopulations may benefit from extended observation.
Policy Level		
☐ No ☒ Probably no ☐ Probably yes ☐ Yes ☐ Varies ☐ Don't know	We would not recommend policy level interventions to mandate specific observation times or incorporate specific risk factors to predict biphasic anaphylaxis, as the certainty of evidence relating to this	Well-performed future randomized controlled trials would better inform practice and understanding of risk factors to predict biphasic anaphylaxis.

	question is very low.	
--	-----------------------	--

1238

1239 TOPIC AREA 1: Summary of judgements

	JUDGEMENT						
PROBLEM IS A PRIORITY	No	Probably no	Probably yes	<u>Yes</u>		Varies	Don't know
DESIRABLE EFFECTS	Trivial	Small	<u>Moderate</u>	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	Moderate	Small	Trivial		<u>Varies</u>	Don't know
CERTAINTY OF EVIDENCE	<u>Very low</u>	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	<u>Possibly important uncertainty or variability</u>	Probably no important uncertainty or variability	No important uncertainty or variability			
BALANCE OF EFFECTS BENEFIT S. HARMS AND BURDENS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	<u>Probably favors the intervention</u>	Favors the intervention	Varies	Don't know
RESOURCES REQUIRED	Large costs	Moderate costs	Negligible costs and savings	Moderate savings	Large savings	<u>Varies</u>	Don't know
CERTAINTY OF EVIDENCE OF REQUIRED RESOURCES	Very low	<u>Low</u>	Moderate	High			No included studies
COST EFFECTIVENESS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	<u>Probably favors the intervention</u>	Favors the intervention	Varies	No included studies
EQUITY	Reduced	Probably reduced	Probably no impact	Probably increased	Increased	<u>Varies</u>	Don't know
ACCEPTABILITY	No	Probably no	Probably yes	<u>Yes</u>		Varies	Don't know

FEASIBILITY	JUDGEMENT						
	No	Probably no	Probably yes	Yes		<u>Varies</u>	<u>Don't know</u>

1240

1241

TOPIC AREA 2: Should antihistamines or glucocorticoids be used to prevent anaphylactic reactions?

Question 2. Should antihistamines and/or glucocorticoids be used to prevent biphasic anaphylaxis?

Question 3. Should antihistamine and/or glucocorticoid premedication be used to prevent index hypersensitivity/infusion reactions to chemotherapy?

Question 4. Should antihistamine and/or glucocorticoid premedication be used to prevent recurrent hypersensitivity reactions to radiocontrast media?

Question 5. Should antihistamine and/or glucocorticoid premedication be used to prevent hypersensitivity reactions to allergen immunotherapy or other agents?

Patients: Adults and children experiencing anaphylaxis who are treated with glucocorticoids, antihistamines, or both to: (a) prevent biphasic anaphylaxis, (b) prevent index anaphylaxis with chemotherapeutic, (c) prevent recurrence of anaphylaxis to nonionic low-osmolar or iso-osmolar, radiocontrast media, and (d) prevent index anaphylaxis with non-chemotherapeutic agent. The analysis did not include patients with prior reactions attributed to chemotherapy or preventative treatment for children receiving chemotherapy.

Intervention: Use of antihistamine and/or glucocorticoid

Comparator: Management without antihistamine and/or glucocorticoid

Outcome: Occurrence of (a) biphasic anaphylaxis and (b-d) anaphylaxis.

Background: A systematic review by Alqurashi et al.(44) found thirty-one observational studies that reviewed the role of glucocorticoids for the treatment of anaphylaxis, suggesting that biphasic reactions were more likely to occur in moderate to severe anaphylaxis or when anaphylaxis was not treated with timely epinephrine. The authors concluded there was a lack of compelling evidence to support the routine use of glucocorticoids to prevent biphasic anaphylaxis.(44) Similar to the assumption that glucocorticoids provide proven benefit in acute anaphylaxis management, common practice has adopted the use of antihistamines, glucocorticoids, or both prior to chemotherapy, radiocontrast dye administration, and many other procedures or medications thought to involve risk of allergic reactions or anaphylaxis. However, the actual rigor to which these therapies have been evaluated is questionable. Paclitaxel, an

antitumor agent, is one example, with hypersensitivity reactions to this agent reported since early clinical use. In one early report (197) of 301 patients treated, 32 patients had definite (27 patients) or possible (5 patients) hypersensitivity reactions (HSRs) and all but one patient had the reaction from the first or second exposure. Of interest, 13 patients (41%) had received premedication to prevent toxicity but nonetheless experienced HSRs. While prolongation of infusion time appears to have decreased the rate of HSRs, the addition of premedication has also become common practice in some circumstances. (197) Premedication is also used in patients with prior reactions to RCM; however, it has been suggested that the most important change in decreasing rates of HSR associated with RCM has been use of alternative low- or iso-osmolar non-ionic agents. (17) Evidence supporting the use of premedication in the setting of non-ionic RCM agents for high risk patients is poorly described and there is concern that the routine use of glucocorticoid premedication in the setting of prior HSR to RCM may cause more morbidity than benefit. (17)

Study characteristics. The search for suitable studies was completed by the JTFPP (Figure 4). Sixty-seven articles were identified for inclusion. Odds ratios (OR) were used in analysis of Q2a and Q2b due to the case-control analytic strategy as biphasic and uniphasic anaphylaxis were analysed by retrospective evaluation of therapies received before the outcome of interest. Conversely, Q2c and Q2d were evaluated using the risk ratio (RR), which is useful in the setting of a prospective analysis plan to evaluate differences in outcome between exposure and control. Of note, if the prevalence/incidence of the event is low, then the RR and OR typically give very similar results. The Peto OR can be useful if there are no events or low number of events in arms evaluated, but was avoided in the Q2 analysis due to unbalanced arms which could lead to skewed findings using the Peto OR. (198)

Topic Area 2 Included Studies:

Question 2: Adults and children treated for anaphylaxis who are treated with glucocorticoids, antihistamines, or both to prevent biphasic anaphylaxis:

Alqurashi 2015 (42); Brady 1997 (173); Brown 2013 (21); Calvani 2011 (175); Douglas 1994 (178); Ellis 2007 (39); Grunau 2015 (199); Guiot 2017 (200); Inoue 2013 (179); Jirapongsanunuruk 2007 (180); Kawano 2017 (201); Ko 2015 (181); Lee 2017 (202); Lee 2000 (142); Lee 2013 (182); Lertnawapan 2011(183); Lin 2000 (203); Manuyakorn 2015 (185); Mehr 2009 (186)Michelson 2015 (166); Oya 2014 (204); Poachanukoon 2006 (189);Rohacek 2014 (41); Scranton 2009 (190); Smit 2005 (191); Sricharoen 2015 (55); Stark 1986 (37); Vezir 2013 (192)

Question 3: Adults treated for anaphylaxis who are treated with glucocorticoids, antihistamines, or both to prevent index anaphylaxis with chemotherapeutic:

Chang 2016 (205); Francis 1994 (206); Jerzak 2018 (207); Mach 2016 (208); Onetto 1993 (209); Rougier 1995 (210); Seki 2011 (211); Shen 2018 (212); Thompson 2014 (213); Trudeau 1996 (214); Weiss 1990 (197)

Question 4: Adults and children treated for anaphylaxis who are treated with glucocorticoids, antihistamines, or both to prevent recurrence of anaphylaxis to radiocontrast media:

Abe 2016 (215); Katayama 1990 (216); Kolbe 2014 (217); Lee 2016 (218); Park 2017 (219); Park 2018 (220)

Question 5: Adults and children treated for anaphylaxis who are treated with glucocorticoids, antihistamines, or both to prevent index anaphylaxis with non-chemotherapeutic agent:

Augustsson 2007 (221); Berchtold 1992 (222); Braaton 2015 (223); Brockow 1997 (224); Caron 2009 (225); Fan 1999 (226); Gold 2017 (227); Hejjaoui 1990 (228); Jacobstein 2005 (229); Jagdis 2014 (230); Lorenz 1980 (231); Mueller 2008 (232); Neilson 1996 (233); Portnoy 1994 (234); Reimers 2000 (235); Sanders 2005 (236); Schoening 1982 (237); Tankersley 2002 (238); Yoshihiro 2006 (46)

Key results (Question 2)

As shown in Figure 5, very low-certainty evidence suggests that glucocorticoids do not provide clear benefit in terms of reducing the risk for biphasic anaphylactic reactions (OR 0.87, 95% CI 0.74-1.02). Prolonged hospitalization and revisits were analysed as surrogate markers in Michelson 2015 (166), in which glucocorticoids was associated with decreased length of hospital stay but not with 3-day ED revisit. However, this study was limited by the poor distinction between protracted or biphasic anaphylaxis, introducing possible classification bias. Meta-regression analyses were performed to address potential confounding by differential rates of epinephrine use, with the summary estimate adjusted by accounting for whether there were differences across studies with regards to the odds of the biphasic versus the uniphasic group also receiving epinephrine at baseline. In meta-regression analyses epinephrine use accounted for about half of the between study variance, with moderate variance remaining after this correction ($\text{Tau}^2 = 0.4$).

Similar to findings regarding glucocorticoid use in anaphylaxis, antihistamines also did not provide benefit in reduction of biphasic reactions (OR 0.71, 95% CI 0.47-1.06 for H1-antihistamines and OR 1.21, 95% CI 0.80-1.83 for H2-antihistamines). Additional analyses were performed excluding Mehr 2009 (186) and Lee 2013 (182) to account for uncertainty in antihistamine preparations used without change in findings (OR 0.69, 95% CI 0.44-1.09 for H1-antihistamine). To address potential confounding by differential rates of epinephrine use, the summary estimate was adjusted by accounting for whether there were differences across studies with regards to the odds of the biphasic versus the uniphasic group also receiving epinephrine at baseline. In the meta-regression analysis, epinephrine use did not account for significant variation across studies. Kawano 2017 reported findings of a retrospective cohort to evaluate the effect of antihistamine treatment to prevent progression of anaphylaxis, so was excluded from the final analysis. (201) However, the inclusion of Kawano did result in a significant OR in favor of antihistamine use (OR 0.65, 95% CI 0.47-0.91). The significance of Kawano 2017 is difficult to interpret because patients were selected using an ED diagnostic code of “allergic reaction” (ICD-9 code 995.3) and patients receiving H1 antihistamines were more likely to receive epinephrine and glucocorticoids in their report. Similarly, Lin 2000 was excluded as the comparator in this analysis was an antihistamine (203), and Sricharoen 2015 was excluded as all subjects received antihistamines.(55)

[Table 2]

Key results (Question 3)

Premedication for chemotherapy was evaluated by outcome of hypersensitivity reaction or infusion-related reaction. Specific agents evaluated included pegaspargase, docetaxel, carboplatin, oxaliplatin, and paclitaxel. Given heterogeneity of premedication, specific analysis of premedication variant strategies was not performed. Very low-certainty evidence suggests that glucocorticoid and/or antihistamine premedication does provide benefit in terms of reducing the risk for hypersensitivity or infusion-related reactions in adults receiving chemotherapy who have not previously experienced a reaction to the drug when used in the context of a chemotherapy protocol (OR 0.49, 95% CI 0.37-0.66) (Figure 6). The test for heterogeneity yielded a statistically significant difference between studies ($P=0.002$; $I^2=64.0\%$). Jung 2014 (239) evaluated glucocorticoid premedication for rituximab in patients with B cell malignancies, demonstrating a reduced rate of rituximab infusion-related reactions in glucocorticoid-pretreated patients (2.7%) compared to patients who did not receive premedication (13%)(OR 0.18, 95% CI 0.07-0.50, $p<0.001$). Additional sensitivity analyses including the Jung 2014 analysis in the overall chemotherapy meta-analysis enhanced the benefit of chemotherapy premedication identified (OR of 0.45, 95% CI 0.34-0.6).

(Table 3)

Key results (Question 4)

Very low-certainty evidence suggests that glucocorticoid and/or antihistamine premedication does not provide benefit in terms of reducing the risk for hypersensitivity reactions in patients with prior RCM reactions (RR 1.07 95% CI 0.67-1.71) (Figure 7). The test for heterogeneity yielded a statistically significant difference between studies ($P<0.001$; $I^2=93\%$). Lasser 1994 (240) was excluded from the primary analysis because it was unclear which patients in this cohort who received non-ionic contrast had experienced prior RCM hypersensitivity reactions; however, in sensitivity analyses including patients with overall hypersensitivity as well as more severe (Grade II/III) reactions, premedication did not provide clear benefit (overall reactions, RR 0.97, 95% CI 0.61-1.52; Grade II/III RR 1.00, 95% CI 0.64-1.57). It is important to note that specific evaluation of patients with prior severe delayed onset allergic reactions tor RCM is not

well studied and was not addressed in the current analysis. Severe delayed RCM reactions have included Stevens-Johnson syndrome, toxic epidermal necrolysis, drug-related eosinophilia with systemic symptoms (DRESS), and vasculitis - with fatalities reported. (241-249) For instance, although iodixanol is a low-osmolar nonionic dimer delayed T-cell mediated reactions have been described.(243) While skin testing with delayed readings at 48 and 72 hours may play a role in identifying non-cross reactive agents (243), there remains uncertainty as to whether such an approach is necessary when compared to simply choosing a non-cross reactive RCM for presumed T-cell mediated severe delayed onset reactions. (17) Similarly, the necessity of other measures to prevent recurrent severe delayed reactions, which have included IVIG, desensitization, and cyclosporine, is unknown.(250-252) A simple approach was recently proposed by Macy who reviewed RCM hypersensitivity reactions and described four non-cross-reacting RCM groups from the perspective of delayed-onset T-cell mediated reactions (defined as groups A, B, C, and ungrouped). Group A RCM agents (which include the low-osmolar monomers iopamidol, iomeprol, iversol, iothalamate and low-osmolar dimer iodixanol) were contrasted from Group B (including the low-osmolar monomer iobitridol and low-osmolar dimer ioxaglate), Group C (high-osmolar ionic monomer amidotrizoate/diatrizoate), and ungrouped agents (low-osmolar monomers iopamide, iopamidol, iohalamate). One management strategy suggested that glucocorticoid premedication begun one day before the procedure (and continued for five days) may have a role in severe delayed-onset reactions to Group A RCM agents together with selection of a non-cross reactive group (such as iopromide or iopamidol).(17) The optimal approach to patients with delayed severe RCM reactions requires further study.

(Table 4)

Key results (Question 5)

Very low-certainty evidence suggests that glucocorticoid and/or antihistamine premedication does not provide benefit in terms of reducing the risk for hypersensitivity reactions in subjects receiving infliximab, allergen immunotherapy, or other (non-chemotherapy, non-RCM) medications (RR 0.74, 95% CI 0.49-1.11) (Figure 8). In contrast to infliximab, an analysis by Jung (239) demonstrated glucocorticoid premedication was effective in preventing rituximab infusion reactions in the context of B-cell malignancies. Additionally, the subgroup analysis of allergen immunotherapy did demonstrate a significant benefit of premedication, driven largely by studies of premedication in accelerated allergen immunotherapy schedules, which present greater risks of anaphylaxis (RR 0.62, 95% CI 0.41-0.94). This benefit may relate to a high baseline rate of systemic reactions. For example, Portnoy 1994 (234) reported a double-blind placebo controlled trial of rush immunotherapy in 22 allergic children aged 6 to 18 years of age. Systemic reactions (inclusive of isolated urticaria) were reported in 27% of subjects treated with H1 antagonist, H2 antagonists, and glucocorticoids compared with 73% of placebo subjects. One of 11 children experienced anaphylaxis in the treatment group compared to 3/11 in the placebo group. However, if additional consideration was given to patients receiving rush immunotherapy who experienced either anaphylaxis or investigator classified pulmonary symptoms (wheezing, shortness of breath, or chest tightness), the difference between active treatment and placebo was 18% vs 45%, respectively. (234) Additional sensitivity analysis performed using this modified definition of anaphylaxis from Portnoy 1994 did not significantly change results. Exclusion of the RIT patients from Portnoy 1994 and Hejjaoui 1990 resulted in an OR of 0.65 (95% CI, 0.41-1.04) for patients in the immunotherapy subgroup.

1440 **(Table 5)**

Journal Pre-proof

EVIDENCE TO RECOMMENDATIONS: TOPIC AREA 2

Evaluation and use of supplemental glucocorticoid and/or antihistamine premedication for anaphylaxis prevention	
POPULATION:	Adults and children with anaphylaxis
INTERVENTION:	Use of antihistamines and/or glucocorticoids to prevent anaphylactic reactions
COMPARISON:	Not using antihistamines and/or glucocorticoids for the purpose of preventing anaphylaxis
MAIN OUTCOMES:	Prevention of anaphylaxis
SETTING:	Emergency Department, out-patient, medical office, community
PERSPECTIVE:	Clinicians and patients want to know if anaphylaxis can be prevented with antihistamines and/or glucocorticoids.
BACKGROUND:	Clinicians frequently recommend antihistamines and/or glucocorticoids to prevent anaphylaxis. Premedication is often used for chemotherapy, monoclonal antibody infusions, and allergen immunotherapy. However, the benefit of antihistamines and/or glucocorticoids premedication for RCM, as well as each of these other settings, is uncertain. In addition, there is uncertainty if antihistamines and/or glucocorticoids prevent biphasic anaphylaxis recurrence following resolved anaphylaxis of any cause.
CONFLICT OF INTERESTS:	None

1441 CLINICAL STATEMENT

Very low-certainty evidence suggests that treatment with glucocorticoids,

antihistamines, or both as part of initial anaphylaxis management does not provide clear added benefit in preventing biphasic anaphylaxis in patients with resolved anaphylaxis. While a premedication strategy may provide benefit in patients receiving rush aeroallergen immunotherapy and patients receiving some forms of protocol chemotherapy, evidence is lacking to support clear benefit in patients receiving an infliximab without a prior history of anaphylaxis, or in patients with a history of anaphylaxis to RCM receiving an alternative low- or iso-osmolar non-ionic RCM agent.

1442

1443 ASSESSMENT

Problem Is the problem a priority?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
☐ No ☐ Probably no ☐ Probably yes ☒ Yes ☐ Varies ☐ Don't know	The lifetime prevalence of anaphylaxis is estimated between 1.6% to 5.1%, and biphasic anaphylaxis may occur in up to 20% of patients.(1, 4) Medications are a leading trigger of anaphylaxis in adults. The prevalence of fatal anaphylaxis is between 0.47 to 0.69 per million persons and 0.25%-0.33% of ED visits or hospitalizations.(9, 29, 31) Anaphylaxis prevention strategies have used antihistamines and glucocorticoids to prevent	There is some uncertainty as to the exact rate of biphasic anaphylaxis and evidence regarding optimal treatment for biphasic anaphylaxis is scant. There is variation in the patient event rate of anaphylaxis in particular clinical settings.

	subsequent biphasic anaphylaxis in patients with resolved initial anaphylaxis, as well as premedication strategies in instances where the risk of anaphylaxis has been thought to be significant (chemotherapy, monoclonal therapy, RCM use, allergen immunotherapy, and others)	
Desirable Effects How substantial are the desirable anticipated effects?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
○ Trivial ● Small ○ Moderate ○ Large ○ Varies ○ Don't know	The JTFPP analysis did find a nonsignificant trend to prevention of biphasic anaphylaxis with glucocorticoids (OR 0.87, 95% CI 0.74-1.02) and H1 antihistamines (OR 0.71, 95% CI 0.47-1.06), but not for H2 antihistamines H2 antihistamines (OR 1.21, 95% CI 0.80-1.83). Premedication did show benefit with rush allergen immunotherapy (RIT), with a NNT of 19 (range 12 to 119) at an anaphylaxis patient expected event rate (PEER) of 14%	Certainty of evidence is very low and findings are imprecise. However, it is possible that benefit could be evident in some circumstances. Based on the understanding of antihistamine and glucocorticoid mechanism of action, these therapies could decrease symptoms associated with anaphylaxis, such as urticaria. While this affect could confound the

	from the immunotherapy analysis that included RIT. The JTFPP analysis also showed reduction in anaphylaxis and infusion reaction events with premedication for some chemotherapy agents (OR 0.46, 95% CI 0.35,0.6), but not infliximab (RR 1.58, 95% CI 0.87-2.87), or RCM (RR 1.07, 95% CI 0.67-1.71). However, under the best possible circumstances within these confidence limits, the NNT to prevent anaphylaxis by the administration of premedication would be 13 for chemotherapy and 385 for infliximab therapy. Within the confidence limits, in the setting of alternative low-osmolar or iso-osmolar RCM in patients with prior RCM reactions, the NNT would be 36 under the most optimistic scenario of premedication benefit.	diagnosis of anaphylaxis, it may also provide some benefit in averting unnecessary care for patients who do not experience progression beyond urticaria as the only manifestation of an allergic response.
--	--	---

Undesirable Effects		
How substantial are the undesirable anticipated effects?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
- o Large • Moderate - o Small - o Trivial - o Varies - o Don't know	Glucocorticoids and first-generation antihistamines may have adverse effects, particularly in certain more vulnerable populations, which may include sedation and confusion, particularly in the elderly.(253-257) Side effects of these therapies may confound recognition, assessment, and/or treatment of anaphylaxis. It is unlikely that antihistamines and glucocorticoids increase anaphylaxis risk; however, within the JTF analysis the precision of estimate included the possibility of increased biphasic anaphylaxis. This effect could be confounded by severity of anaphylaxis. Reliance on antihistamines could also result in delay in epinephrine use.	Additional medical complexity of these treatments may create obstacles to efficient healthcare delivery.

Certainty of evidence (Intentional vagueness) What is the overall certainty of the evidence of effects?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• Very low ○ Low ○ Moderate ○ High ○ No included studies	Due to very low-certainty of evidence and absence of a randomized controlled trial to address this question, there remains uncertainty and potential bias in the assessment of benefit or harms from glucocorticoids and/or antihistamines to prevent anaphylaxis.	The evidence base is of low-certainty and a randomized controlled trial in regard to premedication may be warranted.
Values (Value judgments) Is there important uncertainty about or variability in how much people value the main outcomes?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
• Important uncertainty or variability ○ Possibly important uncertainty or variability ○ Probably no important uncertainty or variability ○ No important uncertainty or variability	With greater certainty of benefit patients would likely accept a greater rate of adverse effects from glucocorticoids and/or antihistamines; however, with the degree of uncertainty identified in the JTFPP analysis, value-judgements may be made by patients and providers in a more personalized context. Patients with comorbidities such as diabetes and	Patients may choose to defer more complex treatment protocols that involve glucocorticoids and/or antihistamines if the addition of these agents creates obstacles to care until there is greater certainty of benefit.

	poorly controlled hypertension may choose to defer glucocorticoids or antihistamine therapy in some circumstances.	
Balance of effects (Benefit-harm assessment) Does the balance between desirable and undesirable effects favor the intervention or the comparison?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
☐ Favors the comparison ☒ Probably favors the comparison ☐ Does not favor either the intervention or the comparison ☐ Probably favors the intervention ☐ Favors the intervention ☐ Varies Don't know	Sedation from 1 st generation antihistamines could be mitigated with the use of a 2 nd generation antihistamine. In patients without comorbidities, the rare use of oral or intravenous glucocorticoids carries a low, overall risk, especially in comparison to anaphylaxis. While rare severe adverse events may occur from 1 st generation antihistamine or glucocorticoid (e.g., fatal automobile accidents and aseptic necrosis of the hip), the likelihood of such events after single course of therapy would be very low. While under the best-case scenario, benefit from glucocorticoids and antihistamines could be evident with a NNT of 20 to 30 patients in	While this analysis is focused on anaphylaxis prevention, the greatest harm of glucocorticoids and/or antihistamines is the risk for delay in treatment with epinephrine.

	some settings, all patients receiving therapy experience increased risk of adverse effects, medical complexity, and cost.	
Resources required How large are the resource requirements (costs)?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
○ Large costs ● Moderate costs ○ Negligible costs and savings ○ Moderate savings ○ Large savings ○ Varies ○ Don't know	Costs on a societal level could be moderate, particularly if sedating antihistamines are used and lead to job-related opportunity costs or sedation-related traffic accidents. Indirect costs include time delays, opportunity costs, sedation, traffic accidents, management of hyperglycemia, and other adverse effects of therapy. However, in the best-case scenario costs of anaphylaxis could be prevented for every 20-30 patients treated in some settings.	If extended observation times are associated with additional treatment, or if parenteral treatments are administered, costs would be greater.

Certainty of evidence of required resources What is the certainty of the evidence of resource requirements (costs)?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
○ Very low ○ Low ○ Moderate ○ High ● No included studies	There is uncertainty in the evidence of required resources as randomized controlled trials of glucocorticoid and antihistamine premedication are sparse. While treatment protocols of glucocorticoids and antihistamines to prevent biphasic anaphylaxis and prevention of monoclonal antibody anaphylaxis may vary, strategies for RCM premedication are more standardized.(17) Portnoy et al. began pretreatment one day prior to RIT.(234)	There is some uncertainty as to whether more or fewer resources would be required for observation, given that the current use of antihistamines and glucocorticoids may provide a false sense of security that the patient has a significantly lower risk of anaphylaxis
Cost effectiveness Does the cost-effectiveness of the intervention favor the intervention or the comparison?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
○ Favors the comparison ○ Probably favors the comparison ○ Does not favor either the intervention or the comparison	If observation time is unaffected, there would be a minimal reduction in cost from omitting treatment with antihistamines and glucocorticoids to prevent biphasic anaphylaxis. However, if observation time was	Cost-effectiveness would likely be sensitive to rates of anaphylaxis, hospitalization, and fatality risk reduction.

○ Probably favors the intervention ○ Favors the intervention ○ Varies Don't know ● No included studies	increased due to the withholding of these medications, there could be increased overall costs. Lower costs would be expected with opportunity cost-savings from decreased medical complexity in premedication regimens; however, costs could be offset by increased rates of anaphylaxis. In the setting of RIT, costs of antihistamine and glucocorticoid premedication are small, and with benefit evident in at least one RCT the premedication approach is likely cost-effective.(234) In addition, one small study suggested benefit from antihistamine premedication before conventional immunotherapy.(46)	
Equity What would be the impact on health equity?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
○ Reduced ○ Probably reduced ● Probably no impact ○ Probably increased ○ Increased ○ Varies ○ Don't know	Increased medical complexity may increase disparities in health equity. In rural settings, access to 24-hour pharmacies may limit immediate availability of antihistamine and glucocorticoid treatments if an outpatient course is prescribed	Oral antihistamines and oral glucocorticoids are relatively inexpensive, so it is possible in some circumstances health equity impact could be minimal. However, if

	following resolution of anaphylaxis. In addition, as the complexity of care increases by the use of premedication regimens, the degree to which delivery of care shifts from primary to subspecialty is uncertain. Patients with poor health literacy may be at risk for incorrect dosing of home regimens as preventative anaphylaxis strategies become more complicated.	patients are treated for anaphylaxis at home for complete symptom resolution and further extended observation is driven by the practice of administering antihistamines and glucocorticoids, the effect on health equity could be more pronounced. As such, elimination of routine use of antihistamines and glucocorticoids to prevent biphasic anaphylaxis could improve health equity
Acceptability & Quality Improvement Opportunity Is the intervention acceptable to key stakeholders?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
☐ No ☐ Probably no ☐ Probably yes ☐ Yes • Varies ☐ Don't know	Antihistamines and glucocorticoids are common medications used to treat and prevent allergic reactions. While these treatments should not interfere with prompt administration of epinephrine in anaphylaxis treatment, they are	The practice of treating patients experiencing anaphylaxis with antihistamines and glucocorticoids is fairly embedded into common practice styles.

	often administered as first-line drugs with a wait-and-see approach before epinephrine is administered. It has been shown that epinephrine is often omitted in the ED setting while antihistamines and glucocorticoids are administered for a diagnosis of anaphylaxis. Therefore, the administration of epinephrine for all patients with anaphylaxis and the withholding of antihistamines and corticosteroids for some patients will not be acceptable to all professional stakeholders. Many patients are very willing to take an antihistamine but delay self-administration of epinephrine even when they know they are having severe anaphylaxis. This guideline will likely do little to change patient behavior. Conveying the message to professionals and patients that these agents should be considered as adjunct therapies to decrease symptoms associated with anaphylaxis, such as urticaria, and not a primary treatment for anaphylaxis will require continued educational efforts.	Stakeholders may weigh the risks of biphasic anaphylaxis more heavily than the risks of these medications and be uncomfortable with the risk-benefit of denying adjunct treatment.
--	---	---

	When antihistamines and corticosteroids are used with the intent of anaphylaxis prevention, evidence generally suggests that the likelihood of benefit is low and uncertain in most settings. However, as in situations of anaphylaxis treatment, antihistamines and corticosteroids may decrease risks of symptoms associated with anaphylaxis, such as urticaria. While the administration of these agents may delay recognition of anaphylaxis, they may also prevent unnecessary escalation of treatment for non-anaphylactic allergic symptoms. Evidence suggests benefit of corticosteroids and antihistamines in RIT to prevent anaphylaxis. Given that a similar mechanism of action by corticosteroids and antihistamines could also occur in anaphylaxis prevention in other situations, the beneficial use of these agents may be identified in future therapeutic trials. The NNT to prevent anaphylaxis will depend upon the underlying patient expected event rate for anaphylaxis	
--	---	--

	from a specific trigger.	
Feasibility Is the intervention feasible to implement?		
JUDGEMENT	RESEARCH EVIDENCE	ADDITIONAL CONSIDERATIONS
☐ No ☐ Probably no ☐ Probably yes ☐ Yes ☒ Varies ☐ Don't know	Use of antihistamines and glucocorticoids by ED physicians to both treat and prevent anaphylaxis is widespread. The very low-certainty evidence from this meta-analysis and the current placement of these drugs as adjunctive agents (in addition to epinephrine) for the treatment of anaphylaxis makes practice change challenging. Likewise, office-based clinicians and patients are comfortable using an antihistamine for both the prevention and treatment of an allergic reactions. Given the evidence provided in this analysis, clinicians may consider withholding glucocorticoids prior to infliximab treatment and in patients with prior RCM anaphylaxis receiving an alternative low- or iso-osmolar agent. Patients receiving RIT may consider treatment with antihistamines and glucocorticoids	Additional high-certainty evidence is needed to better inform practice as to the role of antihistamines and glucocorticoids for the purpose of preventing anaphylaxis.

	While further study is needed, one study suggests possible benefit from antihistamine premedication before conventional aeroallergen immunotherapy.(46)	
Intentional Vagueness		
Yes	Due to low-certainty of evidence and absence of a randomized controlled trials in most settings evaluated, there remains uncertainty in the role of antihistamines and glucocorticoids in the prevention of anaphylaxis.	Additional high-certainty evidence is needed to better inform practice.
Role of Patient Preference		
Probably yes	Patients may feel “safer” with the use of antihistamines and/or glucocorticoids, but this preference is likely to be highly influenced by counseling and education they receive from healthcare providers. The patient will need education and re-education on the signs and symptoms of anaphylaxis and on the use of epinephrine as the only first-line medication for the treatment of anaphylaxis. Providers cannot allow the patient to “prefer” an antihistamine over epinephrine for the treatment of anaphylaxis.	Shared decision-making would be appropriate in some circumstances given the absence of clear benefit in prevention of anaphylaxis with antihistamines and glucocorticoids in many settings. Patient-preference sensitive care could address unwarranted practice variation to prevent biphasic anaphylaxis, monoclonal antibody anaphylaxis, and

	Patient preference may be a consideration in the use of antihistamines and glucocorticoids as second-line medications following epinephrine administration. Antihistamines and glucocorticoids may provide some role in treating the urticaria and pruritus occurring during anaphylaxis.	RCM anaphylaxis prevention.
Exclusions		
Yes	Given the low-certainty of evidence it is not possible to completely exclude subpopulations that may experience more pronounced benefit from a particular intervention to prevent anaphylaxis. The meta-analysis evaluated the role of antihistamine and/or glucocorticoid in prevention (not treatment) of anaphylaxis. In addition, children receiving chemotherapy, patients receiving chemotherapy desensitization, and patients with delayed RCM reactions were not included in the meta-analysis.	
Policy Level		

No	We would not recommend policy level interventions to either mandate or limit the use of supplemental therapy in anaphylaxis as the certainty of evidence relating to this question is very low.	
-----------	---	--

1444

1445 TOPIC AREA 2 SUMMARY OF JUDGEMENTS

	JUDGEMENT						
PROBLEM IS A PRIORITY	No	Probably no	Probably yes	<u>Yes</u>		Varies	Don't know
DESIRABLE EFFECTS	Trivial	<u>Small</u>	Moderate	Large		Varies	Don't know
UNDESIRABLE EFFECTS	Large	<u>Moderate</u>	Small	Trivial		Varies	Don't know
CERTAINTY OF EVIDENCE	<u>Very low</u>	Low	Moderate	High			No included studies
VALUES	<u>Important uncertainty or variability</u>	Possibly important uncertainty or variability	Probably no important uncertainty or variability	No important uncertainty or variability			
BALANCE OF EFFECTS BENEFIT S. HARMS AND BURDENS	Favors the comparison	<u>Probably favors the comparison</u>	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	Don't know
RESOURCES REQUIRED	Large costs	<u>Moderate costs</u>	Negligible costs and savings	Moderate savings	Large savings	Varies	Don't know
CERTAINTY OF EVIDENCE OF	Very low	Low	Moderate	High			<u>No included</u>

REQUIRED RESOURCES	JUDGEMENT						
							<u>studies</u>
COST EFFECTIVENESS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	No included studies
EQUITY	Reduced	Probably reduced	<u>Probably no impact</u>	Probably increased	Increased	Varies	Don't know
ACCEPTABILITY	No	Probably no	Probably yes	Yes		<u>Varies</u>	Don't know
FEASIBILITY	No	Probably no	Probably yes	Yes		<u>Varies</u>	Don't know

RECOMMENDATIONS:

QUESTION #1: What risk factors should clinicians take into consideration in determining the likelihood of biphasic anaphylaxis?

Recommendation 1: We suggest that a clinician incorporate severity of anaphylaxis presentation and/or the administration of more than one dose of epinephrine for the treatment of initial anaphylaxis as a guide to determining a patient's risk for developing biphasic anaphylaxis. Conditional recommendation; Certainty rating of evidence: very low

Technical statement: The JTFPP findings suggest biphasic anaphylaxis is associated with a more severe initial presentation of anaphylaxis (OR=2.11, 95% CI 1.23-3.61) or repeated epinephrine doses (i.e., more than one epinephrine dose) required with the initial presentation (OR 4.82, 95% CI 2.70-8.58). Additional risk factors identified included wide pulse pressure (OR 2.11, 95% CI 1.32 – 3.37), unknown anaphylaxis trigger (OR 1.63, 95% CI 1.14-2.33), cutaneous signs and symptoms (OR 2.54, 95% CI 1.25-5.15), and drug trigger in children (OR 2.35, 95% CI 1.16-4.76). While dyspnea on presentation was associated with a decreased risk for anaphylaxis, overall confidence in this estimate was low (OR 0.6, 95% CI 0.38-0.96).

Recommendation 2: We suggest in favor of extended clinical observation in a setting capable of managing anaphylaxis (to detect biphasic anaphylaxis) for patients with resolved severe anaphylaxis and/or the need for more than one dose of epinephrine.

Strength of recommendation: Conditional

Certainty of evidence: Very low

Technical statement: At present, evidence is lacking to clearly demonstrate the period of universal extended observation that may be required or cost-effective in all patients with severe anaphylaxis or those who require multiple doses of epinephrine. A recent meta-analysis of observation times suggested 1-hour observation was associated with a 95% negative predictive value (NPV) of biphasic anaphylaxis, while a 6-hour or longer observation period was associated with a 97.3% NPV of biphasic anaphylaxis occurring after discharge.(57) Based on this analysis, the incremental patient expected biphasic event rate (PEER) between asymptomatic 1-hour and ≥ 6 -hour observation is 2.3%. Therefore, the number needed to treat (NNT) with extended observation to be able to detect one episode of biphasic anaphylaxis before discharge (Figure 9) would be 41 (range, 18 to 195) for patients with a more severe initial presentation of anaphylaxis and 13 (range, 7 to 27) for patients with multiple epinephrine doses. (194) For patients at high risk for biphasic anaphylaxis or those with a higher risk of anaphylaxis fatality (e.g., serious medical comorbidities), more prolonged monitoring can be cost-effective. (58) In a recent analysis 6-hour observation was cost-effective if it was able to provide a high-degree of protection against anaphylaxis fatality (24% fatality relative risk for extended vs 1-hour observation). (58) Patients with comorbidities such as severe respiratory or cardiac disease and corresponding higher risks for poor anaphylaxis outcomes may therefore benefit from more extended observation. Conversely, in patients presenting with non-severe anaphylaxis and promptly responding to a single dose of epinephrine without recurrence, evidence suggests that a 1-hour observation may be reasonable in the context of appropriate patient education. (57, 58) Such lower risk patients would be characterized as having a very small risk of biphasic anaphylaxis (<5%) following discharge associated with a less than 50% fatality risk reduction from extended observation. (58) Therefore, the JTFPP suggests that in patients with a severe initial presentation of anaphylaxis (for example, those with hypotension, wide pulse pressures,

multiple doses of epinephrine, or other markers of severity), extended observation be considered following resolution of the index episodes without recurrence. At present, evidence is lacking to clearly demonstrate the exact period of universal extended observation that may be required or cost-effective in all patients with severe anaphylaxis or those who require multiple doses of epinephrine.(36, 58) In some circumstances a role may exist for shared decision-making tools around the duration of prolonged ED observation.

The JTFPP analysis found additional factors associated with risk of biphasic anaphylaxis that would be difficult to incorporate into clinical triage strategies, such as anaphylaxis caused by a drug trigger in children, anaphylaxis with cutaneous signs and symptoms, and use of glucocorticoids in children. Some of these associations may be confounded by anaphylaxis severity and practice variation, with very low-certainty of evidence challenging the applicability of these factors to patient care until they can be further substantiated. For instance, it is highly unlikely that administration of more than one dose of epinephrine or glucocorticoids contributed to biphasic reactions, but very likely that these were indicative of a more significant anaphylactic reaction. It is possible that medication-induced anaphylaxis in children may be a risk factor for biphasic anaphylaxis, but it is not possible to determine if this is due to having more severe anaphylaxis or if medication, as a trigger, is an independent risk factor for biphasic anaphylaxis in children. In regard to the association of idiopathic anaphylaxis, follow-up for post ED identification of a specific trigger was not explored; therefore, the significance of this factor is uncertain. While wide pulse pressures may be considered a marker for severe anaphylaxis, the clinician may also consider extended observation for patients with an unknown anaphylaxis trigger and children with a drug trigger. Incorporating cutaneous signs and symptoms into a clinical decision for extended observation may be limited by the common occurrence of cutaneous signs and symptoms in patients presenting with anaphylaxis. There was no signal that any medication other than epinephrine used for treatment of initial anaphylaxis reduced the risk of biphasic anaphylaxis. Notably, there does appear to be a trend to lower rates of biphasic reactions with earlier epinephrine administration following development of anaphylaxis. While early epinephrine in the setting of anaphylaxis is important, evidence suggests preemptive epinephrine before symptom onset may not be a cost-effective strategy.(54)

Prompt and adequate treatment of anaphylaxis appears central to reducing biphasic anaphylaxis risk. The implications for the clinician, based upon this systematic review and meta-analysis, is that the patient presenting with severe anaphylaxis and/or requiring more aggressive treatment (e.g., more than one dose of epinephrine), following complete resolution of symptoms, may benefit from longer observation time for a potential biphasic reaction. While the possibility of biphasic anaphylaxis should be emphasized in this higher risk group, it is important to educate all patients on the chance of a biphasic reaction as well as avoiding known triggers, identifying

symptoms of anaphylaxis, the use of auto-injector epinephrine for the treatment of anaphylaxis, and timely follow-up with an allergist.

QUESTION #2: Should antihistamines or glucocorticoids be used to prevent biphasic anaphylaxis?

Recommendation: We suggest against administering glucocorticoids or antihistamines as an intervention to prevent biphasic anaphylaxis

Strength of recommendation: Conditional

Certainty of evidence: Very low

Technical comment: As a secondary therapy, antihistamines and glucocorticoids may be considerations in anaphylaxis treatment.(45) In particular, antihistamines may treat urticaria and itching to improve comfort during anaphylaxis, but if used prior to epinephrine administration could lead to a delay in first-line treatment of anaphylaxis. The JTFPP analysis did not identify significant benefit in prevention of biphasic anaphylaxis from either H1 antihistamines (OR 0.71, 95% CI 0.47-1.06), H2 antihistamines (OR 1.21, 95% CI 0.80-1.83), or glucocorticoids (OR 0.87, 95% CI 0.74-1.02). An interaction was identified between age and glucocorticoid use, with glucocorticoids actually increasing risk for biphasic anaphylaxis in children (OR 1.55, 95% CI 1.01-2.38); however, confounding effect of severity could not be excluded. Evaluation of the number of patients needed to treat (NNT) to potentially reduce biphasic anaphylaxis rates is useful.(194)

H1 antihistamines: At a biphasic anaphylaxis patient expected event rate (PEER) of 5%, the number needed to treat (NNT) for H1 antihistamines is 72 to prevent one episode of biphasic anaphylaxis. At a biphasic anaphylaxis PEER of 20%, the NNT (to prevent one case of biphasic anaphylaxis) for H1 antihistamines is 20. However, neither of these values was certain and confidence in the benefit of treatment is low, with an association of increased biphasic anaphylaxis rates within the confidence estimate.

H2 antihistamines: At a biphasic anaphylaxis PEER of 5% and 20%, H2 antihistamine use was not associated with a decreased risk of biphasic anaphylaxis. However, the degree of certainty that H2 antihistamine therapy did not provide any possibility of benefit was uncertain.

Glucocorticoids: At a biphasic anaphylaxis PEER of 5%, the number needed to treat (NNT) for glucocorticoids is 161 to prevent one case of biphasic anaphylaxis (and 47 at a biphasic anaphylaxis PEER of 20%). Again, neither of these values was certain and confidence in the benefit of treatment is low, with an association of increased biphasic anaphylaxis rates within the confidence estimate.

Certainty of evidence is very low, and additional well-designed controlled trials are needed to further inform this practice. However, the JTFPP strongly recommends that secondary therapies never interfere with early epinephrine treatment, as this is the primary medication for the treatment of anaphylaxis.(45) The use of antihistamines may be associated with side-effects that could confound assessment of anaphylaxis, such as altered level of consciousness with 1st generation antihistamines. Harms from high dose glucocorticoids may also outweigh benefits; however, due to the very low-certainty of evidence (risk of bias, inconsistency, and imprecision), there remains uncertainty in the assessment of benefit vs. no benefit from supplemental therapies.

QUESTION #3: Should antihistamine and/or glucocorticoid premedication be used to prevent index hypersensitivity/infusion reactions to chemotherapy?

Recommendation: We suggest in favor of administering glucocorticoids and/or antihistamines to prevent anaphylaxis or infusion-related reaction when indicated for specific agents in chemotherapy protocols.

Strength of recommendation: Conditional

Certainty of evidence: Very low

Technical Comment: The JTFPP analysis did identify a significant change in rates of anaphylaxis and/or infusion reactions for some chemotherapy protocols. The use of premedication was associated with a decreased rate of hypersensitivity reactions for

chemotherapy (OR 0.49, 95% CI 0.37-0.66). In contrast to chemotherapy premedication, benefit was not observed when using premedication to prevent anaphylaxis in the setting of infliximab therapy without prior reaction to the administered agent (RR 1.58, 95% CI 0.87-2.87). We did not evaluate premedication in the context of desensitization to chemotherapy agents and to monoclonal antibodies. Furthermore, the use of premedication in patients who had previously experienced anaphylaxis from these agents was not evaluated.

Chemotherapy Premedication: At an anaphylaxis PEER of 12.9%, premedication was associated with a decreased risk of anaphylaxis. The NNT was 16 (range, 13 – 25).

Infliximab Premedication: At an anaphylaxis PEER of 2%, premedication was not associated with a decreased risk of anaphylaxis. However, the degree of certainty that therapy did not provide any possibility of benefit was uncertain.

It is not possible to exclude some potential benefit from the use of glucocorticoids and/or antihistamines to prevent anaphylaxis, and additional well-designed controlled trials are needed to further inform this practice. A clinician may reasonably defer premedication use for the intention of preventing anaphylaxis. If standard practice dictates the use of premedication prior to the administration of a infliximab, it would be reasonable to discontinue the premedication following tolerance of the 1st or 2nd course of treatment.

QUESTION #4: Should antihistamine and/or glucocorticoid premedication be used to prevent recurrent hypersensitivity reactions to radiocontrast media?

Recommendation: We suggest against routinely administering glucocorticoids and/or antihistamines to prevent anaphylaxis in patients with prior radiocontrast hypersensitivity reactions when re-administration of a low- or iso-osmolar, non-ionic radiocontrast media agent is required.

Strength of recommendation: Conditional

Certainty of evidence: Very low

Technical Comment: The JTFPP analysis did not identify significant benefit from the use of premedication prior to the RCM to prevent anaphylaxis (RR 1.07 95% CI 0.67-1.71). The absence of benefit of premedication in patients with prior immediate hypersensitivity reactions to RCM who are receiving a different low- or iso-osmolar agent is consistent with prior literature; however, it is important to distinguish the immediate index reaction associated with RCM from a severe, delayed, cutaneous T-cell mediated reaction, where premedication may add value to management.(17) Risk of bias, inconsistency, imprecision, and indirectness attenuate the confidence in this guidance.

RCM Premedication: At a PEER of 8.7%, premedication was not associated with a decreased risk of anaphylaxis. However, the degree of certainty that therapy did not provide any possibility of benefit was low.

Given the diversity of clinical circumstances evaluated and low-confidence in the literature base, higher certainty evidence is needed to better inform practice, and future recommendations could potentially change as a result of new information. As such, clinicians may reasonably consider premedication in clinical circumstances associated with a high level of perceived risk of anaphylaxis or comorbidities associated with greater anaphylaxis fatality risk (such as underlying cardiovascular disease or use of beta-blockers, prior severe anaphylaxis), although evidence is lacking to clearly support this practice. Additional well-designed controlled trials are needed to further clarify the need for premedication prior to alternative low- or iso-osmolar RCM use in patients with prior anaphylaxis to prevent recurrence. This analysis evaluated patients with both mild and severe RCM reactions but we were unable to stratify prophylaxis by severity of index reaction. Our analysis evaluated only low- and iso-osmolar non-ionic radiocontrast agents, and as such does not apply to patients receiving high-osmolar contrast agents for whom prophylaxis may be appropriate.(258)

QUESTION 5: Should antihistamine and/or glucocorticoid premedication be used to prevent hypersensitivity reactions to allergen immunotherapy or other agents?

Recommendation: We suggest in favor of the administration of glucocorticoids and/or antihistamines as an intervention to prevent anaphylaxis in patients undergoing aeroallergen rush immunotherapy (RIT).

Strength of recommendation: Conditional

Certainty of evidence: Very low

Technical Comment: Evidence suggests that in the setting of aeroallergen RIT, premedication may provide value in reducing systemic reactions and anaphylaxis (immunotherapy analysis including RIT, RR 0.62, 95% CI 0.41- 0.94). In the study by Portnoy et al, patients received H1 and H2 antagonists and oral glucocorticoids for 3 days, beginning one day before the 2-day rush immunotherapy protocol.(234) The evidence base for premedication before conventional aeroallergen immunotherapy is limited; however, one study by Ohashi Yoshirio et al. suggested some benefit with fexofenadine pretreatment 2 hours before conventional immunotherapy using cedar pollen or dust mite allergens.(46) The evaluation of the number of patients needed to treat (NNT) to prevent one episode of anaphylaxis is useful.

RIT Premedication: The NNT to prevent one case of anaphylaxis with RIT premedication at a 4.5% rate of anaphylaxis is 58, based on the immunotherapy analysis including RIT studies. At a 9% rate of anaphylaxis, the NNT of premedication for RIT is 29. Assuming a patient expected anaphylaxis event rate of 14%, the premedication NNT is 19.

The JTFPP is unable to exclude the possibility that specific situations and subpopulations may exist where premedication could provide benefit to immunotherapy in those with concomitant risk factors (e.g., in situations associated with higher rates of systemic reactions). Given the diversity of clinical circumstances evaluated and low-confidence in the literature base, higher certainty evidence is needed to better inform practice, and future recommendations could potentially change as a result of new information. As such, clinicians may reasonably consider immunotherapy premedication in other clinical circumstances associated with a high level of perceived risk of anaphylaxis or comorbidities associated with greater anaphylaxis fatality risk (such as underlying cardiovascular disease or use of beta-blockers), although high-certainty evidence is lacking to support this practice.

Additional Good Practice Statements

Good Practice Statement # 1: Administer epinephrine as the 1st line pharmacotherapy for uniphasic and/or biphasic anaphylaxis.

Good Practice Statement #2: Do not delay the administration of epinephrine for anaphylaxis, as doing so may be associated with higher morbidity and mortality.

Good Practice Statement #3: After diagnosis and treatment of anaphylaxis, all patients should be kept under observation in a setting capable of managing anaphylaxis until symptoms have fully resolved.

Good Practice Statement #4: All patients with anaphylaxis should receive education on anaphylaxis, including avoidance of identified triggers, presenting signs and symptoms, biphasic anaphylaxis, treatment with epinephrine, and the use of epinephrine auto-injectors and referral to an allergist. Of note, there may be some circumstances where self-injectable epinephrine is deferred (i.e., resolved anaphylaxis and drug trigger with high likelihood of successful avoidance) and shared decision-making may play a role in some circumstances.

Limitations

Unfortunately, the certainty of evidence around supplemental therapies in anaphylaxis management is very low. While early epinephrine is recommended by the JTFPP when anaphylaxis is recognized in any setting, whether or not clinicians should also administer antihistamines and/or glucocorticoids is a question that has not been subjected to rigorous methodologic evaluation.

All patients with anaphylaxis should be educated regarding the risk for biphasic reactions, and self-injectable epinephrine should be available at discharge for prompt treatment if this occurs. Patients who experience greater severity of anaphylaxis are at greater risk for biphasic reaction, but the absolute risk of biphasic reactions in this population is less clear. While more than one

dose of epinephrine was identified as a risk factor for biphasic anaphylaxis, we did not specifically evaluate this risk factor in the context of repeated sub-therapeutic epinephrine dosing. The JTFPP recommends epinephrine be given promptly in appropriate doses when anaphylaxis is recognized. It is important to distinguish biphasic anaphylaxis (with an interval period of clear resolution) from protracted anaphylaxis. In circumstances where prescribed self-injectable epinephrine is not immediately available upon discharge, e.g., limited pharmacy hours or affordability, clinical judgement regarding risk of biphasic or recurrent anaphylaxis, access to subsequent emergency care, and shared decision making will be required to determine discharge decisions.

Our analysis is similar to results obtained by Ellis et al. in which glucocorticoids demonstrated a nonsignificant inverse trend with biphasic anaphylaxis (39); however, caution is warranted in interpretation of these findings – particularly given the opposite association of glucocorticoids with biphasic anaphylaxis in children (which may be confounded by severity of index anaphylaxis and practice variation). Ultimately a randomized controlled trial of supplemental glucocorticoids and antihistamines in patients adequately treated with epinephrine with resolved anaphylaxis is needed to determine if these agents prevent biphasic anaphylaxis.

We did not find clear evidence to support the role of glucocorticoids and/or antihistamines to prevent biphasic anaphylaxis. Clear evidence is also lacking to support a role for glucocorticoids and/or antihistamines in acute anaphylaxis, although the Cross-Canada Anaphylaxis registry recently suggested supplemental antihistamines may provide benefit when used with epinephrine.(164) In the same study, supplemental use of glucocorticoids with epinephrine resulted in worse outcome.(164)

The absence of benefit of premedication in patients with prior immediate hypersensitivity reactions to RCM who are receiving a different low- or iso-osmolar agent is consistent with prior literature (17, 258, 259); however, it is important to distinguish the immediate index reaction associated with RCM from a severe, delayed, cutaneous T-cell mediated reaction, where premedication may add value to management. Patients receiving RCM may experience acute or delayed reactions. (17) Four categories of reactions to RCM have been described: benign acute-

onset, anaphylaxis, benign delayed-onset, and severe delayed-onset. (17) In one 2016 review of 120,822 patients receiving low- or iso-osmolar agents (iopromide, iodixanol, iopamidol, ioversol, iobitridol, or iohexol), hypersensitivity reactions were reported in 0.4% with only 1.4% of these reactions described as severe. (260) The JTFPP agrees with the suggestion that most individuals with acute RCM hypersensitivity can be effectively managed by selecting an alternative low- or iso-osmolar RCM without premedication (17); however, some controversy exists around the management of patients with prior RCM reactions.(17, 258, 259, 261) The American College of Radiology (ACR) Manual on Contrast Media Version 10.3 emphasizes that no premedication strategy is a substitute for anaphylaxis preparedness, breakthrough reactions occur, and changing to an alternative low- or iso-osomlar contrast agent may provide a greater effect size than premedication alone. (261) While premedication before high-osomolar agents has been shown to reduce immediate reactions of all severity in average-risk patients and mild immediate adverse effects in average-risk patients receiving low- osmolar agents, protection from premedication against moderate to severe reactions in high-risk patients receiving low-osmolar agents is unproven by high certainty evidence, with estimates suggesting the NNT to prevent a fatal reaction in a high risk patient to be 50,000 (at a cost of \$131,211,400 per death prevented).(258, 261, 262) The ACR Manual on Contrast Media suggests the utility of premedication in high-risk patients receiving low-osmolar contrast is uncertain and may be accompanied by direct and indirect harms, but that it may be considered in outpatients with prior allergic-like or unknown-type contrast reactions and in similar inpatients where the use of premedication does not adversely delay care or treatment decisions. (261) The ACR Manual suggests that regardless of patient status, a history of a severe contrast reaction be considered a relative contraindication to the future use of the same class of media and premedication be considered (if feasible) if there are no alternatives. (261) High quality studies are needed to better inform the practice of RCM premedication in high risk patients, and future studies should distinguish between immediate and delayed, cutaneous and non-cutaneous, mild and severe reactions and stratify premedication by anaphylactic, hemodynamic, and chemotactic reaction type.

The role of glucocorticoid and/or antihistamine premedication in more high-risk settings (such as rush immunotherapy) may be significant, and until additional evidence better informs practice,

premedication may be appropriate in circumstance where a high risk of anaphylaxis exists. The lack of benefit from infliximab premedication in patients without prior infusion reactions is consistent with a recent meta-analysis.(263)

Large heterogeneity in analyses and limitations in study design attenuate the confidence in this evidence synthesis. We did not evaluate premedication in the context of desensitization to chemotherapy and monoclonal antibodies. (264) The JTFPP continues to recommend prompt treatment of anaphylaxis with epinephrine and highlight that the addition of glucocorticoids and antihistamines should never delay or substitute for this primary management.

Future Directions

At present high-certainty evidence is lacking to determine if antihistamines and/or glucocorticoids provide benefit as supplemental therapies in anaphylaxis management in patients promptly and appropriately treated with epinephrine. In addition, it seems unlikely that antihistamine and/or glucocorticoid premedication is likely to offer clear benefit in the prevention of RCM anaphylaxis in patients with a history of immediate RCM hypersensitivity receiving an alternative low- or iso-osmolar RCM agent or in patients receiving infliximab who have not previously experienced an infliximab hypersensitivity reaction. However, because the evidence synthesis contained in this report is derived from low- certainty, non-randomized trials, additional research evaluating common practices in anaphylaxis treatment and prevention is urgently needed. Further studies are needed to evaluate the use of premedication in children receiving chemotherapy and the use of premedication in subjects undergoing chemotherapy desensitization. In some situations involving anaphylaxis prevention and management, shared decision-making, taking into account patients' preferences and values, should be utilized, particularly when determining the length of medical observation following resolved anaphylaxis. In anaphylaxis, as in many other medical conditions, shared decision-making – which entails patients (and their families) being fully informed of pros and cons of receiving a diagnostic or therapeutic intervention and participating in the medical decision making process – is appropriate in the context of desirable outcomes being closely balanced with undesirable outcomes, which in our guideline is reflected by the navigational signal to the clinician of a conditional (or “weak”) recommendation.

Conclusion

Anaphylaxis is a multi-system allergic emergency. Early recognition and prompt administration of intramuscular epinephrine remain the cornerstone of management. Risk factors for biphasic reactions include severe anaphylaxis and/or the need for more than one dose of epinephrine. Additional biphasic anaphylaxis risk factors include wide pulse pressures, unknown anaphylaxis trigger, cutaneous signs and symptoms, and drug trigger in children. Although treatment of anaphylaxis in the United States also traditionally has included use of antihistamines and glucocorticoids, data demonstrating the benefit of these additional approaches is very low-certainty and when evaluated on the whole does not offer clear support for this practice to prevent biphasic anaphylaxis. Supplemental therapies such as glucocorticoids and antihistamines should never delay the rapid administration of epinephrine as soon as anaphylaxis is recognized. Consistent with the lack of clear benefit of antihistamines and/or glucocorticoids in prevention of biphasic anaphylaxis, current evidence is poor that these therapies prevent anaphylaxis in patients with a history of RCM anaphylaxis (versus using a low- or iso- osmolar contrast without premedication, preferably an alternative agent) or in patients receiving infliximab without prior anaphylaxis; however, some circumstances do exist where premedication with antihistamines and/or glucocorticoids is warranted (e.g., rush immunotherapy and some forms of chemotherapy). As such, while prompt recognition and administration of epinephrine remains paramount in anaphylaxis management, clinical judgement is an irreplaceable key factor to optimize high quality care.

References

1. Wood RA, Camargo CA, Jr., Lieberman P, Sampson HA, Schwartz LB, Zitt M, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. *J Allergy Clin Immunol*. 2014;133(2):461-7.
2. Buka RJ, Knibb RC, Crossman RJ, Melchior CL, Huissoon AP, Hackett S, et al. Anaphylaxis and Clinical Utility of Real-World Measurement of Acute Serum Tryptase in UK Emergency Departments. *J Allergy Clin Immunol Pract*. 2017;5(5):1280-7 e2.
3. Loprinzi Brauer CE, Motosue MS, Li JT, Hagan JB, Bellolio MF, Lee S, et al. Prospective Validation of the NIAID/FAAN Criteria for Emergency Department Diagnosis of Anaphylaxis. *J Allergy Clin Immunol Pract*. 2016;4(6):1220-6.

4. Lieberman P, Camargo CA, Jr., Bohlke K, Jick H, Miller RL, Sheikh A, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. *Ann Allergy Asthma Immunol.* 2006;97(5):596-602.
5. Simons FE, Arduso LR, Bilo MB, Cardona V, Ebisawa M, El-Gamal YM, et al. International consensus on (ICON) anaphylaxis. *The World Allergy Organization journal.* 2014;7(1):9.
6. Jacobs TS, Greenhawt MJ, Hauswirth D, Mitchell L, Green TD. A survey study of index food-related allergic reactions and anaphylaxis management. *Pediatr Allergy Immunol.* 2012;23(6):582-9.
7. Clark S, Wei W, Rudders SA, Camargo CA, Jr. Risk factors for severe anaphylaxis in patients receiving anaphylaxis treatment in US emergency departments and hospitals. *J Allergy Clin Immunol.* 2014;134(5):1125-30.
8. Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. *J Allergy Clin Immunol.* 2014;134(6):1318-28.e7.
9. Turner PJ, Gowland MH, Sharma V, Ierodiakonou D, Harper N, Garcez T, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. *J Allergy Clin Immunol.* 2015;135(4):956-63.e1.
10. Liew WK, Chiang WC, Goh AE, Lim HH, Chay OM, Chang S, et al. Paediatric anaphylaxis in a Singaporean children cohort: changing food allergy triggers over time. *Asia Pac Allergy.* 2013;3(1):29-34.
11. Grabenhenrich LB, Dolle S, Moneret-Vautrin A, Kohli A, Lange L, Spindler T, et al. Anaphylaxis in children and adolescents: The European Anaphylaxis Registry. *J Allergy Clin Immunol.* 2016;137(4):1128-37.e1.
12. Gonzalez-Estrada A, Silvers SK, Klein A, Zell K, Wang XF, Lang DM. Epidemiology of anaphylaxis at a tertiary care center: A report of 730 cases. *Ann Allergy Asthma Immunol.* 2017;118(1):80-5.
13. Carrard A, Rizzuti D, Sokollik C. Update on food allergy. *Allergy.* 2015;70(12):1511-20.
14. Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. *Pediatrics.* 2011;128(1):e9-17.
15. Gupta RS, Warren CM, Smith BM, Jiang J, Blumenstock JA, Davis MM, et al. Prevalence and Severity of Food Allergies Among US Adults. *JAMA Netw Open.* 2019;2(1):e185630.
16. World Allergy Organization. White Book on Allergy: Update 2013, Executive Summary: World Allergy Organ.; 2013.
17. Macy EM. Current Epidemiology and Management of Radiocontrast-Associated Acute- and Delayed-Onset Hypersensitivity: A Review of the Literature. 2018;22.
18. Galli SJ, Tsai M. IgE and mast cells in allergic disease. *Nature medicine.* 2012;18(5):693-704.
19. Finkelman FD, Khodoun MV, Strait R. Human IgE-independent systemic anaphylaxis. *J Allergy Clin Immunol.* 2016;137(6):1674-80.
20. Stone SF, Cotterell C, Isbister GK, Holdgate A, Brown SG, Emergency Department Anaphylaxis I. Elevated serum cytokines during human anaphylaxis: Identification of potential mediators of acute allergic reactions. *J Allergy Clin Immunol.* 2009;124(4):786-92 e4.
21. Brown SG, Stone SF, Fatovich DM, Burrows SA, Holdgate A, Celenza A, et al. Anaphylaxis: clinical patterns, mediator release, and severity. *J Allergy Clin Immunol.* 2013;132(5):1141-9 e5.
22. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Jr., Bock SA, Branum A, et al. Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. *Ann Emerg Med.* 2006;47(4):373-80.
23. Curtis C, Stukus D, Scherzer R. Epinephrine preparedness in pediatric patients with food allergy: an ideal time for change. *Ann Allergy Asthma Immunol.* 2014;112(6):560-2.
24. Prince BT, Mikhail I, Stukus DR. Underuse of epinephrine for the treatment of anaphylaxis: missed opportunities. *J Asthma Allergy.* 2018;11:143-51.

25. Robinson M, Greenhawt M, Stukus DR. Factors associated with epinephrine administration for anaphylaxis in children before arrival to the emergency department. *Ann Allergy Asthma Immunol.* 2017;119(2):164-9.
26. Simons KJ, Simons FE. Epinephrine and its use in anaphylaxis: current issues. *Current opinion in allergy and clinical immunology.* 2010;10(4):354-61.
27. Kaliner M, Austen KF. Cyclic AMP, ATP, and reversed anaphylactic histamine release from rat mast cells. *J Immunol.* 1974;112(2):664-74.
28. Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. *J Allergy Clin Immunol.* 2009;123(2):434-42.
29. Castells M. *An Epidemiological Approach to Reducing the Risk of Fatal Anaphylaxis.* Totowa, NJ 2011.
30. Lauritano EC, Novi A, Santoro MC, Casagrande I. Incidence, clinical features and management of acute allergic reactions: the experience of a single, Italian Emergency Department. *European review for medical and pharmacological sciences.* 2013;17 Suppl 1:39-44.
31. Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. *J Allergy Clin Immunol.* 2014;133(4):1075-83.
32. Church MK, Church DS. Pharmacology of antihistamines. *Indian journal of dermatology.* 2013;58(3):219-24.
33. Inagaki N, Miura T, Nagai H, Koda A. Inhibitory effects of glucocorticoids on increased vascular permeability caused by passive cutaneous anaphylaxis and some chemical mediators in rats. *Japanese journal of pharmacology.* 1988;46(2):189-92.
34. Choo KJ, Simons FE, Sheikh A. Glucocorticoids for the treatment of anaphylaxis. *Evidence-based child health : a Cochrane review journal.* 2013;8(4):1276-94.
35. Pourmand A, Robinson C, Syed W, Mazer-Amirshahi M. Biphasic anaphylaxis: A review of the literature and implications for emergency management. *Am J Emerg Med.* 2018;36(8):1480-5.
36. Lieberman P. Biphasic anaphylactic reactions. *Annals of Allergy, Asthma & Immunology.* 2005;95(3):217-26.
37. Stark BJ, Sullivan TJ. Biphasic and protracted anaphylaxis. *J Allergy Clin Immunol.* 1986;78(1 Pt 1):76-83.
38. Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. *N Engl J Med.* 1992;327(6):380-4.
39. Ellis AK, Day JH. Incidence and characteristics of biphasic anaphylaxis: a prospective evaluation of 103 patients. *Ann Allergy Asthma Immunol.* 2007;98(1):64-9.
40. Grunau BE, Li J, Yi TW, Stenstrom R, Grafstein E, Wiens MO, et al. Incidence of clinically important biphasic reactions in emergency department patients with allergic reactions or anaphylaxis. *Ann Emerg Med.* 2014;63(6):736-44 e2.
41. Rohacek M, Edenhofer H, Bircher A, Bingisser R. Biphasic anaphylactic reactions: occurrence and mortality. *Allergy.* 2014;69(6):791-7.
42. Alqurashi W, Stiell I, Chan K, Neto G, Alsadoon A, Wells G. Epidemiology and clinical predictors of biphasic reactions in children with anaphylaxis. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.* 2015;115(3):217-23.e2.
43. Lee S, Bellolio MF, Hess EP, Erwin P, Murad MH, Campbell RL. Time of Onset and Predictors of Biphasic Anaphylactic Reactions: A Systematic Review and Meta-analysis. *J Allergy Clin Immunol Pract.* 2015;3(3):408-16 e1.
44. Alqurashi W, Ellis AK. Do Corticosteroids Prevent Biphasic Anaphylaxis? *J Allergy Clin Immunol Pract* 2017;5(5):1194-205.
45. Campbell RL, Li JT, Nicklas RA, Sadosty AT. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. *Annals of Allergy, Asthma & Immunology.* 2014;113(6):599-608.

- 1936 46. Ohashi Y, Nakai Y, Murata K. Effect of pretreatment with fexofenadine on the safety of
1937 immunotherapy in patients with allergic rhinitis. 2006;96(4):600-5.
- 1938 47. Klein JS, Yocum MW. Underreporting of anaphylaxis in a community emergency room. *J Allergy*
1939 *Clin Immunol*. 1995;95(2):637-8.
- 1940 48. Clark S, Long AA, Gaeta TJ, Camargo CA, Jr. Multicenter study of emergency department visits
1941 for insect sting allergies. *J Allergy Clin Immunol*. 2005;116(3):643-9.
- 1942 49. Russell WS, Farrar JR, Nowak R, Hays DP, Schmitz N, Wood J, et al. Evaluating the management
1943 of anaphylaxis in US emergency departments: Guidelines vs. practice. *World journal of emergency*
1944 *medicine*. 2013;4(2):98-106.
- 1945 50. Lieberman P, Nicklas RA, Randolph C, Oppenheimer J, Bernstein D, Bernstein J, et al.
1946 Anaphylaxis--a practice parameter update 2015. *Ann Allergy Asthma Immunol*. 2015;115(5):341-84.
- 1947 51. Simons FE, Ebisawa M, Sanchez-Borges M, Thong BY, Worm M, Tanno LK, et al. 2015 update of
1948 the evidence base: World Allergy Organization anaphylaxis guidelines. *The World Allergy Organization*
1949 *journal*. 2015;8(1):32.
- 1950 52. Turner PJ, DunnGalvin A, Hourihane JO. The Emperor Has No Symptoms: The Risks of a Blanket
1951 Approach to Using Epinephrine Autoinjectors for All Allergic Reactions. *J Allergy Clin Immunol Pract*.
1952 2016;4(6):1143-6.
- 1953 53. Shaker MS. An economic evaluation of prophylactic self-injectable epinephrine to prevent
1954 fatalities in children with mild venom anaphylaxis. *Ann Allergy Asthma Immunol*. 2007;99(5):424-8.
- 1955 54. Shaker M, Greenhawt M. The Health and Economic Outcomes of Peanut Allergy Management
1956 Practices. *J Allergy Clin Immunol Pract*. 2018;6(6):2073-80.
- 1957 55. Sricharoen P, Sittichanbuncha Y, Wibulpolprasert A, Srabongkosh E, Sawanyawisuth K. What
1958 clinical factors are associated with biphasic anaphylaxis in Thai adult patients? *Asian Pac J Allergy*
1959 *Immunol*. 2015;33(1):8-13.
- 1960 56. Lee S, Bellolio MF, Hess EP, Campbell RL. Predictors of biphasic reactions in the emergency
1961 department for patients with anaphylaxis. *J Allergy Clin Immunol Pract*. 2014;2(3):281-7.
- 1962 57. Kim TH, Yoon SH, Hong H, Kang HR, Cho SH, Lee SY. Duration of Observation for Detecting a
1963 Biphasic Reaction in Anaphylaxis: A Meta-Analysis. *International archives of allergy and immunology*.
1964 2019;179(1):31-6.
- 1965 58. Shaker M WD, Golden D, Oppenheimer J, Greenhawt M. Simulation of Health and Economic
1966 Benefits of Extended Observation of Resolved Anaphylaxis. *JAMA Network Open*. 2019;2(10)e:1913951.
1967 doi:10.1001/jamanetworkopen.2019.13951.
- 1968 59. Lee S, Hess EP, Lohse C, Gilani W, Chamberlain AM, Campbell RL. Trends, characteristics, and
1969 incidence of anaphylaxis in 2001-2010: A population-based study. *J Allergy Clin Immunol*.
1970 2017;139(1):182-8 e2.
- 1971 60. Worm M, Moneret-Vautrin A, Scherer K, Lang R, Fernandez-Rivas M, Cardona V, et al. First
1972 European data from the network of severe allergic reactions (NORA). *Allergy*. 2014;69(10):1397-404.
- 1973 61. Simons FE, Arduzzo LR, Bilo MB, El-Gamal YM, Ledford DK, Ring J, et al. World Allergy
1974 Organization anaphylaxis guidelines: summary. *J Allergy Clin Immunol*. 2011;127(3):587-93 e1-22.
- 1975 62. Celikel S, Karakaya G, Yurtsever N, Sorkun K, Kalyoncu AF. Bee and bee products allergy in
1976 Turkish beekeepers: determination of risk factors for systemic reactions. *Allergol Immunopathol (Madr)*.
1977 2006;34(5):180-4.
- 1978 63. Simons FE, Arduzzo LR, Dimov V, Ebisawa M, El-Gamal YM, Lockey RF, et al. World Allergy
1979 Organization Anaphylaxis Guidelines: 2013 update of the evidence base. *International archives of allergy*
1980 *and immunology*. 2013;162(3):193-204.
- 1981 64. Faria E, Rodrigues-Cernadas J, Gaspar A, Botelho C, Castro E, Lopes A, et al. Drug-induced
1982 anaphylaxis survey in Portuguese Allergy Departments. *Journal of investigational allergology & clinical*
1983 *immunology*. 2014;24(1):40-8.

- 1984 65. Worm M, Eckermann O, Dolle S, Aberer W, Beyer K, Hawranek T, et al. Triggers and treatment of
1985 anaphylaxis: an analysis of 4,000 cases from Germany, Austria and Switzerland. *Deutsches Arzteblatt*
1986 international. 2014;111(21):367-75.
- 1987 66. Decker WW, Campbell RL, Manivannan V, Luke A, St Sauver JL, Weaver A, et al. The etiology and
1988 incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. *J*
1989 *Allergy Clin Immunol*. 2008;122(6):1161-5.
- 1990 67. Ross MP, Ferguson M, Street D, Klontz K, Schroeder T, Luccioli S. Analysis of food-allergic and
1991 anaphylactic events in the National Electronic Injury Surveillance System. *J Allergy Clin Immunol*.
1992 2008;121(1):166-71.
- 1993 68. Allen KJ, Koplin JJ. The epidemiology of IgE-mediated food allergy and anaphylaxis. *Immunology*
1994 and allergy clinics of North America. 2012;32(1):35-50.
- 1995 69. Clark S, Bock SA, Gaeta TJ, Brenner BE, Cydulka RK, Camargo CA. Multicenter study of
1996 emergency department visits for food allergies. *J Allergy Clin Immunol*. 2004;113(2):347-52.
- 1997 70. Rudders SA, Banerji A, Vassallo MF, Clark S, Camargo CA, Jr. Trends in pediatric emergency
1998 department visits for food-induced anaphylaxis. *J Allergy Clin Immunol*. 2010;126(2):385-8.
- 1999 71. Clark S, Camargo CA, Jr. Epidemiology of anaphylaxis. *Immunology and allergy clinics of North*
2000 *America*. 2007;27(2):145-63, v.
- 2001 72. Harduar-Morano L, Simon MR, Watkins S, Blackmore C. A population-based epidemiologic study
2002 of emergency department visits for anaphylaxis in Florida. *J Allergy Clin Immunol*. 2011;128(3):594-
2003 600.e1.
- 2004 73. Alvarez-Perea A, Tomas-Perez M, Martinez-Lezcano P, Marco G, Perez D, Zubeldia JM, et al.
2005 Anaphylaxis in Adolescent/Adult Patients Treated in the Emergency Department: Differences Between
2006 Initial Impressions and the Definitive Diagnosis. *Journal of investigational allergology & clinical*
2007 *immunology*. 2015;25(4):288-94.
- 2008 74. Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. *Ann Allergy Asthma Immunol*.
2009 2006;97(1):39-43.
- 2010 75. Muraro A, Roberts G, Worm M, Bilo MB, Brockow K, Fernandez Rivas M, et al. Anaphylaxis:
2011 guidelines from the European Academy of Allergy and Clinical Immunology. *Allergy*. 2014;69(8):1026-45.
- 2012 76. Banerji A, Rudders S, Clark S, Wei W, Long AA, Camargo CA, Jr. Retrospective study of drug-
2013 induced anaphylaxis treated in the emergency department or hospital: patient characteristics,
2014 management, and 1-year follow-up. *J Allergy Clin Immunol Pract*. 2014;2(1):46-51.
- 2015 77. Arroabarren E, Lasa EM, Olaciregui I, Sarasqueta C, Munoz JA, Perez-Yarza EG. Improving
2016 anaphylaxis management in a pediatric emergency department. *Pediatr Allergy Immunol*.
2017 2011;22(7):708-14.
- 2018 78. Campbell RL, Luke A, Weaver AL, St Sauver JL, Bergstralh EJ, Li JT, et al. Prescriptions for self-
2019 injectable epinephrine and follow-up referral in emergency department patients presenting with
2020 anaphylaxis. *Ann Allergy Asthma Immunol*. 2008;101(6):631-6.
- 2021 79. Garvey LH, Belhage B, Kroigaard M, Husum B, Malling HJ, Mosbech H. Treatment with
2022 epinephrine (adrenaline) in suspected anaphylaxis during anesthesia in Denmark. *Anesthesiology*.
2023 2011;115(1):111-6.
- 2024 80. Gelincik A, Demirturk M, Yilmaz E, Ertek B, Erdogan D, Colakoglu B, et al. Anaphylaxis in a
2025 tertiary adult allergy clinic: a retrospective review of 516 patients. *Ann Allergy Asthma Immunol*.
2026 2013;110(2):96-100.
- 2027 81. Grabenhenrich LB, Dolle S, Rueff F, Renaudin JM, Scherer K, Pfohler C, et al. Epinephrine in
2028 Severe Allergic Reactions: The European Anaphylaxis Register. *J Allergy Clin Immunol Pract*.
2029 2018;6(6):1898-906 e1.
- 2030 82. Mehl A, Wahn U, Niggemann B. Anaphylactic reactions in children--a questionnaire-based
2031 survey in Germany. *Allergy*. 2005;60(11):1440-5.

83. Mostmans Y, Grosber M, Blykers M, Mols P, Naeije N, Gutermuth J. Adrenaline in anaphylaxis treatment and self-administration: experience from an inner city emergency department. *Allergy*. 2017;72(3):492-7.
84. O'Keefe A, Clarke A, St Pierre Y, Mill J, Asai Y, Eisman H, et al. The Risk of Recurrent Anaphylaxis. *J Pediatr*. 2017;180:217-21.
85. Pourang D, Batech M, Sheikh J, Samant S, Kaplan M. Anaphylaxis in a health maintenance organization: International Classification of Diseases coding and epinephrine auto-injector prescribing. *Ann Allergy Asthma Immunol*. 2017;118(2):186-90 e1.
86. Rueter K, Ta B, Bear N, Lucas M, Borland ML, Prescott SL. Increased Use of Adrenaline in the Management of Childhood Anaphylaxis Over the Last Decade. 2018.
87. Sidhu N, Jones S, Perry T, Thompson T, Storm E, Melguizo Castro MS, et al. Evaluation of Anaphylaxis Management in a Pediatric Emergency Department. *Pediatr Emerg Care*. 2016;32(8):508-13.
88. Wright CD, Longjohn M, Lieberman PL, Lieberman JA. An analysis of anaphylaxis cases at a single pediatric emergency department during a 1-year period. *Ann Allergy Asthma Immunol*. 2017;118(4):461-4.
89. Helbling A, Hurni T, Mueller UR, Pichler WJ. Incidence of anaphylaxis with circulatory symptoms: a study over a 3-year period comprising 940,000 inhabitants of the Swiss Canton Bern. *Clin Exp Allergy*. 2004;34(2):285-90.
90. Tanno LK, Bierrenbach AL, Simons FER, Cardona V, Thong BY-H, Molinari N, et al. Critical view of anaphylaxis epidemiology: open questions and new perspectives. *Allergy, Asthma & Clinical Immunology*. 2018;14(1):12.
91. Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. *Clin Exp Allergy*. 2000;30(8):1144-50.
92. Moneret-Vautrin DA, Morisset M, Flabbee J, Beaudouin E, Kanny G. Epidemiology of life-threatening and lethal anaphylaxis: a review. *Allergy*. 2005;60(4):443-51.
93. Pichichero ME, Zagursky R. Penicillin and cephalosporin allergy. *Ann Allergy Asthma Immunol*. 2014;112(5):404-12.
94. Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Current opinion in allergy and clinical immunology. 2004;4(4):285-90.
95. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. *J Allergy Clin Immunol*. 2001;107(1):191-3.
96. Yocum MW, Butterfield JH, Klein JS, Volcheck GW, Schroeder DR, Silverstein MD. Epidemiology of anaphylaxis in Olmsted County: A population-based study. *J Allergy Clin Immunol*. 1999;104(2 Pt 1):452-6.
97. Sampson HA. Anaphylaxis and emergency treatment. *Pediatrics*. 2003;111(6 Pt 3):1601-8.
98. Jackson KD, Howie LD, Akinbami LJ. Trends in allergic conditions among children: United States, 1997-2011. *NCHS data brief*. 2013(121):1-8.
99. Clark S, Espinola JA, Rudders SA, Banerji A, Camargo CA. Favorable trends in the frequency of U.S. emergency department visits for food allergy, 2001-2009. *Allergy Asthma Proc*. 2013;34(5):439-45.
100. Parlaman JP, Oron AP, Uspal NG, DeJong KN, Tieder JS. Emergency and Hospital Care for Food-Related Anaphylaxis in Children. *Hospital pediatrics*. 2016;6(5):269-74.
101. Hess EP, Nestler DM. Transforming the emergency department observation unit: a look into the future. *Cardiology clinics*. 2012;30(4):501-21.
102. Motosue MS, Bellolio MF, Van Houten HK, Shah ND, Campbell RL. National trends in emergency department visits and hospitalizations for food-induced anaphylaxis in US children. *Pediatr Allergy Immunol*. 2018;29(5):538-44.

103. Bollinger ME, Dahlquist LM, Mudd K, Sonntag C, Dillinger L, McKenna K. The impact of food allergy on the daily activities of children and their families. *Ann Allergy Asthma Immunol.* 2006;96(3):415-21.
104. Patel DA, Holdford DA, Edwards E, Carroll NV. Estimating the economic burden of food-induced allergic reactions and anaphylaxis in the United States. *J Allergy Clin Immunol.* 2011;128(1):110-5.e5.
105. Sicherer SH, Forman JA, Noone SA. Use assessment of self-administered epinephrine among food-allergic children and pediatricians. *Pediatrics.* 2000;105(2):359-62.
106. Shaker M, Kanaoka T, Feenan L, Greenhawt M. An economic evaluation of immediate vs non-immediate activation of emergency medical services after epinephrine use for peanut-induced anaphylaxis. *Ann Allergy Asthma Immunol.* 2019;122(1):79-85.
107. Sousa-Pinto B, Fonseca JA, Gomes ER. Frequency of self-reported drug allergy: A systematic review and meta-analysis with meta-regression. *Ann Allergy Asthma Immunol.* 2017;119(4):362-73 e2.
108. Harper NJN, Cook TM, Garcez T, Lucas DN, Thomas M, Kemp H, et al. Anaesthesia, surgery, and life-threatening allergic reactions: management and outcomes in the 6th National Audit Project (NAP6). *Br J Anaesth.* 2018;121(1):172-88.
109. Golden DB, Demain J, Freeman T, Graft D, Tankersley M, Tracy J, et al. Stinging insect hypersensitivity: A practice parameter update 2016. *Ann Allergy Asthma Immunol.* 2017;118(1):28-54.
110. Bilo MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. *Clin Exp Allergy.* 2009;39(10):1467-76.
111. Graft DF. Insect sting allergy. *Medical Clinics of North America.* 2006;90(1):211-+.
112. Golden DB, Marsh DG, Kagey-Sobotka A, Freidhoff L, Szkló M, Valentine MD, et al. Epidemiology of insect venom sensitivity. *JAMA.* 1989;262(2):240-4.
113. Hoffman DR. Fatal reactions to hymenoptera stings. *Allergy Asthma Proc.* 2003;24(2):123-7.
114. Oude Elberink JN, van der Heide S, Guyatt GH, Dubois AE. Immunotherapy improves health-related quality of life of adult patients with dermal reactions following yellow jacket stings. *Clin Exp Allergy.* 2009;39(6):883-9.
115. Oude Elberink JN, van der Heide S, Guyatt GH, Dubois AE. Analysis of the burden of treatment in patients receiving an EpiPen for yellow jacket anaphylaxis. *J Allergy Clin Immunol.* 2006;118(3):699-704.
116. Oude Elberink JN, De Monchy JG, Van Der Heide S, Guyatt GH, Dubois AE. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. *J Allergy Clin Immunol.* 2002;110(1):174-82.
117. de Groot H. Allergy to bumblebees. *Current opinion in allergy and clinical immunology.* 2006;6(4):294-7.
118. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. *J Allergy Clin Immunol.* 2017;140(2):335-48.
119. Francis A, Bosio E, Stone SF, Fatovich DM, Arendts G, Nagree Y, et al. Neutrophil activation during acute human anaphylaxis: analysis of MPO and sCD62L. *Clin Exp Allergy.* 2017;47(3):361-70.
120. Castells M. Diagnosis and management of anaphylaxis in precision medicine. *J Allergy Clin Immunol.* 2017;140(2):321-33.
121. Voehringer D. Protective and pathological roles of mast cells and basophils. *Nature reviews Immunology.* 2013;13(5):362-75.
122. Kaliner M, Sigler R, Summers R, Shelhamer JH. Effects of infused histamine: analysis of the effects of H-1 and H-2 histamine receptor antagonists on cardiovascular and pulmonary responses. *J Allergy Clin Immunol.* 1981;68(5):365-71.
123. Vigorito C, Russo P, Picotti GB, Chiariello M, Poto S, Marone G. Cardiovascular effects of histamine infusion in man. *J Cardiovasc Pharmacol.* 1983;5(4):531-7.

124. Lin RY, Schwartz LB, Curry A, Pesola GR, Knight RJ, Lee HS, et al. Histamine and tryptase levels in patients with acute allergic reactions: An emergency department-based study. *J Allergy Clin Immunol.* 2000;106(1 Pt 1):65-71.
125. Vadas P, Perelman B, Liss G. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. *J Allergy Clin Immunol.* 2013;131(1):144-9.
126. Laroche D, Gomis P, Gallimidi E, Malinovsky JM, Mertes PM. Diagnostic value of histamine and tryptase concentrations in severe anaphylaxis with shock or cardiac arrest during anesthesia. *Anesthesiology.* 2014;121(2):272-9.
127. De Schryver S, Halbrich M, Clarke A, La Vieille S, Eisman H, Alizadehfar R, et al. Tryptase levels in children presenting with anaphylaxis: Temporal trends and associated factors. *J Allergy Clin Immunol.* 2016;137(4):1138-42.
128. Dua S, Dowey J, Foley L, Islam S, King Y, Ewan P, et al. Diagnostic Value of Tryptase in Food Allergic Reactions: A Prospective Study of 160 Adult Peanut Challenges. *J Allergy Clin Immunol Pract.* 2018.
129. Francis A, Fatovich DM, Arendts G, Macdonald SP, Bosio E, Nagree Y, et al. Serum mast cell tryptase measurements: Sensitivity and specificity for a diagnosis of anaphylaxis in emergency department patients with shock or hypoxaemia. *Emerg Med Australas.* 2018;30(3):366-74.
130. Grandel KE, Farr RS, Wanderer AA, Eisenstadt TC, Wasserman SI. Association of platelet-activating factor with primary acquired cold urticaria. *N Engl J Med.* 1985;313(7):405-9.
131. Archer CB, Page CP, Paul W, Morley J, MacDonald DM. Inflammatory characteristics of platelet activating factor (PAF-acether) in human skin. *Br J Dermatol.* 1984;110(1):45-50.
132. Krause K, Gimenez-Arnau A, Martinez-Escala E, Farre-Albadalejo M, Abajian M, Church MK, et al. Platelet-activating factor (PAF) induces wheal and flare skin reactions independent of mast cell degranulation. *Allergy.* 2013;68(2):256-8.
133. Lai CK, Ollier S, Lau CK, Holgate ST. Effect of azelastine and ketotifen on the bronchial and skin responses to platelet-activating factor in humans. *Clin Exp Allergy.* 1991;21(4):489-96.
134. Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. *N Engl J Med.* 2008;358(1):28-35.
135. Soter NA, Lewis RA, Corey EJ, Austen KF. Local effects of synthetic leukotrienes (LTC₄, LTD₄, LTE₄, and LTB₄) in human skin. *J Invest Dermatol.* 1983;80(2):115-9.
136. Weiss JW, Drazen JM, Coles N, McFadden ER, Jr., Weller PF, Corey EJ, et al. Bronchoconstrictor effects of leukotriene C in humans. *Science.* 1982;216(4542):196-8.
137. Weiss JW, Drazen JM, McFadden ER, Jr., Weller P, Corey EJ, Lewis RA, et al. Airway constriction in normal humans produced by inhalation of leukotriene D. Potency, time course, and effect of aspirin therapy. *JAMA.* 1983;249(20):2814-7.
138. van der Linden PW, Hack CE, Kerckhaert JA, Struyvenberg A, van der Zwan JC. Preliminary report: complement activation in wasp-sting anaphylaxis. *Lancet.* 1990;336(8720):904-6.
139. Khodoun M, Strait R, Orekov T, Hogan S, Karasuyama H, Herbert DR, et al. Peanuts can contribute to anaphylactic shock by activating complement. *J Allergy Clin Immunol.* 2009;123(2):342-51.
140. Fukuoka Y, Xia HZ, Sanchez-Munoz LB, Dellinger AL, Escibano L, Schwartz LB. Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5. *J Immunol.* 2008;180(9):6307-16.
141. Smith PL, Kagey-Sobotka A, Bleecker ER, Traystman R, Kaplan AP, Gralnick H, et al. Physiologic manifestations of human anaphylaxis. *J Clin Invest.* 1980;66(5):1072-80.
142. Lee JM, Greenes DS. Biphasic anaphylactic reactions in pediatrics. *Pediatrics.* 2000;106(4):762-6.
143. Sicherer SH, Simons FER. Epinephrine for First-aid Management of Anaphylaxis. *Pediatrics.* 2017;139(3).

144. Lieberman P, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM, Bernstein DI, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. *J Allergy Clin Immunol*. 2010;126(3):477-80 e1-42.
145. Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. *J Allergy Clin Immunol*. 1998;101(1 Pt 1):33-7.
146. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. *J Allergy Clin Immunol*. 2001;108(5):871-3.
147. Dreborg S, Kim L, Tsai G, Kim H. Epinephrine auto-injector needle lengths: Can both subcutaneous and periosteal/intraosseous injection be avoided? *Ann Allergy Asthma Immunol*. 2018;120(6):648-53 e1.
148. Lippert WC, Wall EJ. Optimal intramuscular needle-penetration depth. *Pediatrics*. 2008;122(3):e556-63.
149. Manuyakorn W, Bamrungchaowkasem B, Ruangwattanapaisarn N, Kamchaisatian W, Benjaponpitak S. Optimal needle length for epinephrine prefilled syringe in children. *Ann Allergy Asthma Immunol*. 2017;118(6):740-1 e1.
150. Manuyakorn W, Bamrungchaowkasem B, Ruangwattanapaisarn N, Kamchaisatian W, Benjaponpitak S. Needle length for epinephrine prefilled syringes in children and adolescents: Is one inch needle appropriate? *Asian Pac J Allergy Immunol*. 2018;36(2):113-9.
151. Rawas-Qalaji MM, Simons FE, Simons KJ. Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. *J Allergy Clin Immunol*. 2006;117(2):398-403.
152. Rawas-Qalaji M, Rachid O, Mendez BA, Losada A, Simons FE, Simons KJ. Adrenaline (epinephrine) microcrystal sublingual tablet formulation: enhanced absorption in a preclinical model. *The Journal of pharmacy and pharmacology*. 2015;67(1):20-5.
153. ARS Pharmaceuticals Announces FDA Fast Track Designation for ARS-1 Intranasal Epinephrine Spray [news release]. San Diego, California; February 19, 2019: Pure Communications [Available from: <https://www.businesswire.com/news/home/20190219005141/en/ARS-Pharmaceuticals-Announces-FDA-Fast-Track-Designation>].
154. Srisawat C, Nakponetong K, Benjasupattananun P, Suratannon C, Wachirutmanggur L, Boonchoo S, et al. A preliminary study of intranasal epinephrine administration as a potential route for anaphylaxis treatment. *Asian Pac J Allergy Immunol*. 2016;34(1):38-43.
155. Campbell RL, Bellolio MF, Knutson BD, Bellamkonda VR, Fedko MG, Nestler DM, et al. Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine. *J Allergy Clin Immunol Pract*. 2015;3(1):76-80.
156. Shaker M, Toy D, Lindholm C, Low J, Reigh E, Greenhawt M. Summary and simulation of reported adverse events from epinephrine autoinjectors and a review of the literature. *J Allergy Clin Immunol Pract*. 2018.
157. Brown JC, Tuuri RE, Akhter S, Guerra LD, Goodman IS, Myers SR, et al. Lacerations and Embedded Needles Caused by Epinephrine Autoinjector Use in Children. *Ann Emerg Med*. 2016;67(3):307-15 e8.
158. Turner PJ, Jerschow E, Umasunthar T, Lin R, Campbell DE, Boyle RJ. Fatal Anaphylaxis: Mortality Rate and Risk Factors. *J Allergy Clin Immunol Pract*. 2017;5(5):1169-78.
159. Yu Y, Wang P, Bian L, Hong S. Rare Death Via Histamine Poisoning Following Crab Consumption: A Case Report. *J Forensic Sci*. 2018;63(3):980-2.
160. Nurmatov UB, Rhatigan E, Simons FE, Sheikh A. H2-antihistamines for the treatment of anaphylaxis with and without shock: a systematic review. 2014;112(2):126-31.

161. Horak F, Stubner UP, Ziegelmayer R, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. *J Allergy Clin Immunol*. 2002;109(6):956-61.
162. Derakhshandeh K, Mohebbi M. Oral bioavailability and pharmacokinetic study of cetirizine HCl in Iranian healthy volunteers. *Res Pharm Sci*. 2009;4(2):113-21.
163. Zyrtec (cetirizine) prescribing information [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/19835s15,%2020346s8lbl.pdf.
164. Gabrielli S, Clarke A, Morris J, Eisman H, Gravel J, Enarson P, et al. Evaluation of Prehospital Management in a Canadian Emergency Department Anaphylaxis Cohort. *J Allergy Clin Immunol Pract*. 2019;7(7):2232-8 e3.
165. Liyanage CK, Galappatthy P, Seneviratne SL. Corticosteroids in management of anaphylaxis; a systematic review of evidence. *European annals of allergy and clinical immunology*. 2017;49(5):196-207.
166. Michelson KA, Monuteaux MC, Neuman MI. Glucocorticoids and Hospital Length of Stay for Children with Anaphylaxis: A Retrospective Study. 2015;167(3):719-24.e1.
167. Croxtall JD, Choudhury Q, Flower RJ. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. *British journal of pharmacology*. 2000;130(2):289-98.
168. Schardt C, Adams Mb Fau - Owens T, Owens T Fau - Keitz S, Keitz S Fau - Fontelo P, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. (1472-6947 (Electronic)).
169. Linstone HA, Turoff M. The Delphi method : techniques and applications. Reading, Mass.: Addison-Wesley Pub. Co., Advanced Book Program; 1975. xx, 620 p. p.
170. Dalkey NH, Olaf. An Experimental Application of the DELPHI Method to the Use of Experts. *Management Science*. 1963;9(3):458-67.
171. Schunemann H, Santesso N. How to GRADE the Evidence: The Cochrane Collaboration 2016 [Available from: <http://training.cochrane.org/>.
172. Brown B. Delphi Process: A Methodology Used for the Elicitation of Opinions of Experts. Santa Monica, CA: Rand; 1968.
173. Brady Jr WJ, Lubner S, Carter CT, Guertler A, Lindbeck G. Multiphasic anaphylaxis: An uncommon event in the emergency department. *Academic Emergency Medicine*. 1997;4(3):193-7.
174. Brazil E, MacNamara AF. 'Not so immediate' hypersensitivity - The danger of biphasic anaphylactic reactions. *Journal of Accident and Emergency Medicine*. 1998;15(4):252-3.
175. Calvani M, Cardinale F, Martelli A, Muraro A, Pucci N, Savino F, et al. Risk factors for severe pediatric food anaphylaxis in Italy. *Pediatr Allergy Immunol*. 2011;22(8):813-9.
176. Cianferoni A, Novembre E, Mugnaini L, Lombardi E, Bernardini R, Pucci N, et al. Clinical features of acute anaphylaxis in patients admitted to a university hospital: an 11-year retrospective review (1985-1996). *Ann Allergy Asthma Immunol*. 2001;87(1):27-32.
177. Confino-Cohen R, Goldberg A. Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study. *Ann Allergy Asthma Immunol*. 2010;104(1):73-8.
178. Douglas DM, Sukenick E, Andrade WP, Brown JS. Biphasic systemic anaphylaxis: an inpatient and outpatient study. *J Allergy Clin Immunol*. 1994;93(6):977-85.
179. Inoue N, Yamamoto A. Clinical evaluation of pediatric anaphylaxis and the necessity for multiple doses of epinephrine. *Asia Pacific Allergy*. 2013;3(2):106-14.
180. Jirapongsananuruk O, Bunsawansong W, Piyaphanee N, Visitsunthorn N, Thongngarm T, Vichyanond P. Features of patients with anaphylaxis admitted to a university hospital. *Ann Allergy Asthma Immunol*. 2007;98(2):157-62.

181. Ko BS, Kim WY, Ryoo SM, Ahn S, Sohn CH, Seo DW, et al. Biphasic reactions in patients with anaphylaxis treated with corticosteroids. *Ann Allergy Asthma Immunol.* 2015;115(4):312-6.
182. Lee J, Garrett JPD, Brown-Whitehorn T, Spergel JM. Biphasic reactions in children undergoing oral food challenges. *Allergy and Asthma Proceedings.* 2013;34(3):220-6.
183. Lertnawapan R, Maek-a-nantawat W. Anaphylaxis and biphasic phase in Thailand: 4-year observation. *Allergol Int.* 2011;60(3):283-9.
184. Manivannan V, Hess EP, Bellamkonda VR, Nestler DM, Bellolio MF, Hagan JB, et al. A multifaceted intervention for patients with anaphylaxis increases epinephrine use in adult emergency department. *J Allergy Clin Immunol Pract.* 2014;2(3):294-9 e1.
185. Manuyakorn W, Benjaponpitak S, Kamchaisatian W, Vilaiyuk S, Sasisakulporn C, Jotikasthira W. Pediatric anaphylaxis: triggers, clinical features, and treatment in a tertiary-care hospital. *Asian Pac J Allergy Immunol.* 2015;33(4):281-8.
186. Mehr S, Liew WK, Tey D, Tang MLK. Clinical predictors for biphasic reactions in children presenting with anaphylaxis. *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.* 2009;39(9):1390-6.
187. Noone S, Ross J, Sampson HA, Wang J. Epinephrine use in positive oral food challenges performed as a screening test for food allergy therapy trials. *The journal of allergy and clinical immunology In practice.* 2015;3(3):424-8.
188. Orhan F, Canitez Y, Bakirtas A, Yilmaz O, Boz AB, Can D, et al. Anaphylaxis in Turkish children: a multi-centre, retrospective, case study. *Clin Exp Allergy.* 2011;41(12):1767-76.
189. Poachanukoon O, Paopairochanakorn C. Incidence of anaphylaxis in the emergency department: a 1-year study in a university hospital. *Asian Pac J Allergy Immunol.* 2006;24(2-3):111-6.
190. Scranton SE, Gonzalez EG, Waibel KH. Incidence and characteristics of biphasic reactions after allergen immunotherapy. *The Journal of allergy and clinical immunology.* 2009;123(2):493-8.
191. Smit DV, Cameron PA, Rainer TH. Anaphylaxis presentations to an emergency department in Hong Kong: incidence and predictors of biphasic reactions. *J Emerg Med.* 2005;28(4):381-8.
192. Vezir E, Erkocoglu M, Kaya A, Toyran M, Ozcan C, Akan A, et al. Characteristics of anaphylaxis in children referred to a tertiary care center. *Allergy & Asthma Proceedings.* 2013;34(3):239-46.
193. Yang MS, Lee SH, Kim TW, Kwon JW, Lee SM, Kim SH, et al. Epidemiologic and clinical features of anaphylaxis in Korea. *Ann Allergy Asthma Immunol.* 2008;100(1):31-6.
194. Evidence-Based Medicine Toolbox. Odds Ratio to NNT Converter [Available from: <https://ebm-tools.knowledgetranslation.net/calculator/converter/>].
195. Blumenthal KG, Li Y, Banerji A, Yun BJ, Long AA, Walensky RP. The Cost of Penicillin Allergy Evaluation. *J Allergy Clin Immunol Pract.* 2018;6(3):1019-27 e2.
196. Yu YR, Abbas PI, Smith CM, Carberry KE, Ren H, Patel B, et al. Time-driven activity-based costing: A dynamic value assessment model in pediatric appendicitis. *J Pediatr Surg.* 2017;52(6):1045-9.
197. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. *J Clin Oncol.* 1990;8(7):1263-8.
198. Cochrane.org. General Methods for Cochrane Reviews. Peto Odds Ratio Method. [Available from: https://handbook-5-1.cochrane.org/chapter_9/9_4_4_2_peto_odds_ratio_method.htm].
199. Grunau BE, Wiens MO, Rowe BH, McKay R, Li J, Yi TW, et al. Emergency Department Corticosteroid Use for Allergy or Anaphylaxis Is Not Associated With Decreased Relapses. 2015;66(4):381-9.
200. Guiot A, Ambroggio L, Parker M, Goodman MA, Perez Ramirez L, Lierl M, et al. Variation in the Inpatient Management of Pediatric Anaphylaxis. 2017;56(11):1064-7.
201. Kawano T, Scheuermeyer FX, Gibo K, Stenstrom R, Rowe B, Grafstein E, et al. H1-antihistamines Reduce Progression to Anaphylaxis Among Emergency Department Patients With Allergic Reactions. 2017;24(6):733-41.

- 2312 202. Lee S, Peterson A, Lohse CM, Hess EP, Campbell RL. Further Evaluation of Factors That May
2313 Predict Biphasic Reactions in Emergency Department Anaphylaxis Patients. *J Allergy Clin Immunol Pract.*
2314 2017;5(5):1295-301.
- 2315 203. Lin RY, Curry A, Pesola GR, Knight RJ, Lee HS, Bakalchuk L, et al. Improved outcomes in patients
2316 with acute allergic syndromes who are treated with combined H1 and H2 antagonists. *Ann Emerg Med.*
2317 2000;36(5):462-8.
- 2318 204. Oya S, Nakamori T, Kinoshita H. Incidence and characteristics of biphasic and protracted
2319 anaphylaxis: Evaluation of 114 inpatients. 2014;1(4):228-33.
- 2320 205. Chang A, Kim M, Seyer M, Patel S. Allergic reactions associated with pegaspargase in adults.
2321 *Leuk Lymphoma.* 2016;57(7):1665-8.
- 2322 206. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, et al. Phase II trial of docetaxel
2323 in patients with stage III and IV non-small-cell lung cancer. *J Clin Oncol.* 1994;12(6):1232-7.
- 2324 207. Jerzak KJ, Deghan Manshadi S, Ng P, Maganti M, McCuaig JM, Bulter M, et al. Prevention of
2325 carboplatin-induced hypersensitivity reactions in women with ovarian cancer. 2018;24(2):83-90.
- 2326 208. Mach CM, Lapp EA, Weddle KJ, Hunter RJ, Burns KA, Parker C, et al. Adjunct Histamine Blockers
2327 as Premedications to Prevent Carboplatin Hypersensitivity Reactions. 2016;36(5):482-7.
- 2328 209. Onetto N, Canetta R, Winograd B, Catane R, Dougan M, Grechko J, et al. Overview of Taxol
2329 safety. *J Natl Cancer Inst Monogr.* 1993(15):131-9.
- 2330 210. Rougier P. Docetaxel delivers new management opportunities for gastrointestinal carcinomas.
2331 1995;6 Suppl 4:25-9.
- 2332 211. Seki K, Senzaki K, Tsuduki Y, Ioroi T, Fujii M, Yamauchi H, et al. Risk factors for oxaliplatin-
2333 induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. *Int J Med Sci.*
2334 2011;8(3):210-5.
- 2335 212. Shen Y, Li C, Liu W, Mao W, Qian H, Wang H, et al. Clinical Analysis of Hypersensitivity Reactions
2336 to Oxaliplatin among Colorectal Cancer Patients. 2018.
- 2337 213. Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, et al. Incidence, risk
2338 factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab.
2339 *Oncologist.* 2014;19(3):228-34.
- 2340 214. Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, et al. Docetaxel in
2341 patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-
2342 Clinical Trials Group. *J Clin Oncol.* 1996;14(2):422-8.
- 2343 215. Abe S, Fukuda H, Tobe K, Ibukuro K. Protective effect against repeat adverse reactions to
2344 iodinated contrast medium: Premedication vs. changing the contrast medium. *Eur Radiol.*
2345 2016;26(7):2148-54.
- 2346 216. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to
2347 ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast
2348 Media. *Radiology.* 1990;175(3):621-8.
- 2349 217. Kolbe AB, Hartman RP, Hoskin TL, Carter RE, Maddox DE, Hunt CH, et al. Premedication of
2350 patients for prior urticarial reaction to iodinated contrast medium. 2014;39(2):432-7.
- 2351 218. Lee SH, Park HW, Cho SH, Kim SS. The efficacy of single premedication with antihistamines for
2352 radiocontrast media hypersensitivity. *Asia Pac Allergy.* 2016;6(3):164-7.
- 2353 219. Park HJ, Park JW, Yang MS, Kim MY, Kim SH, Jang GC, et al. Re-exposure to low osmolar
2354 iodinated contrast media in patients with prior moderate-to-severe hypersensitivity reactions: A
2355 multicentre retrospective cohort study. *Eur Radiol.* 2017;27(7):2886-93.
- 2356 220. Park SJ, Kang DY, Sohn KH, Yoon SH, Lee W, Choi YH, et al. Immediate Mild Reactions to CT with
2357 Iodinated Contrast Media: Strategy of Contrast Media Readministration without Corticosteroids.
2358 *Radiology.* 2018;288(3):710-6.

221. Augustsson J, Eksborg S, Ernestam S, Gullstrom E, van Vollenhoven R. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. 2007;66(11):1462-6.
222. Berchtold E, Maibach R, Muller U. Reduction of side effects from rush-immunotherapy with honey bee venom by pretreatment with terfenadine. Clin Exp Allergy. 1992;22(1):59-65.
223. Braaten K, Holcombe RF, Kim SS. Premedication with IV steroids effectively prevented anaphylactic reactions following ferumoxytol given as IV push in hematology and oncology patients. 2015;90(10):E207.
224. Brockow K, Kiehn M, Riethmüller C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial 1997; 100(4):[458-63 pp.]. Available from: <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/372/CN-00144372/frame.html>.
225. Caron EJ, Manock SR, Maudlin J, Koleski J, Theakston RD, Warrell DA, et al. Apparent marked reduction in early antivenom reactions compared to historical controls: was it prophylaxis or method of administration? Toxicon. 2009;54(6):779-83.
226. Fan H, Marcopito L, Cardoso J, França F, Malaque C, Ferrari R, et al. Sequential randomised and double blind trial of promethazine prophylaxis against early anaphylactic reactions to antivenom for bothrops snake bites 1999; 318(7196):[1451-2 pp.]. Available from: <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/621/CN-00163621/frame.html>.
227. Gold SL, Cohen-Mekelburg S, Schneider Y, Shen N, Faggen A, Rupert A, et al. Premedication Use in Preventing Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease: A Single Center Cohort Study. 2017;23(10):1882-9.
228. Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol. 1990;85(2):473-9.
229. Jacobstein DA, Markowitz JE, Kirschner BS, Ferry G, Cohen SA, Gold BD, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. 2005;11(5):442-6.
230. Jagdis A, Berlin N, Barron C, Giruparajah M, Leader N, MacLachlan S, et al. Effect of ketotifen premedication on adverse reactions during peanut oral immunotherapy. 2014;10(1).
231. Lorenz W, Doenicke A, Schöning B, Mamorski J, Weber D, Hinterlang E, et al. H1 + H2-receptor antagonists for premedication in anaesthesia and surgery: a critical view based on randomized clinical trials with Haemaccel and various antiallergic drugs 1980; 10(1 Pt 2):[114-24 pp.]. Available from: <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/888/CN-00022888/frame.html>.
232. Muller UR, Jutel M, Reimers A, Zumkehr J, Huber C, Krieger C, et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. 2008;122(5):1001-7.e4.
233. Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol. 1996;97(6):1207-13.
234. Portnoy J, Bagstad K, Kanarek H, Pacheco F, Hall B, Barnes C. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy. 1994;73(5):409-18.
235. Reimers A, Hari Y, Müller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial 2000; 55(5):[484-8 pp.]. Available from: <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/221/CN-00297221/frame.html>.

236. Sanders RP, Maddirala SD, Geiger TL, Pounds S, Sandlund JT, Ribeiro RC, et al. Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children. 2005;130(5):781-7.
237. Schoning B, Lorenz W, Doenicke A. Prophylaxis of anaphylactoid reactions to a polypeptidal plasma substitute by H1- plus H2-receptor antagonists: synopsis of three randomized controlled trials. 1982;60(17):1048-55.
238. Tankersley M, Walker R, Butler W, Hagan L, Napoli D, Freeman T. Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment 2002; 109(3):[556-62 pp.]. Available from: <http://cochranelibrary-wiley.com/o/cochrane/clcentral/articles/814/CN-00378814/frame.html>.
239. Jung JW, Kang HR, Lee SH, Cho SH. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital. *Oncology*. 2014;86(3):127-34.
240. Lasser EC, Berry CC, Mishkin MM, Williamson B, Zheutlin N, Silverman JM. Pretreatment with corticosteroids to prevent adverse reactions to nonionic contrast media. 1994;162(3):523-6.
241. Brockow K. Immediate and delayed reactions to radiocontrast media: is there an allergic mechanism? *Immunology and allergy clinics of North America*. 2009;29(3):453-68.
242. Goodfellow T, Holdstock GE, Brunton FJ, Bamforth J. Fatal acute vasculitis after high-dose urography with iohexol. *Br J Radiol*. 1986;59(702):620-1.
243. Hasdenteufel F, Waton J, Cordebar V, Studer M, Collignon O, Luyasu S, et al. Delayed hypersensitivity reactions caused by iodixanol: an assessment of cross-reactivity in 22 patients. *J Allergy Clin Immunol*. 2011;128(6):1356-7.
244. Laffitte E, Nenadov Beck M, Hofer M, Hohl D, Panizzon RG. Severe Stevens-Johnson syndrome induced by contrast medium iopentol (Imagopaque). *Br J Dermatol*. 2004;150(2):376-8.
245. Miranda-Romero A, Sanchez-Sambucety P, Esquivias Gomez JI, Martinez Fernandez M, Bajo del Pozo C, Aragonese Fraile H, et al. Vegetating iododerma with fatal outcome. *Dermatology*. 1999;198(3):295-7.
246. Rosado A, Canto G, Veleiro B, Rodriguez J. Toxic epidermal necrolysis after repeated injections of iohexol. *AJR Am J Roentgenol*. 2001;176(1):262-3.
247. Savill JS, Barrie R, Ghosh S, Muhlemann M, Dawson P, Pusey CD. Fatal Stevens-Johnson syndrome following urography with iopamidol in systemic lupus erythematosus. *Postgrad Med J*. 1988;64(751):392-4.
248. Schmidt BJ, Foley WD, Bohorfoush AG. Toxic epidermal necrolysis related to oral administration of diluted diatrizoate meglumine and diatrizoate sodium. *AJR Am J Roentgenol*. 1998;171(5):1215-6.
249. Vaillant L, Pengloan J, Blanchier D, De Muret A, Lorette G. Iododerma and acute respiratory distress with leucocytoclastic vasculitis following the intravenous injection of contrast medium. *Clin Exp Dermatol*. 1990;15(3):232-3.
250. Al-Ahmad M, Bouza TR. Successful desensitization to radiocontrast media in two high-risk cardiac patients. *Ann Saudi Med*. 2017;37(4):333-5.
251. Hebert AA, Bogle MA. Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome. *J Am Acad Dermatol*. 2004;50(2):286-8.
252. Romano A, Artesani MC, Andriolo M, Viola M, Pettinato R, Vecchioli-Scaldazza A. Effective prophylactic protocol in delayed hypersensitivity to contrast media: report of a case involving lymphocyte transformation studies with different compounds. *Radiology*. 2002;225(2):466-70.
253. Turner C, Handford AD, Nicholson AN. Sedation and memory: studies with a histamine H-1 receptor antagonist. *J Psychopharmacol*. 2006;20(4):506-17.
254. Bower EA, Moore JL, Moss M, Selby KA, Austin M, Meeves S. The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. *Aviat Space Environ Med*. 2003;74(2):145-52.

255. Mansfield L, Mendoza C, Flores J, Meeves SG. Effects of fexofenadine, diphenhydramine, and placebo on performance of the test of variables of attention (TOVA). *Ann Allergy Asthma Immunol.* 2003;90(5):554-9.
256. Witek TJ, Jr., Canestrari DA, Miller RD, Yang JY, Riker DK. Characterization of daytime sleepiness and psychomotor performance following H1 receptor antagonists. *Ann Allergy Asthma Immunol.* 1995;74(5):419-26.
257. Schroeck JL, Ford J, Conway EL, Kurtzhals KE, Gee ME, Vollmer KA, et al. Review of Safety and Efficacy of Sleep Medicines in Older Adults. *Clin Ther.* 2016;38(11):2340-72.
258. Davenport MS, Cohan RH. The Evidence for and Against Corticosteroid Prophylaxis in At-Risk Patients. *Radiol Clin North Am.* 2017;55(2):413-21.
259. Mervak BM, Davenport MS, Ellis JH, Cohan RH. Rates of Breakthrough Reactions in Inpatients at High Risk Receiving Premedication Before Contrast-Enhanced CT. *AJR Am J Roentgenol.* 2015;205(1):77-84.
260. Li X, Liu H, Zhao L, Liu J, Cai L, Liu L, et al. Clinical observation of adverse drug reactions to non-ionic iodinated contrast media in population with underlying diseases and risk factors. *Br J Radiol.* 2017;90(1070):20160729.
261. ACR manual on contrast media version 10.3. ACR Committee on Drugs and Contrast Media [Available from: <https://www.acr.org/Clinical-Resources/Contrast-Manual>].
262. Davenport MS, Mervak BM, Ellis JH, Dillman JR, Dunnick NR, Cohan RH. Indirect Cost and Harm Attributable to Oral 13-Hour Inpatient Corticosteroid Prophylaxis before Contrast-enhanced CT. *Radiology.* 2016;279(2):492-501.
263. Fumery M, Tilmant M, Yzet C, Brazier F, Loreau J, Turpin J, et al. Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis. *Dig Liver Dis.* 2019;51(4):484-8.
264. Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, et al. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. *J Allergy Clin Immunol Pract.* 2016;4(3):497-504.

Figure Titles and Legends

Figure 1[*color*].Clinical criteria for the diagnosis of anaphylaxis. Anaphylaxis as likely when one of three criteria are fulfilled: (1) acute onset of an illness (minutes to hours) with involvement of the skin, mucosal tissue, or both with either respiratory involvement or reduced blood pressure / associated symptom of end-organ dysfunction; or (2) two or more of the following that occur rapidly after exposure to a likely allergen for the patient, including (a) involvement of skin-mucosal tissue, (b) respiratory involvement, (c) reduced blood pressure or associated symptoms, or (d) gastrointestinal symptoms; or (3) reduced blood pressure as a result of exposure to a known allergen trigger. Adapted from Simons FE, Arduzzo LR, Bilo MB, El-Gamal YM, Ledford DK, Ring J, Sanchez-Borges M, Senna GE, Sheikh A, Thong BY; World Allergy Organization. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol. 2011; 127(3): 587-93.e1-22.

Figure 2. Topic Area 1 PRISMA flow diagram.

Figure 3. Question 1: Risk factors for biphasic anaphylaxis.

Figure 3a: Comparison: biphasic versus no biphasic, Outcome: severe initial symptoms

Figure 3b: Comparison: biphasic versus no biphasic, Outcome: more than one dose of epinephrine

Figure 4. Topic Area 2 PRISMA flow diagram

Figure 5. Should glucocorticoids or antihistamines be used to prevent biphasic anaphylaxis?

Figure 5a. Use of glucocorticoids among patients with biphasic versus uniphasic outcomes

Figure 5b. Use of H1 antihistamines among patients with biphasic versus uniphasic outcomes

Figure 5c. Use of H2 antihistamines among patients with biphasic versus uniphasic outcomes

Figure 6: Should Antihistamine and/or Glucocorticoid Premedication Be Used To Prevent Index Hypersensitivity/Infusion Reactions to Chemotherapy?

Events = Hypersensitivity or Infusion-Related Reactions; **Premedication** = Glucocorticoids and/or Antihistamines

Figure 7. Should Antihistamine and/or Glucocorticoid Premedication Be Used To Prevent Recurrent Hypersensitivity Reactions Radiocontrast Media?

Figure 8. Should Antihistamine and/or Glucocorticoid Premedication Be Used To Prevent Hypersensitivity Reactions to Infliximab, Allergen Immunotherapy, or Other Agents?

Figure 9. Extended Observation to Detect Biphasic Anaphylaxis: Number Needed to Observe [color]

Table 2. Question 2 GRADE Summary of Findings Table**Should Glucocorticoids or Antihistamines be Used to Prevent Biphasic Reactions?**



Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Biphasic	Uniphasic	Relative (95% CI)	Absolute (95% CI)		
Glucocorticoids to prevent biphasic anaphylaxis												
26	observational studies	very serious ^a	serious ^b	serious ^c	serious ^d	all plausible residual confounding would reduce the demonstrated effect	616/871 (70.7%)	10270/14762 (69.6%)	OR 0.87 (0.74 to 1.02)	30 fewer per 1,000 (from 4 more to 67 fewer)	⊕○○○ VERY LOW	IMPORTANT
H1 Antihistamines to prevent biphasic anaphylaxis												
16	observational studies	very serious ^a	serious ^b	serious ^c	serious ^d	all plausible residual confounding would reduce the demonstrated effect	210/245 (85.7%)	2875/3304 (87.0%)	OR 0.71 (0.47 to 1.06)	44 fewer per 1,000 (from 6 more to 111 fewer)	⊕○○○ VERY LOW	IMPORTANT
H2 Antihistamines to prevent biphasic anaphylaxis												
10	observational studies	very serious ^a	not serious	serious ^b	serious ^c	all plausible residual confounding would reduce the demonstrated effect	60/173 (34.7%)	763/1955 (39.0%)	OR 1.21 (0.80 to 1.83)	46 more per 1,000 (from 52 fewer to 149 more)	⊕○○○ VERY LOW	IMPORTANT

CI: Confidence interval; **OR:** Odds ratio. a. Risk of bias across studies related to lack of blinding, lack of randomization, potential confounding by severity of presentation, practice variation, and differential use of epinephrine, b. Significant heterogeneity across studies, c. Endpoint included outcomes reported as surrogate to biphasic reactions included emergency department revisits, d. Several studies with wide ranging 95% Confidence Intervals



Journal Pre-proof

Anaphylaxis is highly likely when any one of the following three criteria is fulfilled

- 1** Sudden onset of an illness (minutes to several hours), with involvement of the skin, mucosal tissue, or both (e.g. generalized hives, itching or flushing, swollen lips-tongue-uvula)

 AND AT LEAST ONE OF THE FOLLOWING:	 Sudden respiratory symptoms and signs (e.g. shortness of breath, wheeze, cough, stridor, hypoxemia)	 Sudden reduced BP or symptoms of end-organ dysfunction (e.g. hypotonia [collapse], incontinence)
---	--	--

- OR 2** Two or more of the following that occur suddenly after exposure to a *likely allergen or other trigger** for that patient (minutes to several hours)

 Sudden skin or mucosal symptoms and signs (e.g. generalized hives, itch-flush, swollen lips-tongue-uvula)	 Sudden respiratory symptoms and signs (e.g. shortness of breath, wheeze, cough, stridor, hypoxemia)	 Sudden reduced BP or symptoms of end-organ dysfunction (e.g. hypotonia [collapse], incontinence)	 Sudden gastrointestinal symptoms (e.g. crampy abdominal pain, vomiting)
---	--	--	--


- OR 3** Reduced blood pressure (BP) after exposure to a *known allergen*** for that patient (minutes to several hours)


 Infants and children: low systolic BP (age specific) or greater than 30% decrease in systolic BP ***	 Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease from that person's baseline
---	--


* For example, immunological but IgE-independent, or non-immunologic (direct mast cell activation)


** For example, after an insect sting, reduced blood pressure might be the only manifestation of anaphylaxis; or after allergen immunotherapy, generalized hives might be the only initial manifestation of anaphylaxis.


*** Low systolic blood pressure for children is defined as less than 70 mm Hg from 1 month to 1 year, less than (70 mm Hg + [2 x age]) from 1 to 10 years and less than 90 mm Hg from 11 to 17 years. Normal heart rate ranges from 80 - 120 beats/minute at age 3 years; and from 70 - 115 beats/minute after age 3 years. In infants and children, respiratory compromise is more likely than hypotension or shock and shock is more likely to be manifest initially by tachycardia than by hypotension.



























Severe Initial Anaphylaxis Symptoms



Severe initial anaphylaxis symptoms
Biphasic OR 2.11 (95% CI, 1.23-3.61)
NNT = 41 (18-195)

Multiple Epinephrine Doses



Multiple Epinephrine doses
Biphasic OR 4.82 (95% CI, 2.70 – 8.58)
NNT = 13 (7 - 27)

Table 1. Question 1 GRADE Summary of Findings Table

What are the risk factors are associated with biphasic anaphylaxis?

Certainty assessment							Summary of findings				
№ of participants (studies) Follow-up	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Overall certainty of evidence	Study event rates (%)		Relative effect (95% CI)	Anticipated absolute effects	
							With No Biphasic	With Biphasic		Risk with No Biphasic	Risk difference with Biphasic
Unknown Trigger											
4275 (21 observational studies)	very serious ^{a,c,d,e}	serious ^f	not serious	not serious	none	⊕○○ ○ VERY LOW	624/4005 (15.6%)	56/270 (20.7%)	OR 1.63 (1.14 to 2.33)	156 per 1,000	75 more per 1,000 (18 more to 145 more)
Drug Trigger ≤18 years old											
996 (5 observational studies)	very serious ^{a,c}	serious ^f	not serious	serious ^b	none	⊕○○ ○ VERY LOW	135/886 (15.2%)	18/110 (16.4%)	OR 2.35 (1.16 to 4.76)	152 per 1,000	145 more per 1,000 (20 more to 309 more)
Cutaneous Signs and Symptoms											

Certainty assessment							Summary of findings				
1949 (6 observational studies)	very serious ^{a,c,d}	very serious ^{f,i}	not serious	very serious ^{b,g}	none	⊕○○ ○ VERY LOW	1546/1838 (84.1%)	104/111 (93.7%)	OR 2.54 (1.25 to 5.15)	841 per 1,000	90 more per 1,000 (28 more to 123 more)
Dyspnea Symptoms											
1841 (6 observational studies)	serious ^{a,c}	serious ^h	not serious	serious ^b	none	⊕○○ ○ VERY LOW	831/1743 (47.7%)	34/98 (34.7%)	OR 0.60 (0.38 to 0.96)	477 per 1,000	123 fewer per 1,000 (220 fewer to 10 fewer)
Wide Pulse Pressure											
1356 (2 observational studies)	serious ^a	not serious	not serious	serious ^b	none	⊕○○ ○ VERY LOW	247/1249 (19.8%)	40/107 (37.4%)	OR 2.11 (1.32 to 3.37)	198 per 1,000	144 more per 1,000 (48 more to 256 more)
Severe Initial Symptoms											

724 (5 observational studies)	very serious ^{a,d}	Very serious ^{f,j}	not serious	serious ^b	none	⊕○○ ○ VERY LOW	248/638 (38.9%)	44/86 (51.2%)	OR 2.11 (1.23 to 3.61)	389 per 1,000	184 more per 1,000 (50 more to 308 more)
> 1 dose of Epinephrine											
1584 (5 observational studies)	very serious ^{a,c}	very serious ^h	not serious	serious ^b	none	⊕○○ ○ VERY LOW	130/1449 (9.0%)	34/135 (25.2%)	OR 4.82 (2.70 to 8.58)	90 per 1,000	232 more per 1,000 (120 more to 368 more)
Glucocorticoids ≤ 18 years old											
1203 (7 observational studies)	very serious ^{a,c,d}	not serious	not serious	serious ^b	none	⊕○○ ○○ VERY LOW	632/1089 (58.0%)	78/114 (68.4%)	OR 1.55 (1.01 to 2.38)	580 per 1,000	102 more per 1,000 (2 more to 187 more)

Explanations

a. Retrospective data may introduce selection bias and increase possible confounding errors

b. Low number of events (less than 250 biphasic reactions)

c. Included study or studies with limited follow-up of 24 hours or no follow-up resulting in possible missed biphasic patients

- d. Included study or studies with limited patient selection including patients from inpatient setting or from a specialty clinic
- e. Included study or studies with larger exclusion of patients due to missing data
- f. Moderate heterogeneity as evidence by I^2 of 30-60%
- g. Wide confidence interval
- h. Substantial heterogeneity as evidence by I^2 of 50-90%
- i. Different definitions of cutaneous signs and symptoms
- j. Different scales for measuring severity of anaphylactic reaction

Table 2. Question 2 GRADE Summary of Findings Table**Should Glucocorticoids or Antihistamines be Used to Prevent Biphasic Anaphylaxis?**

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Biphasic	Uniphasic	Relative (95% CI)	Absolute (95% CI)		
Glucocorticoids to prevent biphasic anaphylaxis												
26	observational studies	very serious ^a	serious ^b	serious ^c	serious ^d	all plausible residual confounding would reduce the demonstrated effect	616/871 (70.7%)	10270/14762 (69.6%)	OR 0.87 (0.74 to 1.02)	30 fewer per 1,000 (from 4 more to 67 fewer)	⊕○○○ VERY LOW	IMPORTANT
H1 Antihistamines to prevent biphasic anaphylaxis												
16	observational studies	very serious ^a	serious ^b	serious ^c	serious ^d	all plausible residual confounding would reduce the demonstrated effect	210/245 (85.7%)	2875/3304 (87.0%)	OR 0.71 (0.47 to 1.06)	44 fewer per 1,000 (from 6 more to 111 fewer)	⊕○○○ VERY LOW	IMPORTANT
H2 Antihistamines to prevent biphasic anaphylaxis												
10	observational studies	very serious ^a	not serious	serious ^b	serious ^c	all plausible residual confounding would reduce the demonstrated effect	60/173 (34.7%)	763/1955 (39.0%)	OR 1.21 (0.80 to 1.83)	46 more per 1,000 (from 52 fewer to 149 more)	⊕○○○ VERY LOW	IMPORTANT

CI: Confidence interval; OR: Odds ratio. a. Risk of bias across studies related to lack of blinding, lack of randomization, potential confounding by severity of presentation, practice variation, and differential use of epinephrine, b. Significant heterogeneity across studies, c. Endpoint included outcomes reported as surrogate to biphasic reactions included emergency department revisits, d. Several studies with wide ranging 95% Confidence Intervals

Table 3: Question 3 GRADE Summary of Findings Table**Should Antihistamine and/or Glucocorticoid Premedication Be Used To Prevent Index Hypersensitivity/Infusion Reactions to Chemotherapy?**

№ of studies	Study design	Risk of bias	Certainty assessment			Other considerations	№ of patients		Effect		Certainty	Importance
			Inconsistency	Indirectness	Imprecision		Premedication	No Premedication	Relative (95% CI)	Absolute (95% CI)		
Rate of Premedication Use in Subjects with or without reactions to chemotherapy												
11	observational studies	serious ^a	serious ^b	serious ^c	serious ^d	none	132/2579 (5.1%)	181/1430 (12.7%)	OR 0.49 (0.37 to 0.66)	60 fewer per 1,000 (from 76 fewer to 39 fewer)	⊕○○○ VERY LOW	IMPORTANT

CI: Confidence interval; OR: Odds ratio, a. Some inconsistency in protocol design could affect outcome assessments, b. Moderate heterogeneity identified in meta-analysis, c. Studies evaluated non-selected patient populations without identified risk factors. Various protocols for premedication were evaluated. The relevance of findings to specific at risk populations is unclear, d. Several studies with wide ranging 95% Confidence Intervals

Table 4: Question 4 GRADE Summary of Findings Table**Should Antihistamine and/or Glucocorticoid Premedication Be Used To Prevent Recurrent Hypersensitivity Reactions Radiocontrast Media?**

No of studies	Study design	Certainty assessment					No of patients		Effect		Certainty	Importance
		Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Premedication	No Premedication	Relative (95% CI)	Absolute (95% CI)		

Subsequent RCM reaction with or without premedication

No of studies	Study design	Certainty assessment					No of patients		Effect		Certainty	Importance
		Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Premedication	No Premedication	Relative (95% CI)	Absolute (95% CI)		
6	observational studies	serious ^a	serious ^b	not serious	serious ^c	none	523/4277 (12.2%)	1218/15851 (7.7%)	RR 1.07 (0.67 to 1.71)	5 more per 1,000 (from 25 fewer to 55 more)	⊕○○○ ○ VERY LOW	IMPORTANT

CI: Confidence interval; RR: Risk ratio, a. Due to observations study design sources of bias could affect effect estimate, b. Significant heterogeneity among studies, c. Several studies with wide ranging 95% Confidence Intervals

Table 5: Question 5 GRADE Summary of Findings Table

Should Antihistamine and/or Glucocorticoid Premedication Be Used To Prevent Hypersensitivity Reactions to Infliximab, Allergen Immunotherapy, or Other Agents?

№ of studies	Study design	Certainty assessment					№ of patients		Effect		Certainty	Importance
		Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Premedication	No Premedication	Relative (95% CI)	Absolute (95% CI)		
Rate of investigator defined allergic reactions												
19	observational studies	serious ^a	serious ^b	serious ^c	serious ^d	all plausible residual confounding would reduce the demonstrated effect	228/9473 (2.4%)	395/15922 (2.5%)	RR 0.74 (0.49 to 1.11)	6 fewer per 1,000 (from 13 fewer to 3 more)	⊕○○○ VERY LOW	IMPORTANT

CI: Confidence interval; **RR:** Risk ratio. a. Risk of bias across studies related to lack of blinding, lack of randomization, potential confounding by severity of presentation, practice variation, b. Significant heterogeneity across studies, c. Significant degree of heterogeneity in outcomes reported, d. Several studies with wide ranging 95% Confidence Intervals

Journal Pre-proof